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Summary {#efs25891-sec-0001}
=======

Following a request from the European Commission, the Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on the coccidiostat Elancoban^®^ G200 containing monensin sodium as active substance produced by fermentation.

Limited data on the taxonomic identification of the production strain did not allow the proper identification of the strain as *Streptomyces cinnamonensis*. The FEEDAP Panel cannot conclude on the absence of genetic determinants for antimicrobial resistance in the production strain, on the presence of viable cells/spores of the production strain/DNA in the final product. Therefore, the FEEDAP Panel cannot conclude on the safety of the additive for the target species, consumer, user and environment with regard to the safety of the production strain.

The following conclusions apply to monensin sodium included in the additive.

Based on the available data set, the FEEDAP Panel cannot conclude on the safety of the highest applied dietary concentration of monensin (125 mg/kg) for chickens for fattening and to derive a margin of safety. Monensin sodium is safe for turkeys for fattening at inclusion level of 100 mg/kg complete feed, with a margin of safety of 1.5. Gram‐positive bacteria are susceptible to monensin. Monensin sodium is not considered to be involved in cross‐resistance to other antibiotics. The use of monensin as coccidiostat in chickens did not affect the colonisation or shedding of *Salmonella* in the gastrointestinal tract. The simultaneous use of Elancoban^®^ G200 and certain antibiotic drugs (e.g. tiamulin) is contraindicated.

Monensin sodium is not genotoxic and, based on the results of chronic carcinogenicity studies performed in rats and mice, is not carcinogenic. The lowest no observed adverse effect level (NOAEL) identified from all the toxicological studies was 1.1 mg/kg body weight (bw) per day based on a 2‐year chronic toxicity/carcinogenicity assay in rat. The pharmacological NOAEL of 0.345 mg monensin sodium/kg bw per day identified in a dog for acute pharmacological effects on the cardiovascular system has been considered as an appropriate basis for the acute health‐based guidance value of 0.003 mg monensin sodium/kg bw per day already established by the FEEDAP Panel in its former opinion applying an uncertainty factor of 100.

The chronic exposure to monensin residues resulting from the use of monensin sodium as a feed additive in chickens would amount to up to 10% of the acceptable daily intake (ADI) (toddlers). The combined chronic exposure to monensin residues resulting from use of monensin as a feed additive in chickens and as a veterinary medicine in bovine would reach up to 48% of the ADI. Acute exposures due to the consumption of poultry tissues were found below the ADI for all age classes. These conclusions are extrapolated to chickens reared for laying and turkeys for fattening. Based on this, the FEEDAP Panel considers that Elancoban^®^ G200 containing monensin sodium is safe for the consumer.

The existing maximum residue limits (MRLs) for poultry tissues ensure consumer safety (acute and chronic exposure; all age classes) provided that the withdrawal period of 1 day is respected.

Elancoban^®^ G200 is very irritant for the eye, but it is not a skin irritant. However, systemic toxicity may occur following skin exposure. Elancoban^®^ G200 should be regarded as a potential skin and respiratory sensitiser. Inhalation exposure is considered a risk to persons handling the additive.

The use of monensin sodium from Elancoban^®^ G200 in complete feed for chickens for fattening does not pose a risk for the terrestrial compartment, the aquatic compartment and the sediment. The bioaccumulation potential of monensin in the environment is low. These conclusions are extended to chickens reared for laying and turkeys.

Monensin sodium from Elancoban^®^ G200 has the potential to effectively control coccidiosis at the minimum applied dose of 100 mg/kg complete feed in chickens for fattening and chickens reared for laying. In turkeys for fattening, the efficacy of 60 mg monensin sodium/kg complete feed from Elancoban^®^ G200 was demonstrated in three floor pen studies and in two anticoccidial sensitivity tests (ASTs), a third AST failing to show anticoccidial efficacy. The FEEDAP Panel is therefore not in the position to conclude on the efficacy of monensin sodium from Elancoban^®^ G200 as a coccidiostat for turkeys for fattening.

1. Introduction {#efs25891-sec-0003}
===============

1.1. Background and Terms of Reference {#efs25891-sec-0004}
--------------------------------------

Regulation (EC) No 1831/2003[1](#efs25891-note-1007){ref-type="fn"} establishes the rules governing the Community authorisation of additives for use in animal nutrition. In particular, Article 10(2) of that Regulation also specifies that for existing products within the meaning of Article 10(1), an application shall be submitted in accordance with Article 7, at the latest one year before the expiry date of the authorisation given pursuant to Directive 70/524/EEC for additives with a limited authorisation period, and within a maximum of seven years after the entry into force of this Regulation for additives authorised without a time limit or pursuant to Directive 82/471/EEC.

The European Commission received a request from Eli Lilly and Company Ltd[2](#efs25891-note-1008){ref-type="fn"} for re‐evaluation of the product Elancoban^®^ G200 (monensin sodium), when used as a feed additive for chickens for fattening, chickens reared for laying and turkeys for fattening (category: coccidiostats and histomonostats).

According to Article 7(1) of Regulation (EC) No 1831/2003, the Commission forwarded the application to the European Food Safety Authority (EFSA) as an application under Article 10(2) (re‐evaluation of an authorised feed additive). EFSA received directly from the applicant the technical dossier in support of this application. The particulars and documents in support of the application were considered valid by EFSA as of 13 June 2014.

According to Article 8 of Regulation (EC) No 1831/2003, EFSA, after verifying the particulars and documents submitted by the applicant, shall undertake an assessment in order to determine whether the feed additive complies with the conditions laid down in Article 5. EFSA shall deliver an opinion on the safety for the target animals, consumer, user and the environment and on the efficacy of the product Elancoban^®^ G200 (monensin sodium), when used under the proposed conditions of use (see Section [3.1.4](#efs25891-sec-0018){ref-type="sec"}).

1.2. Additional information {#efs25891-sec-0005}
---------------------------

The additive Elancoban^®^ G200 (monensin sodium) has been authorised for 10 years for use in chickens for fattening, chickens reared for laying and turkeys (authorisation until 30 July 2014).[3](#efs25891-note-1009){ref-type="fn"} The authorisation has been amended as regards the introduction of a maximum residue limit[4](#efs25891-note-1010){ref-type="fn"} (MRL) for monensin sodium and the modification of the withdrawal period.[5](#efs25891-note-1011){ref-type="fn"} The MRLs in force for all the target species are 25 μg monensin sodium/kg of wet skin + fat and 8 μg monensin sodium/kg of wet liver, kidney and muscle. The withdrawal period is 1 day.

The product Coxidin^®^ containing the same active substance (monensin sodium) has been authorised for use in chickens for fattening, turkeys (authorisation until 10 June 2021)[6](#efs25891-note-1012){ref-type="fn"} and chickens reared for laying (authorisation until 9 March 2022).[7](#efs25891-note-1013){ref-type="fn"}

The European Food Safety Authority (EFSA) issued an opinion on the re‐evaluation of the coccidiostat Elancoban^®^ (monensin sodium) for chickens for fattening, chickens reared for laying and turkeys (EFSA, [2004](#efs25891-bib-0008){ref-type="ref"}) followed by the opinions on the MRLs for monensin sodium for chickens and turkeys for fattening (EFSA, [2006a](#efs25891-bib-0010){ref-type="ref"}) and on the withdrawal period for Elancoban^®^ for chickens for fattening, chickens reared for laying and turkeys for fattening (EFSA, [2008a](#efs25891-bib-0015){ref-type="ref"}). In addition, an opinion on the safety and efficacy of Elancoban^®^ (monensin sodium) as a feed additive for calves for rearing and cattle for fattening was issued (EFSA, [2006b](#efs25891-bib-0011){ref-type="ref"}).

The same active substance present in different products were also evaluated by the FEEDAP Panel; seven opinions were issued on the product Coxidin^®^ (EFSA, [2005](#efs25891-bib-0009){ref-type="ref"}, [2006a](#efs25891-bib-0010){ref-type="ref"},[c](#efs25891-bib-0012){ref-type="ref"}, [2007a](#efs25891-bib-0013){ref-type="ref"}, [2008b](#efs25891-bib-0016){ref-type="ref"}, EFSA FEEDAP Panel, [2011a](#efs25891-bib-0021){ref-type="ref"},[b](#efs25891-bib-0022){ref-type="ref"}, [2013](#efs25891-bib-0027){ref-type="ref"}) and two opinions on the product Monimax^®^ (monensin sodium and nicarbazin) (EFSA FEEDAP Panel, [2017a](#efs25891-bib-0028){ref-type="ref"}, [2018a](#efs25891-bib-0030){ref-type="ref"}).

The Committee for Medicinal Products for Veterinary Use (CVMP) of the European Medicine Agency (EMA) issued two reports on monensin when used in cattle, including dairy cows (EMA‐CVMP, [2007](#efs25891-bib-0032){ref-type="ref"} and (EMA‐CVMP, [2013](#efs25891-bib-0033){ref-type="ref"}). The Joint FAO/WHO Expert Committee on Food Additives (JECFA) evaluated monensin sodium for its use as a veterinary drug (JECFA, [2008](#efs25891-bib-0037){ref-type="ref"}, [2012](#efs25891-bib-0038){ref-type="ref"}).

2. Data and methodologies {#efs25891-sec-0006}
=========================

2.1. Data {#efs25891-sec-0007}
---------

The present assessment is based on data submitted by the applicant in the form of a technical dossier[8](#efs25891-note-1014){ref-type="fn"} in support of the authorisation request for the use of Elancoban^®^ G200 (monensin sodium) as a feed additive.

The FEEDAP Panel used the data provided by the applicant together with data from other sources, such as previous risk assessments by EFSA or other expert bodies, peer‐reviewed scientific papers and other scientific reports to deliver the present output.

EFSA has verified the European Union Reference Laboratory (EURL) report as it relates to the methods used for the control of the active substance in animal feed and the marker residue in tissues. The Executive Summary of the EURL report can be found in Annex A.[9](#efs25891-note-1015){ref-type="fn"}

2.2. Methodologies {#efs25891-sec-0008}
------------------

The approach followed by the FEEDAP Panel to assess the safety and the efficacy of Elancoban^®^ G200 (monensin sodium) is in line with the principles laid down in Regulation (EC) No 429/2008[10](#efs25891-note-1016){ref-type="fn"} and the relevant guidance documents: Guidance for the preparation of dossiers for coccidiostats and histomonostats (EFSA FEEDAP Panel, [2011c](#efs25891-bib-0023){ref-type="ref"}), Technical guidance: Tolerance and efficacy studies in target animals (EFSA FEEDAP Panel, [2011d](#efs25891-bib-0024){ref-type="ref"}), Technical Guidance for assessing the safety of feed additives for the environment (EFSA, [2008c](#efs25891-bib-0017){ref-type="ref"}), Guidance for the preparation of dossiers for the re‐evaluation of certain additives already authorised under Directive 70/524/EEC (EFSA, [2008d](#efs25891-bib-0018){ref-type="ref"}), Guidance for establishing the safety of additives for the consumer (EFSA FEEDAP Panel, [2012a](#efs25891-bib-0025){ref-type="ref"}), Guidance on studies concerning the safety of use of the additive for users/workers (EFSA FEEDAP Panel, [2012b](#efs25891-bib-0026){ref-type="ref"}), Technical Guidance: Microbial Studies (EFSA, [2008e](#efs25891-bib-0019){ref-type="ref"}) and Technical Guidance: Extrapolation of data from major species to minor species regarding the assessment of additives for use in animal nutrition (EFSA, [2008f](#efs25891-bib-0020){ref-type="ref"}).

3. Assessment {#efs25891-sec-0009}
=============

The present opinion assesses the safety and efficacy of the coccidiostat Elancoban^®^ G200 containing monensin sodium as active substance when used as a feed additive in chickens for fattening, chickens reared for laying and turkeys for fattening.

3.1. Characterisation {#efs25891-sec-0010}
---------------------

### 3.1.1. Characterisation of the active substance {#efs25891-sec-0011}

Monensin sodium is a polyether ionophore produced by fermentation by a culture of *Streptomyces* spp.[11](#efs25891-note-1017){ref-type="fn"} The manufacturing process is fully described in the technical dossier. No changes in the manufacturing process have been introduced since the FEEDAP Panel made the first assessment in 2004 (EFSA, [2004](#efs25891-bib-0008){ref-type="ref"}). ■■■■■ The composition of monensin granulated is given as follows: monensin activity (23%), pelleting aid clay (1%), mycelial solids (36.2%) and rice hulls (39.8%). Monensin granulated is specified to contain ≥ 140 mg monensin activity/g. ■■■■■[■■■■■](#efs25891-note-2012){ref-type="fn"}

Monensin sodium (CAS number 22373‐78‐0) consists of the main chemical form monensin A sodium (sodium 4‐(2‐(2‐ethyl‐5′‐(6‐hydroxy‐6‐(hydroxymethyl)‐3,5‐dimethyltetrahydro‐2*H*‐pyran‐2‐yl)‐3′‐methyloctahydro‐\[2,2′‐bifuran\]‐5‐yl)‐9‐hydroxy‐2,8‐dimethyl‐1,6‐dioxaspiro\[4.5\]decan‐7‐yl)‐3‐methoxy‐2‐methylpentanoate, C~36~H~61~NaO~11~, molecular weight 692.86), monensin B sodium (sodium 4‐(9‐hydroxy‐2‐(5′‐(6‐hydroxy‐6‐(hydroxymethyl)‐3,5‐dimethyltetrahydro‐2*H*‐pyran‐2‐yl)‐2,3′‐dimethyloctahydro‐\[2,2′‐bifuran\]‐5‐yl)‐2,8‐dimethyl‐1,6‐dioxaspiro\[4.5\]decan‐7‐yl)‐3‐methoxy‐2‐methylpentanoate, C~35~H~59~NaO~11~, molecular weight 678.84) and monensin C sodium (sodium 2‐ethyl‐4‐(2‐(2‐ethyl‐5′‐(6‐hydroxy‐6‐(hydroxymethyl)‐3,5‐dimethyltetrahydro‐2*H*‐pyran‐2‐yl)‐3′‐methyloctahydro‐\[2,2′‐bifuran\]‐5‐yl)‐9‐hydroxy‐2,8‐dimethyl‐1,6‐dioxaspiro\[4.5\]decan‐7‐yl)‐3‐methoxypentanoate, C~37~H~63~NaO~11~, molecular weight 706.89).

The structural formula of monensin sodium is given in Figure [1](#efs25891-fig-0001){ref-type="fig"}.

![Structural formula of monensin sodium](EFS2-17-e05891-g001){#efs25891-fig-0001}

The specifications for the composition of monensin are the following: not less than 90% of the monensin activity must be monensin A, not less than 95% of the monensin activity must be monensin A + monensin B. ■■■■■

The concentration of monensin sodium is expressed as monensin activity which includes the relative biopotency in terms of 'monensin activity' of the different monensin variants. The relative biopotency is based on the microbiological responses against *Enterococcus faecium* and was determined as 1.000, 0.280, 1.560 and 1.484 for variants A, B, C and D,[13](#efs25891-note-1018){ref-type="fn"} respectively. Chemical composition of monensin sodium granulated was determined by high‐performance liquid chromatography (HPLC) analysis and resulted in 94.67%, 3.98%, 0.26% and 0.57% for variants A, B, C and D, respectively. Monensin activity was determined multiplying the chemical concentrations by the relative biopotency responses resulting in biopotencies of 946.7, 11.1, 4.4 and 8.5 μg/mg for variants A, B, C and D, respectively. Calculating the percentage of biopotency contributions (97.6, 1.1, 0.4 and 0.9%) the results are similar to the chemical compositions.

Pure monensin sodium is a white crystalline solid having a melting point of 267--269°C. Its solubility in water is 4.8 mg/L at pH 7 and 8.9 mg/L at pH 9. It is very soluble in ethyl acetate, acetone, chloroform and dimethyl sulfoxide, slightly soluble in hexane and petroleum ether.

#### 3.1.1.1. Characterisation of the production organism {#efs25891-sec-0012}

The active substance monensin sodium is produced by fermentation with a non‐genetically modified strain of *Streptomyces* spp. The producing strain was originally identified as *Streptomyces cinnamonensis* and it is deposited in the American Type Culture Collections with the accession number ATCC 15413.

■■■■■[■■■■■](#efs25891-note-2014){ref-type="fn"}■■■■■ the assignation of the production strain to *S*. *cinnamonensis* species cannot be confirmed. More detailed data on the taxonomic identification were not provided.

Data on antimicrobial susceptibility of the production strain were not provided. Consequently, the FEEDAP Panel cannot conclude on the absence of genetic determinants encoding antimicrobial resistances in the *Streptomyces* spp. under assessment (Guidance on the characterisation of microorganisms used as feed additives or as production organisms, EFSA FEEDAP Panel, [2018b](#efs25891-bib-0031){ref-type="ref"}).

The absence of antimicrobial compounds relevant to the use of antibiotics in humans or animals, other than the monensin sodium in the mycelial product, was assessed[15](#efs25891-note-1019){ref-type="fn"} comparing the minimum inhibitory concentrations (MIC) of three batches of the fermentation product with three batches of pure monensin ■■■■■[■■■■■](#efs25891-note-2016){ref-type="fn"}■■■■■ the product is considered free of antimicrobial activity other than monensin.

A literature review[17](#efs25891-note-1020){ref-type="fn"} has been carried out to assess the information available on the potential of *S. cinnamonensis* to produce secondary metabolites.[18](#efs25891-note-1021){ref-type="fn"} Since a conclusive identification of the production strain as *S. cinnamonensis* has not been provided, these data were not considered relevant for the current assessment.

### 3.1.2. Characterisation of the additive {#efs25891-sec-0013}

■■■■■ The final additive is produced by mixing monensin granulated with 10--25 g antidusting oil/kg additive and rice hulls or granular limestone which is used to ensure monensin content of Elancoban^®^ G200 within the limit of specification. Elancoban^®^ G200 contains by specification 185--215 g monensin activity/kg. ■■■■■[■■■■■](#efs25891-note-2019){ref-type="fn"}

■■■■■[■■■■■](#efs25891-note-2020){ref-type="fn"}■■■■■[■■■■■](#efs25891-note-2021){ref-type="fn"} The concentrations of heavy metals, arsenic and dioxins were considered of no concern.

The presence of viable cells of the production strain was investigated ■■■■■[■■■■■](#efs25891-note-2022){ref-type="fn"}■■■■■ the presence of viable cells/spores cannot be excluded.

The FEEDAP Panel recognises that the manufacturing process, ■■■■■[■■■■■](#efs25891-note-2023){ref-type="fn"} will probably eliminate all vegetative cells and reduce the number of spores of the production strain in the monensin product.

The applicant did not provide evidence of the absence of the DNA of the production strain. Therefore, uncertainty remains on the presence of viable cells of the production organism and/or its DNA, including the possible presence of genes encoding antibiotic resistances, in the final product.

■■■■■[■■■■■](#efs25891-note-2024){ref-type="fn"}■■■■■[■■■■■](#efs25891-note-2025){ref-type="fn"}

■■■■■ Particle size distribution measured by laser diffraction in three batches of the additive indicated ■■■■■[■■■■■](#efs25891-note-2026){ref-type="fn"} The dusting potential ■■■■■ The particle size distribution of the dust ■■■■■ The monensin content of the dust was similar to that of the additive ■■■■■[■■■■■](#efs25891-note-2027){ref-type="fn"}

### 3.1.3. Stability and homogeneity {#efs25891-sec-0014}

#### 3.1.3.1. Shelf‐life of the additive {#efs25891-sec-0015}

Six batches of Elancoban^®^ G200 were stored at 25°C for 24 months. Monensin activity measured at the beginning and at the end of the study showed recoveries in the range of 97.8--100.6% (loss on drying was constant). Other three batches were put on stability test at 30°C/65% relative humidity (RH) for 24 months and at 40°C/75% RH for 12 months with recoveries of 94.9--97.1 and 93.4--96%, respectively, at the end of the studies. In both cases, the water content as indicated by loss on drying increased in the first 3 months of the experiment, and then remained constant (\~ 6% and \~ 7%, respectively). The packaging material was not reported.[28](#efs25891-note-1022){ref-type="fn"}

#### 3.1.3.2. Stability in premixtures and feedingstuffs {#efs25891-sec-0016}

Three batches of Elancoban^®^ G200 were incorporated in a vitamin/mineral premixture (with choline chloride) for chickens for fattening containing 5 g monensin sodium/kg premixture.[29](#efs25891-note-1023){ref-type="fn"} The samples were stored at 25°C/60% RH for 6 months and at 40°C/60% RH for 3 months in permeable paper bags. Water content as indicated by loss on drying increased in the first month of storage and then remained constant (5.6% at 25°C and 4.8% at 40°C). The average recovery rate was determined to be 90%.

A similar study design was applied using a complete diet for chickens for fattening[30](#efs25891-note-1024){ref-type="fn"} (100 and 125 mg monensin sodium/kg feed) and for turkeys for fattening (60 and 100 mg monensin sodium/kg feed).[31](#efs25891-note-1025){ref-type="fn"} Mash and pelleted samples (pelleting temperature 76--77°C) were stored at 25°C/60% RH for up to 3 months and at 40°C for up to 1 month in permeable paper bags. Concentrations of monensin sodium measured at the end of the storage periods showed recoveries of 92% and 96% for chicken mash feed and 90% and 88% turkey mash feed, respectively for the standard and the accelerated conditions of the stability test. Moisture content of the samples was constant (loss on drying was between 10% and 11%). The same measurements were performed with pelleted feed; the results were similar to those obtained with mash feed, thus it was concluded that pelleting did not affect stability.

#### 3.1.3.3. Homogeneity {#efs25891-sec-0017}

The capacity of monensin sodium to homogeneously distribute was studied in 10 subsamples of the premixtures,[32](#efs25891-note-1026){ref-type="fn"} mash feed for chickens for fattening[30](#efs25891-note-1024){ref-type="fn"} and mash feed for turkeys[31](#efs25891-note-1025){ref-type="fn"} described above. The coefficients of variation (CVs) for premixture (three batches) were 3.4, 3.8 and 4.5%. Regarding chicken mash feed, two concentrations were tested (100 and 125 mg monensin sodium/kg feed). CVs for the lower dose were 6.3, 9.0 and 5.0% and for the higher dose were 7.1, 6.2 and 6.1% (thee batches each dose). Regarding turkey mash feed, two concentrations were tested (60 and 100 mg monensin sodium/kg feed). CVs for the lower dose were 10.4, 10.0 and 8.2% and for the higher dose were 7.2, 9.4 and 7.1% (thee batches each dose).

### 3.1.4. Conditions of use {#efs25891-sec-0018}

Elancoban^®^ G200 is intended to be used for the prevention of coccidiosis in chickens for fattening at a concentration of 100--125 mg monensin/kg complete feed, in chickens reared for laying at a concentration of 100--120 mg monensin/kg complete feed up to a maximum of 16 weeks of age and in turkeys at a concentration of 60--100 mg monensin/kg complete feed up to a maximum of 16 weeks of age. The withdrawal period in chickens and turkeys is 1 day.

3.2. Safety {#efs25891-sec-0019}
-----------

### 3.2.1. Safety of the production strain {#efs25891-sec-0020}

Uncertainties remain on the identification and characterisation of the production strain, including the presence of antimicrobial resistance genes. Moreover, the data provided does not allow to exclude the presence of viable cells/spores of the production strain in the additive. In addition, no data has been submitted on the presence of DNA of the production strain in the final additive. Therefore, considering all the above, the Panel cannot conclude on the safety of the additive with regard to the production strain.

### 3.2.2. Absorption, distribution, metabolism and excretion {#efs25891-sec-0021}

No new absorption, distribution, metabolism and excretion (ADME) studies have been provided by the applicant. The data submitted concerning the metabolic fate of monensin sodium in the chicken, turkeys and rat derive from studies already assessed by the FEEDAP Panel in previous opinions on Elancoban^®^ G200 (EFSA, [2004](#efs25891-bib-0008){ref-type="ref"}, [2008a](#efs25891-bib-0015){ref-type="ref"}). The conclusions can be summarised as follows: (i) monensin sodium is absorbed to a limited extent and this fraction is eliminated largely through bile. It is metabolised extensively by the chicken and turkey; its metabolic fate is similar in these two species and also in the rat, (ii) a great number of metabolites has been isolated from the excreta and tissues, of which eight major metabolites have been identified, each representing less than 10% of the whole residues, (iii) the metabolites result from either single or combined demethylation, decarboxylation and hydroxylation of the molecule, (iv) unchanged monensin in chicken and turkey excreta amounts to less than 20% and 8% of the whole monensin derived metabolites, respectively, (v) monensin represents less than 5% of tissue residues; however, it is considered as the marker residue by default, and (vi) selected monensin hydroxylated metabolites showed reduced biological activity compared to monensin; consequently, the FEEDAP Panel concluded that, taking a weight of evidence approach, monensin‐derived residues of toxicological relevance determined after a 1‐day withdrawal period probably represent, as a conservative estimate, not more than 50% of total residues.

### 3.2.3. Residues {#efs25891-sec-0022}

The applicant submitted the total and marker residue studies in chickens for fattening previously assessed by the FEEDAP Panel (EFSA, [2004](#efs25891-bib-0008){ref-type="ref"}, [2006a](#efs25891-bib-0010){ref-type="ref"}, [2008a](#efs25891-bib-0015){ref-type="ref"}). The applicant submitted also one new residue study of monensin in turkey tissues and a new residue study in the eggs of chicken reared for laying.

The conclusions of the former FEEDAP Panel assessments and the analysis of the additional studies are reported below.

*Total residues*

Monensin sodium total residues were measured in a study carried out in chickens for fattening administered 125 mg \[^14^C\]‐monensin sodium/kg feed for 6 days (EFSA, [2004](#efs25891-bib-0008){ref-type="ref"}). A similar study was performed in turkeys administered 110 mg \[^14^C\]‐monensin sodium/kg feed for 5 days (EFSA, [2004](#efs25891-bib-0008){ref-type="ref"}, [2006a](#efs25891-bib-0010){ref-type="ref"}). The results are reported on Table [1](#efs25891-tbl-0001){ref-type="table"}.

###### 

Total residues (expressed as mg monensin equivalent/kg) in tissues of chickens for fattening administered 125 mg \[^14^C\]‐monensin sodium/kg feed for 6 days and of turkeys for fattening administered 110 mg monensin sodium/kg feed for 5 days

  Withdrawal time   Liver                                                                                                 Kidney                  Muscle                  Skin/fat
  ----------------- ----------------------------------------------------------------------------------------------------- ----------------------- ----------------------- --------------------------------------------------------------
  **Chicken**                                                                                                                                                             
  0‐day             0.935 ± 0.201[1](#efs25891-note-0007){ref-type="fn"} (1.377)[2](#efs25891-note-0008){ref-type="fn"}   0.197 ± 0.043 (0.283)   0.059 ± 0.016 (0.091)   0.287 ± 0.138 (0.563)
  1‐day             0.468 ± 0.075 (0.618)                                                                                 0.142 ± 0.024 (0.190)   0.047 ± 0.009 (0.065)   0.171 ± 0.065 (0.301)
  **Turkey**                                                                                                                                                              
  0.25‐day          0.909 ± 0.184 (1.277)                                                                                 0.159 ± 0.031 (0.221)   ˂ 0.03                  0.121 ± 0.025[3](#efs25891-note-0009){ref-type="fn"} (0.171)

Average ± SD.

Average + 2 SD.

Values calculated from skin and fat data, using the proportion one‐third skin and two‐third fat.

John Wiley & Sons, Ltd

Total residues measured after 6‐h withdrawal in turkey liver and kidney were close to those measured in chicken corresponding tissues at steady state, lower in the muscle and skin/fat. The FEEDAP Panel considered that the physiological proximity of chicken and turkey, two species belonging to the Galliformes, added to the similar qualitative metabolic fate of monensin in both species, justify the use of the chicken data when assessing consumer exposure to total residue (see Section [3.2.5](#efs25891-sec-0030){ref-type="sec"}). This supports the view that chickens offer a worst‐case situation, also considering that the administered dose is lower in turkeys.

*Marker residue*

Monensin sodium concentration in chicken and turkey tissues was measured in studies already assessed previously by the FEEDAP Panel (EFSA, [2004](#efs25891-bib-0008){ref-type="ref"}, [2006a](#efs25891-bib-0010){ref-type="ref"}, [2008a](#efs25891-bib-0015){ref-type="ref"}).

In two publications which were not available for the previous assessments (Henri et al., [2009](#efs25891-bib-0035){ref-type="ref"}, [2012](#efs25891-bib-0036){ref-type="ref"}), monensin sodium concentration in chicken and turkey tissues were measured. Six animals per time point were slaughtered after 0, 2, 4, 6, 8, 10, 12, 14, 24 and 72 h. Liver, muscle and fat were sampled and analyzed for monensin content using a validated liquid chromatography with tandem mass spectrometry (LC--MS/MS) method (Table [2](#efs25891-tbl-0002){ref-type="table"}). The relevant results are reported in Table [2](#efs25891-tbl-0002){ref-type="table"}.

###### 

Monensin residues in tissues (mg/kg) of chickens administered 125 mg monensin sodium/kg feed for 33 days and of turkeys administered 100 mg monensin sodium/kg feed for 56 days

  Withdrawal time (h)   Liver                                                                                     Muscle      Fat
  --------------------- ----------------------------------------------------------------------------------------- ----------- -----------
  **Chicken**                                                                                                                 
  0                     0.022[1](#efs25891-note-0010){ref-type="fn"} (6)[2](#efs25891-note-0011){ref-type="fn"}   0.009 (5)   0.066 (6)
  6                     0.002 (2)                                                                                 0.003 (1)   0.017 (6)
  12                    ˂ LOQ[3](#efs25891-note-0012){ref-type="fn"}                                              ˂ LOQ       0.007 (6)
  **Turkey**                                                                                                                  
  0                     0.006 (6)                                                                                 0.007 (4)   0.055 (6)
  6                     0.005 (2)                                                                                 0.007 (2)   0.117 (6)
  12                    ˂ LOQ                                                                                     ˂ LOQ       0.005 (2)

Average + 2 SD.

Number of samples analysed.

Limit of quantification (LOQ) of 0.001 monensin/kg liver and 0.0025 mg/kg muscle and fat.

John Wiley & Sons, Ltd

Residual monensin values in liver, muscle and fat, for withdrawal times comprised between zero and one day (Table [2](#efs25891-tbl-0002){ref-type="table"}) indicates that all monensin concentrations were below the MRLs after 6 h withdrawal in chicken and 12 h in the turkey. However, due to the limitations in the data set (absence of data for kidneys, the measurement of monensin residues in fat instead of skin/fat and the reduced number of animals tested after 6 h withdrawal in liver and muscle, and after 12 h in the fat) the withdrawal time of 1 day should be maintained.

A study of monensin residues in the first eggs laid by chickens reared for laying has been submitted.[33](#efs25891-note-1027){ref-type="fn"} Fifty‐one‐day‐old Isa‐Brown pullets were kept in a single pen for 16 weeks and fed a complete feed (starter feed until day 43 then grower feed until day 112) supplemented with 0.625 mg Elancoban^®^ G200/kg corresponding to 125 mg monensin sodium/kg (analysed, average of three samples each: 127 and 131 mg/kg, respectively). The pullets were then distributed in individual cages and fed an unsupplemented feed (absence of monensin confirmed). The first two eggs were laid on d‐129, then all eggs were collected individually until 10 eggs for at least 10 hens were obtained. Individual egg contents were homogenised and kept at −20°C until analysis. Monensin residues were determined using a validated LC--MS/MS method with a limit of detection (LOD) of 0.06 μg/kg. Monensin content of all eggs was below the LOD.

### 3.2.4. Safety for the target species {#efs25891-sec-0023}

For chickens for fattening the applicant re‐submitted the same four tolerance studies which were already provided for the first assessment (EFSA, [2004](#efs25891-bib-0008){ref-type="ref"}). Since the current assessment is based on Regulation (EC) No 429/2008, the studies were re‐assessed with reference to the EFSA Technical guidance: Tolerance and efficacy studies in target animals (EFSA FEEDAP Panel, [2011d](#efs25891-bib-0024){ref-type="ref"}).

For turkeys for fattening, the applicant re‐submitted the three tolerance studies already provided and assessed in the 2004 opinion. Since all of them were far from current standards, the applicant was requested to provide a recent tolerance study in turkeys in accordance with Reg (EC) No 429/2008.

#### 3.2.4.1. Tolerance studies in chickens for fattening {#efs25891-sec-0024}

The design of the submitted four studies in chickens for fattening is summarised in Table [3](#efs25891-tbl-0003){ref-type="table"}.[34](#efs25891-note-1028){ref-type="fn"} Three of them compared also the toxicity of different monensin sources (e.g. mycelial or crystalline monensin). Since these studies did not show a consistent or relevant effect of the monensin source, data obtained are reported and assessed in the current opinion as mean values irrespective of the monensin source, focusing only on the dietary monensin level. Although male and female birds (1 day old) were used in all studies and sex was considered in statistics as a variable, mean values are used since interactions between monensin treatment and sex were not consistently (rather accidentally) observed and not considered relevant due to the low number of replicates.

###### 

Design of the tolerance studies in chickens for fattening

+-------+-------------------+---------------------------------------------------------+--------------------------------+-----------------------+----------------------------------------+------------------------------------------------------------+
| Study | Year of the study | Total no animals replicates/treatment (birds/replicate) | Breed sex duration (days)      | Monensin sources      | Concentrations tested (mg monensin/kg) | Typical feed composition                                   |
+=======+===================+=========================================================+================================+=======================+========================================+============================================================+
| 1     | 1966              | 1,600                                                   | Arbor Acre                     | Crude, crystalline    | 0                                      | Maize, soybean meal[2](#efs25891-note-0014){ref-type="fn"} |
|       |                   |                                                         |                                |                       |                                        |                                                            |
|       |                   | 2 M and 2 F[1](#efs25891-note-0013){ref-type="fn"}      | Male/Female                    |                       | 147                                    |                                                            |
|       |                   |                                                         |                                |                       |                                        |                                                            |
|       |                   | \(50\)                                                  | 56                             |                       | 442                                    |                                                            |
|       |                   |                                                         |                                |                       |                                        |                                                            |
|       |                   |                                                         |                                |                       | 737                                    |                                                            |
+-------+-------------------+---------------------------------------------------------+--------------------------------+-----------------------+----------------------------------------+------------------------------------------------------------+
| 2     | 1971              | 1,600                                                   | Breed not given                | Commercial additive   | 0                                      | Maize, soybean meal[4](#efs25891-note-0016){ref-type="fn"} |
|       |                   |                                                         |                                |                       |                                        |                                                            |
|       |                   | 2 M and 2 F[3](#efs25891-note-0015){ref-type="fn"}      | Male/Female                    |                       | 121                                    |                                                            |
|       |                   |                                                         |                                |                       |                                        |                                                            |
|       |                   | \(100\)                                                 | 56                             |                       | 363                                    |                                                            |
|       |                   |                                                         |                                |                       |                                        |                                                            |
|       |                   |                                                         |                                |                       | 606                                    |                                                            |
+-------+-------------------+---------------------------------------------------------+--------------------------------+-----------------------+----------------------------------------+------------------------------------------------------------+
| 3     | 1969/70           | 672                                                     | Breed not given                | Mycelial, crystalline | 0                                      | Maize, soybean meal[4](#efs25891-note-0016){ref-type="fn"} |
|       |                   |                                                         |                                |                       |                                        |                                                            |
|       |                   | 2 M and 2 F[1](#efs25891-note-0013){ref-type="fn"}      | Male/Female                    |                       | 121                                    |                                                            |
|       |                   |                                                         |                                |                       |                                        |                                                            |
|       |                   | \(12\)                                                  | 56                             |                       | 363                                    |                                                            |
|       |                   |                                                         |                                |                       |                                        |                                                            |
|       |                   |                                                         |                                |                       | 605                                    |                                                            |
+-------+-------------------+---------------------------------------------------------+--------------------------------+-----------------------+----------------------------------------+------------------------------------------------------------+
| 4     | 1973/74           | 384                                                     | Hubbard × White Mountain Cross | Mycelial, crystalline | 0                                      | Maize, soybean meal[5](#efs25891-note-0017){ref-type="fn"} |
|       |                   |                                                         |                                |                       |                                        |                                                            |
|       |                   | 2 M and 2 F[1](#efs25891-note-0013){ref-type="fn"}      | Male/Female                    |                       | 121                                    |                                                            |
|       |                   |                                                         |                                |                       |                                        |                                                            |
|       |                   | \(12\)                                                  | 56                             |                       | 363                                    |                                                            |
|       |                   |                                                         |                                |                       |                                        |                                                            |
|       |                   |                                                         |                                |                       | 605                                    |                                                            |
+-------+-------------------+---------------------------------------------------------+--------------------------------+-----------------------+----------------------------------------+------------------------------------------------------------+

4 M and 4 F for the control group.

Starter: 23.0% crude protein (CP), 0.44% methionine (Met), 13.1 MJ metabolisable energy (ME)/kg; finisher: 20.7% CP, 0.35% Met, 13.5 MJ ME/kg.

A fifth replicate with 50 M + 50 F was not considered in the statistics, total number of birds is without these replicates.

Starter: 24.4% CP, 0.57% Met, 12.7 MJ ME/kg; finisher: 24.3% CP, 0.52% Met, 13.2 MJ ME/kg.

Starter: 24.0% CP, 0.53% Met, 13.1 MJ ME/kg; finisher: 21.1% CP, 0.64% Met, 13.7 MJ ME/kg.

John Wiley & Sons, Ltd

No statistical methods were reported for study 1.[35](#efs25891-note-1029){ref-type="fn"} Treatment effects in study 2 were analysed for the four pens with either 100 males or 100 females by ANOVA. Group differences were examined by the Dunnett\'s t‐test.[36](#efs25891-note-1030){ref-type="fn"} Statistical evaluation of study 3 was based on Duncan\'s multiple range test.[37](#efs25891-note-1031){ref-type="fn"} All data of study 4 were statistically analysed by ANOVA. Group comparisons were made by Dunnett\'s two‐tailed test.[38](#efs25891-note-1032){ref-type="fn"}

Zootechnical performance was measured in all studies. An overview (final results only) is given in Table [4](#efs25891-tbl-0004){ref-type="table"}. In study 1,[39](#efs25891-note-1033){ref-type="fn"} all levels of monensin caused lower weight gain than those of the control birds. Higher monensin levels showed poorer feed conversion with the highest level resulting in increased mortality. In study 2,[40](#efs25891-note-1034){ref-type="fn"} body weight gain, feed consumption, and feed to gain ratio were significantly lower at the 363 and 606 mg/kg levels compared to the non‐treated controls and the 121 mg monensin/kg group. The 605 mg/kg level of monensin showed significant and negative effects on all parameters compared to the 363 mg/kg level and significantly increased mortality compared to the other treatments. In study 3,[41](#efs25891-note-1035){ref-type="fn"} a significantly reduced feed consumption was seen at the 363 and 605 mg/kg levels compared to control and 121 mg/kg feed which resulted in a significant reduction of body weight gain. Feed to gain ratio was significantly worse only at the highest monensin level. In study 4,[42](#efs25891-note-1036){ref-type="fn"} the intermediate (363 mg/kg) and the high (605 mg/kg) monensin levels significantly depressed feed intake, weight gain and feed to gain ratio. The increase in mortality at the high monensin level (33% compared to 2--7%) is, albeit not significant -- considered relevant.

###### 

Effect of monensin sodium on the performance of chickens for fattening in tolerance studies

  Study                                      Treatments                                     Feed intake (g)                                Body weight gain (g)                           Feed to gain ratio                            Mortality and culling (%)
  ------------------------------------------ ---------------------------------------------- ---------------------------------------------- ---------------------------------------------- --------------------------------------------- --------------------------------------------
  1[1](#efs25891-note-0019){ref-type="fn"}   0                                              --                                             1,436                                          2.12                                          3.0
  147                                        --                                             1,366                                          2.07                                           3.9                                           
  442                                        --                                             435                                            3.42                                           4.0                                           
  737                                        --                                             130                                            6.63                                           32.7                                          
  2                                          0                                              3,268[a](#efs25891-note-0018){ref-type="fn"}   1,462[b](#efs25891-note-0018){ref-type="fn"}   2.24[a](#efs25891-note-0018){ref-type="fn"}   2.9[a](#efs25891-note-0018){ref-type="fn"}
  121                                        3,183[a](#efs25891-note-0018){ref-type="fn"}   1,491[a](#efs25891-note-0018){ref-type="fn"}   2.14[a](#efs25891-note-0018){ref-type="fn"}    3.5[a](#efs25891-note-0018){ref-type="fn"}    
  363                                        1,881[b](#efs25891-note-0018){ref-type="fn"}   632[c](#efs25891-note-0018){ref-type="fn"}     2.98[b](#efs25891-note-0018){ref-type="fn"}    5.1[a](#efs25891-note-0018){ref-type="fn"}    
  606                                        1,190[c](#efs25891-note-0018){ref-type="fn"}   241[d](#efs25891-note-0018){ref-type="fn"}     4.96[c](#efs25891-note-0018){ref-type="fn"}    19.0[b](#efs25891-note-0018){ref-type="fn"}   
  3                                          0                                              3,445[a](#efs25891-note-0018){ref-type="fn"}   1,693[a](#efs25891-note-0018){ref-type="fn"}   2.04[a](#efs25891-note-0018){ref-type="fn"}   2.1
  121                                        3,405[a](#efs25891-note-0018){ref-type="fn"}   1,691[a](#efs25891-note-0018){ref-type="fn"}   2.01[a](#efs25891-note-0018){ref-type="fn"}    3.2                                           
  363                                        2,182[a](#efs25891-note-0018){ref-type="fn"}   991[a](#efs25891-note-0018){ref-type="fn"}     2.20[a](#efs25891-note-0018){ref-type="fn"}    2.6                                           
  605                                        995[a](#efs25891-note-0018){ref-type="fn"}     341[a](#efs25891-note-0018){ref-type="fn"}     2.92[a](#efs25891-note-0018){ref-type="fn"}    11.5                                          
  4[2](#efs25891-note-0020){ref-type="fn"}   0                                              3,593                                          1,665                                          2.18                                          2.1
  121                                        3,578                                          1,683                                          2.14                                           3.2                                           
  363                                        1,640\*                                        612\*                                          2.68\*                                         7.3                                           
  605                                        990\*                                          269\*                                          3.74\*                                         33.4                                          

a,b,c Means within a column/trial with different superscript letters are significantly different (p ≤ 0.05).

Statistical results not presented.

Group comparisons against the control values, differences (p \< 0.05) are indicated by \*.

John Wiley & Sons, Ltd

In studies 2, 3 and 4, five birds/replicate each were selected after 4 and 8 weeks to determine organ weight, for haematology (haemoglobin, haematocrit), blood chemistry (glucose, total protein (TP), alkaline phosphatase (AP), aspartate aminotransferase (AST), in study 4 without AP but with Na and K) and pathological (including histological) examination (weight of heart, liver and kidney). The results summarised below refer to the 8‐week data.

In studies 2, 3 and 4, the absolute organ weights were significantly reduced at the intermediate and the high monensin levels, the relative weights for liver and kidney at the high level only in study 2 and 4; and the intermediate and the high level in study 3. No differences were found for the haematological endpoints in studies 2 and 4, but a significant elevation of haemoglobin at the low level in study 3. Concerning blood chemistry, no differences were seen in study 2. In study 3, a significant decrease for AP and AST values was noted for the use level but not at higher doses, thus not considered relevant. Treatment effects were seen in study 4 for TP and AST, the increase reached significance for the high‐dose group only. For study 4, slight degeneration and regeneration of skeletal muscle of the abdominal wall and legs were reported in several chickens treated with 363 and 605 mg monensin/kg feed.

None of the studies showed full compliance with the requirements of Regulation (EC) No 429/2008. The design of all studies failed to show or to allow estimating a margin of safety for the use level. Three‐ and fivefold overdoses were not tolerated, both depressing feed intake and body weight gain, the fivefold overdose increasing mortality. Study 1 reported only zootechnical parameters. Haematological examinations of studies 2, 3 and 4 were limited to haemoglobin and haematocrit, those for blood chemistry to glucose, total protein and AST, AP was determined in two studies, Na and K in one. The FEEDAP Panel also notes that the final 8‐week body weight data in the control groups of the four studies (1,436--1,693 g/bird) are considerably below those which are reached under practical conditions for the modern chicken breeds. Due to the above limitations, the FEEDAP Panel is not in a position to conclude on the safety of the highest proposed dietary concentration of monensin (125 mg/kg) for chickens for fattening and to derive a margin of safety.

#### 3.2.4.2. Tolerance study in turkeys for fattening {#efs25891-sec-0025}

Since the studies assessed in 2004 could not be considered sufficient according to Reg (EC) No 429/2008, the applicant provided a new tolerance study with Elancoban^®^ G200.[43](#efs25891-note-1037){ref-type="fn"}

The study was carried out in male/female turkeys for fattening (Hybrid Converter). From a total of 440 one‐day‐old birds, 20 were taken for blood sampling shortly after arrival and 360 turkeys (+ 60 spare animals) were distributed into 60 pens of 6 animals (+ 1 spare animal) and allocated to 5 dietary treatments (12 replicates per treatment (6 pens of males and 6 pens of females). After 1 week, the spare birds not required to replace dead birds were removed. The treatment consisted of diets supplemented with 0, 100 (use level), 150 (1.5× use level), 200 (2× use level) and 250 mg monensin sodium/kg (2.5× use level), respectively. The intended monensin concentrations were analytically confirmed except for the intended 250 mg monensin sodium/kg (analysed: 221 mg/kg starter, and 213 mg/kg grower). Both diet types consisted mainly of soybean meal, corn and wheat, the starter diet fed for the first 21 days contained 28.2% CP, 1.132% meth+cyst, and 11.9 MJ apparent metabolisable energy (AMEn)/kg; the grower diet 24% CP, 0.938% meth+cyst, and 12.4 MJ AMEn/kg. The diets were offered in mash form and on ad libitum basis for a total period of 42 days.

Mortality and health status were checked twice daily, and dead animals were necropsied. Animals were weighed on days 1, 8, 15, 22, 29, 36 and 43, feed intake was registered per pen throughout the study period and feed to gain ratio calculated for the corresponding intervals. Blood samples were obtained from 1 animal per pen on days 22 and 43 for haematology and blood biochemistry.[44](#efs25891-note-1038){ref-type="fn"} At the end of the experiment, one bird per pen was selected for necropsy. Liver, kidneys and heart were weighed and samples of heart, skeletal muscle, intestine (jejunum, caecum and colon), kidneys, and liver were taken. No histopathology was performed as there were no significant gross lesions observed on any organs.

An ANOVA was done with the performance data (pen basis) with treatment and sex as factor. Group means were compared with Dunnett test. Mortality was analysed using the Kruskal--Wallis method. The significance level was set at 0.05.

Mortality including culling was high in the first week with 8%, no specific lesions were observed. According to the statistics, mortality was treatment but not dose related. However, a careful review of the individual data by the FEEDAP Panel indicated that the losses are pen related, since in four pens (2 pens from the group 2×, 1 pen from the group 2.5× and 1 pen from the control group) all seven turkeys died (82% of total losses). Only two turkeys died after the first week until study completion, one in the control group with chronic nephritis, another in the group 2× because of cardiac decompensation.

No differences were observed for the total and weekly feed intake, except in weeks 3 and 4 where the high‐dose group showed a lower feed intake than the groups with 100 and 150 mg monensin sodium/kg. Final body weight was not statistically different between the groups (overall mean 2,069 g). It should be noted that the body weight was low compared to the standard values given by the breeder company (2.94 kg for males and 2.47 kg for female turkeys). Significant differences were observed for the body weight after 2, 3, 4 and 5 weeks, in all cases the high‐dose groups showed a significant growth depression compared to the unsupplemented group and the group with the monensin use level. The applicant also calculated the ratio body weight to feed intake. The groups with 200 and 250 mg monensin sodium/kg showed a significantly inferior ratio of body weight to feed than the control group. No significant differences between treatments were observed in water intake.

Results on haematology and clinical biochemistry of the different groups were not different with one exception represented by creatine kinase (CK) at day 22; CK values of the two higher monensin concentrations (1,957 and 5,818 for 200 and 250 mg monensin sodium/kg, respectively) appeared higher than those for the other groups (861, 814 and 834 for the groups with 0, 100 and 150 mg/kg, respectively). CK increase is often considered as a marker of tissue damage (i.e. of muscles and kidneys. However, significant treatment differences could only be identified (Holm--Sidak method) for females (250 mg/kg higher than all other groups). This effect was not seen at the end of the study.

No differences between the treatment groups were identified by necropsy. Also, the relative organ weights of heart, kidneys and liver were not different. It is noted that the test for liver weight had only a power of 0.101 (for α 0.05), the desired power is 0.8. Therefore, differences even when existing were less likely to be detected. Relative liver weight for the control group was 0.0172, 0.0177, 0.0176, 0.0181 and 0.0187, for the groups with 100, 150, 200 and 250 mg monensin/kg, respectively.

Based on the tolerance study it can be concluded that 100 mg monensin sodium/kg complete feed is safe for turkeys for fattening with a margin of safety of about 1.5.

#### 3.2.4.3. Interactions {#efs25891-sec-0026}

In 2004, the FEEDAP Panel concluded that: 'It is well known from the literature that severe interactions between the ionophore coccidiostats and the antibiotic tiamulin but also other antibiotics (mainly macrolides) may occur'. Further toxic interactions with polyethers (mainly monensin) became known for sulfonamides (Frigg et al., [1983](#efs25891-bib-0034){ref-type="ref"}), chloramphenicol (Dorn et al., [1983](#efs25891-bib-0006){ref-type="ref"}; Broz and Frigg, [1987](#efs25891-bib-0003){ref-type="ref"}), sulfachlorpyrazine (Braunius, [1986](#efs25891-bib-0002){ref-type="ref"}), erythromycin, oleandomycin and furazolidone (Anadon and Reeve‐Johnson, [1999](#efs25891-bib-0001){ref-type="ref"}).

In summary, the simultaneous use of Elancoban^®^ and certain antibacterial drugs (e.g. tiamulin) is contra‐indicated.

#### 3.2.4.4. Literature review on tolerance of chickens and turkeys to monensin and drug interactions including pharmacovigilance data {#efs25891-sec-0027}

The applicant performed a literature search[45](#efs25891-note-1039){ref-type="fn"} on the tolerance of chickens and turkeys to monensin sodium.[46](#efs25891-note-1040){ref-type="fn"} The search included the terms 'monensin AND chicken OR turkey OR layer OR broiler OR poultry' 'monensin AND coccidiosis' 'monensin AND toxicity AND chicken OR poultry' 'monensin AND safety AND chicken OR poultry' 'monensin AND tolerance' 'monensin AND drug interaction'.

Six publications were identified by the applicant as relevant to the tolerance in chickens (Appendix [A](#efs25891-sec-1001){ref-type="sec"}). No such study in turkeys was found.

The FEEDAP Panel considered only one of these studies with chickens, since in the other studies monensin was administered at 100 mg/kg feed or below, which is less than the highest proposed use level (125 mg/kg).

Zavala et al. (2011) published a case report, in which peracute onset of disease was described in a 42‐week‐old broiler breeder flock when feed with 638--740 mg monensin/kg was erroneously administered. During the first 10 days post‐ingestion, mortality reached 13.7% in hens and 70.9% in roosters. Hen per day production decreased in the same period from 67% to 3%. Twenty‐one days after removal of the suspect feed, mortality rate returned to normal in both genders, albeit feed consumption and egg production remained extremely low.

Concerning interactions of monensin with other drugs, the applicant identified six studies as potentially relevant. One publication (Islam et al., 2009) is a review reporting interaction of tiamulin with different ionophore antibiotics in poultry. Another publication (Szűcs et al., 2004) reports findings in the rat on the tiamulin--monensin interaction. The study demonstrated a dual behaviour of tiamulin: induction and inhibition of CYP3A in rat liver and in the case of inhibition the metabolism of monensin could be compromised. Two other publications (Chapman et al., 2004; Sims et al., 2002) are efficacy studies in turkeys. These four publications did not examine interactions other than of tiamulin with monensin, and were not considered.

Sureshkumar et al. (2004) studied the interaction of monensin with enrofloxacin (a fluoroquinolone) in chickens for fattening. Day‐old chickens were treated with monensin (100 mg monensin/kg feed) for 41 days and with enrofloxacin (10 mg enrofloxacin/kg bw per os for three consecutive days at days 33, 34 and 35) alone and in combination. Enrofloxacin inhibited in a reversible competitive type manner CYP450 enzymes. Co‐administration of enrofloxacin with monensin produced increased CK, AST and ALT serum enzymes suggesting heart and liver injury. This suggests that the co‐administration could result in adverse interactions.

Crespo et al. (2008) analysed the vitamin E and monensin concentrations in serum and liver of turkeys with and without the knock‐down syndrome. Skeletal muscles and the myocardium were examined by histopathology. From their findings, the authors suggested that monensin could induce lower vitamin E concentration in the liver; but the study did not demonstrate if low vitamin E concentration predisposes birds to knock‐down syndrome.

The FEEDAP Panel concludes that findings published between 2004 and 2014 did not add new knowledge to the tolerance or the safety of monensin in target species. The combined administration of enrofloxacin and monensin appears to produce adverse effects. The simultaneous administration of fluoroquinolones and monensin seems to be contraindicated.

The applicant provided a review of pharmacovigilance case reports, looking specifically at tolerance of target animals along with interactions with other drugs.[46](#efs25891-note-1040){ref-type="fn"} The review returned twelve cases in the target species (chicken, turkey) and three cases in non‐target animal species. Two of the cases in a non‐target animal species were related to accidental exposure to feed and one case to use in a non‐target species (pheasant).

In the target species, 3 out of 12 cases were related to tolerance of target animals. In one case (with high mortality), the dose fed to chickens reared for laying was 638 and 351 mg monensin/kg, in another case 465 mg/kg. A third case referred to turkeys which stopped eating and showed signs of paralysis, the monensin concentration in feed was 153 mg/kg, about double of the labelled dose (80 mg). From the nine remaining cases, two refer to concomitant feeding of monensin and tiamulin and confirm the well‐known interaction. Three cases involved sulfonamides (trimethoprim, sulfaquinoxalin) mostly followed by antibiotics which were fed concomitantly with Elancoban^®^, one case involved neomycin and three reports involved conazoles. In all of these cases there were confounding factors or insufficient data to draw a conclusion that interaction occurred between these compounds and Elancoban^®^.

The FEEDAP Panel concludes that the pharmacovigilance report of the applicant did not identify new facts which should be considered in assessing the tolerance of target species to monensin sodium or potential drug interactions with monensin sodium.

#### 3.2.4.5. Microbial studies {#efs25891-sec-0028}

For the current assessment, the applicant resubmitted the same studies already assessed in the FEEDAP opinion adopted in 2004 (EFSA, [2004](#efs25891-bib-0008){ref-type="ref"}) and some new information.

In 2004, the FEEDAP Panel concluded that: 'Gram‐positive bacteria present in the digestive tract of poultry and other livestock are generally susceptible to monensin. While laboratory studies have shown that Gram‐positive strains can develop resistance to monensin, there was no evidence to suggest that exposure of Gram‐positive bacteria results in the development of cross‐resistance to other antibiotics used for therapy in human and veterinary medicine'. 'The use of monensin as a coccidiostat in chickens did not affect the colonisation or shedding of *Salmonella* in the gastro‐intestinal tract'.

For the current assessment, the applicant submitted a microbiological expert report[47](#efs25891-note-1041){ref-type="fn"} on the use of Elancoban^®^ G200 in poultry and the development of resistance to monensin and cross‐resistance to antibiotics used in human medicine. As part of that report, a literature review has been conducted (Appendix [A](#efs25891-sec-1001){ref-type="sec"}).[48](#efs25891-note-1042){ref-type="fn"} The report concludes that the use of monensin did not promote appearance or selection of monensin‐resistance in susceptible bacteria suggesting that the cross‐resistance to monensin and antibiotics of human and veterinary importance is unlikely. Moreover, as no dedicated genes to monensin resistance are involved, co‐transfer of these and genetic determinants conferring antibiotic resistance is not possible.

New experimental evidence on the development of antibiotic resistance in *Enterococcus* sp. was submitted. *E. faecium* and *Enterococcus faecalis* were isolated from faecal samples of treated and untreated groups collected during two of the three efficacy studies (one in chickens for fattening[49](#efs25891-note-1043){ref-type="fn"} and one in turkeys[50](#efs25891-note-1044){ref-type="fn"}) described in 3.3.[51](#efs25891-note-1045){ref-type="fn"} Increases in MIC values of monensin to *E. faecalis* (687 isolates) or *E. faecium* (596 isolates), isolated up to day 43 of the treatment, were never observed.[52](#efs25891-note-1046){ref-type="fn"} One *E. faecium* strain having a MIC to monensin \> 64 μg/mL was identified in the chickens study at day 42 of the treatment, while 7 isolates of this species (two from day 42 and five from day 43) with a MIC \> 64 μg/mL were recovered from the corresponding untreated control group, which suggests that presence of high‐resistant strains was not treatment related.

In the light of the new studies, the FEEDAP Panel reiterates the conclusion that 'there is no evidence to suggest that exposure of Gram‐positive bacteria to monensin results in the development of cross‐resistance to other antibiotics used for therapy in human and veterinary medicine'. In the absence of new data, the FEEDAP Panel reiterates its previous conclusion that 'The use of monensin as coccidiostat in chickens did not affect the colonisation or shedding of *Salmonella* in the gastro‐intestinal tract'.

#### 3.2.4.6. Conclusions on the safety for the target species {#efs25891-sec-0029}

Based on the available data set, the FEEDAP Panel cannot conclude on the safety of the highest applied dietary concentration of monensin (125 mg/kg) for chickens for fattening and to derive a margin of safety. This conclusion is extended to chickens reared for laying.

Monensin sodium is safe for turkeys for fattening at inclusion level of 100 mg/kg complete feed, with a margin of safety of about 1.5.

Gram‐positive bacteria are susceptible to monensin. Monensin sodium is not considered to be involved in cross‐resistance to other antibiotics. The use of monensin as coccidiostat in chickens did not affect the colonisation or shedding of *Salmonella* in the gastrointestinal tract.

The simultaneous use of Elancoban^®^ G200 and certain antibiotic drugs (e.g. tiamulin) is contraindicated.

Considering the uncertainties on the identity and characterisation of the production strain and the lack of demonstration of the absence of the production strain and its DNA on the final product, the FEEDAP Panel cannot conclude on the safety of the additive for the target species.

### 3.2.5. Toxicological studies {#efs25891-sec-0030}

In 2004, the FEEDAP Panel assessed the toxicity of monensin sodium (EFSA, [2004](#efs25891-bib-0008){ref-type="ref"}). For the current application, the same data assessed in 2004 was submitted with the addition of some studies not available at the time of the previous assessment and a literature search covering the period 2004--2014.

The FEEDAP Panel assessed all the toxicological studies submitted including those evaluated for the previous application (EFSA, [2004](#efs25891-bib-0008){ref-type="ref"}) and those re‐submitted in the current application.

The FEEDAP Panel noted that the studies reported were performed according to standards appropriate to the time, but in some cases, they were not in accordance either with Good laboratory practice (GLP) or with previous and current OECD guidelines. However, the quality of the studies was considered sufficient for the assessment. An overview of the available studies and the main conclusions are given below.

#### 3.2.5.1. Genotoxicity {#efs25891-sec-0031}

All the *in vivo* and *in vitro* genotoxicity studies submitted for the current assessment were already evaluated by the FEEDAP Panel in 2004 (EFSA, [2004](#efs25891-bib-0008){ref-type="ref"}). All the studies were performed with crystalline monensin sodium (93.8% purity) and were GLP‐compliant and gave negative results.[53](#efs25891-note-1047){ref-type="fn"}

#### 3.2.5.2. Subchronic toxicity studies in rats, mice, and dogs {#efs25891-sec-0032}

The applicant submitted a total of eight subchronic studies in rats, one in mice and two in dogs. In a set of five rat studies the subchronic toxicity of mycelial and crystalline monensin sodium was compared. The FEEDAP Panel re‐assessed the old studies and evaluated the studies not considered before.

Two studies in rats,[54](#efs25891-note-1048){ref-type="fn"} one in mice[55](#efs25891-note-1049){ref-type="fn"} and the two studies in dogs[56](#efs25891-note-1050){ref-type="fn"} were already assessed (EFSA, [2004](#efs25891-bib-0008){ref-type="ref"}): the lowest no observed adverse effect level (NOAEL) from the rat studies was based on reduction of body weight gain at a dietary level of 50 mg monensin/kg which was calculated to be equivalent to 3 mg/kg body weight (bw) per day; a NOAEL in mice could not be derived from the available study because growth rate was affected in all the groups tested (the lowest dietary concentration tested was 37.5 mg/kg, corresponding to 7.5 mg/kg bw per day); the lowest observed effect level (LOEL) from the dog studies was 5 mg/kg bw per day, based on liver toxicity together with more generalised toxicity at higher doses (15 and 50 mg/kg bw per day) and slight effects on body weight at 5 mg/kg bw per day in males only).

In an additional rat study, groups of Wistar rats (25 of each sex (control) and 15 of each sex (treated)) were maintained for three months on diets containing mycelial monensin at dietary concentrations of 0, 25, 50, 80, and 125 mg monensin/kg.[57](#efs25891-note-1051){ref-type="fn"} The dietary concentrations provided average daily doses of 0, 0.9--2.4, 1.8--4.6, 3.0--7.7 or 4.5--12 mg monensin/kg bw per day for male and 0, 1.3--2.6, 2.8--5.8, 4.0--12.8 or 10.0--20.2 mg monensin/kg bw per day for female rats. All rats survived the study with no observable physical signs of toxicity. Decreases in body weight, weight gain, and/or food consumption were observed for males at 125 mg/kg and for females in the 50, 80 and 125 mg/kg groups. No effects of treatment were reported in either sex at the lowest dietary concentration of 25 mg monensin/kg. Based on the body weight findings in females, the lowest dietary level of 25 mg/kg, which provided approximately 2 mg monensin/kg bw per day was considered to be the NOAEL in this study.

Four parallel 3‐month studies, not previously reported, were conducted to compare the subchronic toxicity of crystalline and mycelial monensin. In these studies, male and female rats (15/sex per group) were fed diets containing 0, 50, 200 or 400 mg monensin/kg as either crystalline,[58](#efs25891-note-1052){ref-type="fn"} or one of three forms of mycelial monensin: drum‐dried mycelial,[59](#efs25891-note-1053){ref-type="fn"} azeotrope mycelial[60](#efs25891-note-1054){ref-type="fn"} or flash‐dried mycelial.[61](#efs25891-note-1055){ref-type="fn"} Monensin dietary concentrations of 50, 200 and 400 mg/kg provided 3.7, 15.5 and 31.2 mg monensin/kg bw per day (crystalline); 3.7, 15.4 and 30 mg monensin/kg bw per day (drum‐dried mycelial; 4.0, 16.1 and 30.9 mg monensin/kg bw per day (azeotrope mycelial); and 3.7, 14.8 and 29.4 mg monensin/kg bw per day (flash‐dried mycelial). Evidence of toxicity (mortality; decreases in body weight gain, food consumption and efficiency of food utilisation; and a low incidence of focal degeneration and interstitial inflammation of muscle) was similar for the various forms of monensin at the two highest doses. The lowest dietary concentration of 50 mg/kg was determined to be the NOAEL in all studies, equivalent to 3.7 mg monensin/kg bw per day for crystalline monensin and 3.7, 4.0 and 3.7 mg monensin/kg bw per day for the three mycelial monensin studies, respectively.

Another study directly compared the effects of feeding crystalline monensin and mycelial monensin to rats (15/sex per group) administered at identical dietary concentrations of 0, 50, 200 or 400 mg/kg.[62](#efs25891-note-1056){ref-type="fn"} Crystalline and mycelial monensin produced similar effects with substantial growth retardation in both sexes that received either 200 or 400 mg/kg being most severe at 400 mg/kg. At the lowest dietary concentration tested (50 mg/kg) female rats had a transient and very slight retardation of growth during the first 2--4 weeks of the study and male rats were not affected. There were no other differences that could be considered to be consistently associated with treatment. The lowest dietary concentration tested (50 mg/kg), equivalent to approximately 4.5 mg monensin/kg bw per day was considered to be the NOAEL.

#### 3.2.5.3. Chronic oral toxicity studies {#efs25891-sec-0033}

The applicant submitted two 2‐year chronic toxicity/carcinogenicity studies in rats and one in mice. A 1‐year chronic toxicity study was performed in dogs. Both mycelial and crystalline monensin sodium were tested in these studies.

All the submitted studies were previously assessed (EFSA, [2004](#efs25891-bib-0008){ref-type="ref"}): the NOAEL in rats for mycelial monensin was reported to be 1.40 mg/kg bw per day for male rats, based on reduced bodyweight gain at the dose 2.18 mg/kg bw per day[63](#efs25891-note-1057){ref-type="fn"}; the NOAEL for crystalline monensin was 1.14 mg/kg bw per day for male rats, also based on reduced bodyweight gain at 2.57 mg/kg bw per day.[64](#efs25891-note-1058){ref-type="fn"} The NOAEL for mycelial monensin in mice was 1.2 mg/kg bw per day based on reduced body weight gain and decreased leukocyte counts at 3.1 mg/kg bw per day.[65](#efs25891-note-1059){ref-type="fn"} The NOAEL for mycelial monensin in the 1‐year study in dogs was reported to be 2.5 mg/kg bw per day, based on anorexia, hypoactivity and weakness at 5 and 7.5 mg/kg bw per day and lower mean body weight gain at 7.5 mg/kg bw per day.[66](#efs25891-note-1060){ref-type="fn"}

The results of chronic toxicity/carcinogenicity studies performed in rats and mice with either the mycelial or the crystalline form suggest that monensin sodium is not carcinogenic.

#### 3.2.5.4. Reproduction toxicity including teratogenicity {#efs25891-sec-0034}

The applicant submitted two‐three‐generation studies in rats (one with mycelial and the other one with crystalline monensin sodium) and a rabbit teratology study. Both the three‐generation studies included investigations of developmental toxicity.

All the submitted studies were previously assessed (EFSA, [2004](#efs25891-bib-0008){ref-type="ref"}): no treatment‐related adverse effects were seen in rats treated with crystalline monensin sodium[67](#efs25891-note-1061){ref-type="fn"} and the NOAEL for this study was established to be 2.5 mg/kg bw per day, the highest dose tested. The study performed with mycelial monensin sodium[68](#efs25891-note-1062){ref-type="fn"} gave a lowest observed adverse effect level (LOAEL) of 3.3 mg/kg bw per day, based on maternal toxicity (reduced bodyweight). There was no indication of any embryotoxicity and teratogenicity at the doses used for either crystalline and mycelial monensin. There was no indication of fetotoxicity with the crystalline form of monensin sodium and slight evidence, suggesting fetotoxicity with the mycelial product, was unconvincing. As no treatment‐related adverse effects were seen in the teratogenicity study in rabbits,[69](#efs25891-note-1063){ref-type="fn"} the NOAEL for this study was concluded to be the highest dose level, 0.76 mg/kg per day.

The FEEDAP Panel re‐assessed all the submitted studies and reiterates its previous assessment.

#### 3.2.5.5. Safety pharmacology studies {#efs25891-sec-0035}

A series of general pharmacology studies were conducted to determine if the ionophore coccidiostat monensin sodium had any undesirable pharmacological properties. In most of these studies, crystalline monensin sodium was used.

A study assessing general behaviour, coordinating activity of skeletal muscle, anti‐electroshock seizures and analgesic effects was performed in mice orally administered monensin sodium at 0, 10 or 30 mg/kg.[70](#efs25891-note-1064){ref-type="fn"} At 30 mg/kg monensin sodium induced in the animals a slightly sedative condition, decrease sensitivity to tactile stimulation, and a slight depression of muscular coordination. The NOAEL was 10 mg monensin sodium/kg.

A study assessing spinal reflex, electroencephalogram and circulatory, respiratory, and autonomic effects was performed in cats orally administered monensin sodium at 30 mg/kg.[70](#efs25891-note-1064){ref-type="fn"} No effects were seen at the dose tested.

A study assessing charcoal meal transit was performed in mouse orally administered monensin sodium at 0, 10 or 30 mg/kg.[70](#efs25891-note-1064){ref-type="fn"} Charcoal meal transit was significantly reduced at 30 mg/kg. The NOAEL was set at 10 mg/kg.

The effect of monensin on contractions induced by acetylcholine, histamine and barium chloride (BaCl~2~) was evaluated in isolated guinea pig ileal preparations.[70](#efs25891-note-1064){ref-type="fn"} No effects were seen at the concentration of 1 × 10^−5^ g/mL.

Carrageenan‐induced oedema was compared in rats administered orally monensin sodium at 0 or 30 mg/kg feed.[70](#efs25891-note-1064){ref-type="fn"} No effects were seen at the dose tested.

**Cardiac effects**

The applicant submitted one study performed in conscious dogs administered monensin sodium orally or intravenously.[71](#efs25891-note-1065){ref-type="fn"} The study was assessed previously (EFSA, [2004](#efs25891-bib-0008){ref-type="ref"}) and it was concluded that the acute pharmacological NOAEL for increased coronary blood flow and mean blood pressure was 0.345 mg/kg bw after oral administration. In the same study the effects of the intravenous administration of monensin sodium were also evaluated but were considered less relevant to the current assessment. A further study also assessed the cardiac and respiratory effects after intravenous administration to anaesthetised pigs and dogs.[72](#efs25891-note-1066){ref-type="fn"} The administration route of the study was not relevant and consequently, the results of the study were not considered in this assessment.

**Horse toxicity**

The applicant submitted the same studies in horses that were already evaluated by the FEEDAP Panel in 2004 (EFSA, [2004](#efs25891-bib-0008){ref-type="ref"}).[73](#efs25891-note-1067){ref-type="fn"} Based on these studies, the FEEDAP Panel concluded that monensin in doses proposed for feed supplementation in chickens is toxic to horses. The same conclusions are retained.

#### 3.2.5.6. Literature search {#efs25891-sec-0036}

The applicant performed a literature search[45](#efs25891-note-1039){ref-type="fn"} on the toxicology of monensin sodium.[46](#efs25891-note-1040){ref-type="fn"} The search included the terms 'monensin AND acute toxicity', 'monensin AND repeat dose toxicity', 'monensin AND carcinogenicity', 'monensin AND reproductive toxicity', 'monensin AND developmental toxicity', 'monensin AND genotoxicity OR mutagenicity', 'monensin and environmental safety'. The outcome of the literature review (Appendix [A](#efs25891-sec-1001){ref-type="sec"}) did not identify new data requiring consideration in the current opinion.

#### 3.2.5.7. Conclusions {#efs25891-sec-0037}

The FEEDAP Panel concludes that monensin sodium is not genotoxic and, based on the results of carcinogenicity studies performed in rats and mice, is not carcinogenic. The Panel considers that the form of monensin (crystalline or mycelial) is very unlikely to influence these outcomes.

From a total of eight subchronic studies in rats assessing the effects of crystalline and mycelial monensin sodium, it is concluded that crystalline and mycelial monensin produced similar subchronic effects. The lowest subchronic NOAEL is 2 mg/kg bw per day in female rats. A NOAEL in mice could not be derived. The LOAEL in dog was 5 mg/kg bw per day.

No indication of embryotoxicity, fetotoxicity or teratogenicity was found at the doses tested in rats (2.5 and 8 mg/kg per day for crystalline and mycelial monensin, respectively) and rabbits (0.76 mg/kg per day).

The lowest NOAEL identified from all the toxicological studies was 1.1 mg/kg bw per day based on a 2‐year chronic toxicity/carcinogenicity assay in rat. However, a NOAEL of 0.345 mg monensin sodium/kg bw per day was identified in the dog for effects on coronary artery flow and mean blood pressure after oral administration. Potential inotropic effects were considered, but no relevant effects on electrocardiogram results were seen in dogs at doses well above the lowest NOAEL of 0.345 mg monensin sodium/kg bw per day. Consequently, it was considered that a specific investigation of inotropic effects was not necessary for the risk assessment for monensin sodium.

The outcome of the literature review did not identify new data requiring consideration in the current opinion.

Overall, the FEEDAP Panel concludes that the pharmacological NOAEL of 0.345 mg monensin sodium/kg bw per day identified in the dog for acute pharmacological effects on the cardiovascular system can be considered as an appropriate basis for the acute health‐based guidance value of 0.003 mg monensin sodium/kg bw per day already established by the FEEDAP Panel in its former opinion (EFSA, [2004](#efs25891-bib-0008){ref-type="ref"}) applying an uncertainty factor of 100. The FEEDAP Panel will use this reference value to assess acute exposure of the consumers to monensin residues.

Although the guidance value established above is based on acute effects, such effects occur at a significantly lower dose than the lowest NOAEL for chronic effects (1.1 mg/kg bw per day based on absence of reduction in body weight gain in male rats in a 2‐year chronic toxicity/carcinogenicity assay). In consequence, it is considered that the same guidance value, although more conservative, would be equally appropriate for chronic risk assessment. This is supported by the ADI of 0.003 mg/kg bw derived from toxicological studies in an assessment of the same substance and from a developmental study in rabbits for maternal toxicity (EFSA, [2005](#efs25891-bib-0009){ref-type="ref"}).

### 3.2.6. Assessment of consumer safety {#efs25891-sec-0038}

The chronic exposure of consumers to monensin residues in chicken tissues is calculated (Table [6](#efs25891-tbl-0006){ref-type="table"}) following the methodology described in the Guidance on the safety of feed additives for consumers (EFSA FEEDAP Panel, [2017b](#efs25891-bib-0029){ref-type="ref"}) and using the Feed Additives Consumer Exposure (FACE) calculator available on EFSA\'s website (for further details see Appendix [B](#efs25891-sec-1002){ref-type="sec"}). The residue data, originating from residue studies (see Section [3.2.2](#efs25891-sec-0021){ref-type="sec"}), were inserted in the calculator and are summarised in Table [5](#efs25891-tbl-0005){ref-type="table"}.

###### 

Total residues (expressed as mg monensin equivalent/kg) in tissues of chickens for fattening administered 125 mg \[^14^C\]‐monensin sodium/kg feed for 6 days[1](#efs25891-note-0022){ref-type="fn"}

                                                     Liver   Kidney   Muscle[2](#efs25891-note-0023){ref-type="fn"}   Skin/fat[2](#efs25891-note-0023){ref-type="fn"}
  -------------------------------------------------- ------- -------- ----------------------------------------------- -------------------------------------------------
  TRC + 2SD[1](#efs25891-note-0022){ref-type="fn"}   0.618   0.190    0.065                                           0.301

TRC: total residue concentration; SD: standard deviation.

See Section [3.2.2](#efs25891-sec-0021){ref-type="sec"} on residue studies.

The residue concentration in muscle and skin/fat will be applied to the intake of meat at the following proportions: 90% muscle and 10% skin/fat (EFSA FEEDAP Panel, [2017b](#efs25891-bib-0029){ref-type="ref"}). This corresponds to 0.0886 mg/kg.

John Wiley & Sons, Ltd

###### 

Chronic dietary exposure of consumers to monensin total residues based on residue data in chicken tissues ‐ Summary statistics across European dietary surveys

  Population class   Number of surveys   Highest exposure estimate (mg/kg bw per day)   Refined highest exposure estimate (mg/kg bw per day)[1](#efs25891-note-0025){ref-type="fn"}   \% ADI[2](#efs25891-note-0026){ref-type="fn"}
  ------------------ ------------------- ---------------------------------------------- --------------------------------------------------------------------------------------------- -----------------------------------------------
  Infants            6                   0.0006                                         0.0003                                                                                        10%
  Toddlers           10                  0.0007                                         0.0004                                                                                        12%
  Other children     18                  0.0006                                         0.0003                                                                                        10%
  Adolescents        17                  0.0004                                         0.0002                                                                                        7%
  Adults             17                  0.0003                                         0.0002                                                                                        5%
  Elderly            14                  0.0002                                         0.0001                                                                                        3%
  Very elderly       12                  0.0002                                         0.0001                                                                                        3%

Considering only 50% of the total residue are of toxicological relevance.

ADI: 0.003 mg/kg bw.

John Wiley & Sons, Ltd

The results showed that the highest chronic exposure was for the age class 'toddlers' with 0.0007 mg/kg bw per day. Considering the toxicological relevance of the residues (50% of total residues) this exposure represents 12% of the ADI. The other age classes were between 3% and 10% of the ADI (for detailed results per age class, country and survey see Appendix [B](#efs25891-sec-1002){ref-type="sec"}, Table [B.1](#efs25891-tbl-0037){ref-type="table"}).

An acute exposure assessment is considered necessary taking into account acute pharmacological effects seen in toxicological studies. The FACE model provides results of acute dietary exposure for each single tissue for all age classes. The table reported in Appendix [B](#efs25891-sec-1002){ref-type="sec"} (Table [B.2](#efs25891-tbl-0038){ref-type="table"}) indicates that the highest exposure can be found of the age class 'other children' consuming liver (0.0034 mg/kg bw per day corresponding to 100% of the ADI), however, this value would represent 50% of the ADI when considering the toxicological relevance of the residues.

The FEEDAP Panel noted that these results, obtained with residue data in chicken tissues, can be considered as a worst‐case scenario and extrapolated to consumer exposure to monensin residues in chickens reared for laying and turkeys (Section [3.2.2](#efs25891-sec-0021){ref-type="sec"}).

The FEEDAP Panel noted that monensin sodium is authorised in the EU also as veterinary medicine for bovines which may result in exposure of consumers to monensin residues via bovine tissues and milk of dairy cows.[74](#efs25891-note-1068){ref-type="fn"} The CVMP of the EMA assessed in 2013 a residue study performed in dairy cattle (intraruminal administration with controlled release capsule, delivering approximately 335 mg monensin/day for 95 days). Tissue samples of liver, kidney, muscle and fat were collected from 10 animals 14 days after administration of the Controlled release capsule (EMA‐CVMP, [2013](#efs25891-bib-0033){ref-type="ref"}). The residue data from this study (highest values for each tissue/product as a worst‐case scenario) have been used by the FEEDAP Panel to assess the combined consumer exposure resulting from the use of monensin as a feed additive for poultry and as veterinary medicine for bovine. Table [7](#efs25891-tbl-0007){ref-type="table"} reports the marker residue values measured in the above‐mentioned study (maximum values) and the calculated total residues applying the ratios marker to total residues reported by the CVMP.

###### 

Monensin residues (mg/kg) in bovine tissues and milk after its use as veterinary medicine[1](#efs25891-note-0028){ref-type="fn"}

                                                                   Liver    Kidney    Muscle[3](#efs25891-note-0030){ref-type="fn"}   Fat[3](#efs25891-note-0030){ref-type="fn"}   Milk
  ---------------------------------------------------------------- -------- --------- ----------------------------------------------- -------------------------------------------- ---------
  Marker residue measured[2](#efs25891-note-0029){ref-type="fn"}   0.0263   0.00145   0.00084                                         0.00532                                      0.00048
  RMTR[1](#efs25891-note-0028){ref-type="fn"}                      0.05     0.05      0.05                                            0.05                                         0.027
  Calculated total residues                                        0.526    0.029     0.017                                           0.106                                        0.018

RMTR: ratio marker to total residues.

EMA‐CVMP ([2013](#efs25891-bib-0033){ref-type="ref"}).

Highest value reported by CVMP.

The residue concentration in muscle and skin/fat will be applied to the intake of meat at the following proportions: 80% muscle and 20% skin/fat (EFSA FEEDAP Panel, [2017b](#efs25891-bib-0029){ref-type="ref"}). This corresponds to 0.0348 mg/kg.

John Wiley & Sons, Ltd

The combined chronic exposure of consumers to monensin residues originating from the consumption of chicken and bovine tissues and milk is reported in Table [8](#efs25891-tbl-0008){ref-type="table"}. The results showed that the highest chronic exposure was for the age class 'other children' with 0.003 mg/kg bw per day. Considering the toxicological relevance of the residues (50% of total residues) this exposure represents 50% of the ADI. The other age classes were between 12 and 43% of the ADI (for detailed results per age class, country and survey, see Appendix [B](#efs25891-sec-1002){ref-type="sec"}, Table [B.3](#efs25891-tbl-0039){ref-type="table"}).

###### 

Chronic dietary exposure of consumers to monensin total residues based on residue data in chicken + bovine tissues/products ‐ Summary statistics across European dietary surveys

  Population class   Number of surveys   Highest exposure estimate (mg/kg bw per day)   Refined highest exposure estimate (mg/kg bw per day)[1](#efs25891-note-0032){ref-type="fn"}   \% ADI[2](#efs25891-note-0033){ref-type="fn"}
  ------------------ ------------------- ---------------------------------------------- --------------------------------------------------------------------------------------------- -----------------------------------------------
  Infants            6                   0.0026                                         0.0013                                                                                        43%
  Toddlers           10                  0.0025                                         0.0013                                                                                        42%
  Other children     18                  0.0030                                         0.0015                                                                                        50%
  Adolescents        17                  0.0013                                         0.0007                                                                                        22%
  Adults             17                  0.0007                                         0.0004                                                                                        12%
  Elderly            14                  0.0006                                         0.0003                                                                                        10%
  Very elderly       12                  0.0007                                         0.0004                                                                                        12%

Considering only 50% of the total residue are of toxicological relevance.

ADI: 0.003 mg/kg bw.

John Wiley & Sons, Ltd

The FEEDAP Panel noted that the highest contribution to exposure in all age classes comes from milk consumption (55% (adults) -- 93% (infants)).

MRLs for monensin are in force for poultry tissues.[75](#efs25891-note-1069){ref-type="fn"} The chronic exposure calculation following the Guidance on the safety of feed additives for consumers (EFSA FEEDAP Panel, [2017b](#efs25891-bib-0029){ref-type="ref"}) has been also performed calculating the total residue data derived from MRLs in poultry tissues (see Table [9](#efs25891-tbl-0009){ref-type="table"} for input data and Table [10](#efs25891-tbl-0010){ref-type="table"} for the results).

###### 

Monensin total residues calculated from MRL values[1](#efs25891-note-0034){ref-type="fn"} of poultry tissues applying the ratios marker to total residue (RMTR) for each tissue/product (mg/kg)

                                                Liver     Kidney    Muscle[3](#efs25891-note-0036){ref-type="fn"}   Skin/fat[3](#efs25891-note-0036){ref-type="fn"}
  --------------------------------------------- --------- --------- ----------------------------------------------- -------------------------------------------------
  MRLs (mg/kg wet tissue)                       0.008     0.008     0.008                                           0.025
  RMTR[2](#efs25891-note-0035){ref-type="fn"}   0.020     0.020     0.020                                           0.171
  TR~MRL~                                       **0.4**   **0.4**   **0.4**                                         **0.146**

Reg. (EC) No 180/2007.

EFSA ([2008a](#efs25891-bib-0015){ref-type="ref"}).

Considering that the calculated total residue concentration in muscle is higher than in skin/fat, this value will be applied to the intake of meat as worst‐case scenario.

John Wiley & Sons, Ltd

###### 

Chronic dietary exposure of consumers to monensin total residues derived from MRLs in poultry tissues ‐ Summary statistics across European dietary surveys

  Population class   Number of surveys   Highest exposure estimate (mg/kg bw per day)   Refined highest exposure estimate (mg/kg bw per day)[1](#efs25891-note-0038){ref-type="fn"}   \% of ADI[2](#efs25891-note-0039){ref-type="fn"}
  ------------------ ------------------- ---------------------------------------------- --------------------------------------------------------------------------------------------- --------------------------------------------------
  Infants            6                   0.0026                                         0.0013                                                                                        43%
  Toddlers           10                  0.0031                                         0.0016                                                                                        50%
  Other children     18                  0.0026                                         0.0013                                                                                        43%
  Adolescents        17                  0.0017                                         0.0009                                                                                        28%
  Adults             17                  0.0009                                         0.0005                                                                                        15%
  Elderly            14                  0.0008                                         0.0004                                                                                        13%
  Very elderly       12                  0.0008                                         0.0004                                                                                        13%

Considering only 50% of the total residue are of toxicological relevance.

ADI: 0.003 mg/kg bw.

John Wiley & Sons, Ltd

The highest exposure would be for the age class 'toddlers' with 0.0031 mg/kg bw per day representing 50% of the ADI after considering the toxicologically relevant residues (for detailed results per age class, country and survey, see Appendix [B](#efs25891-sec-1002){ref-type="sec"}, Table [B.4](#efs25891-tbl-0040){ref-type="table"}).

Acute exposure calculation has been also performed based on total residue calculated from MRLs in poultry tissues in force. The results showed that the highest exposure is due to the consumption of meat in the age class 'other children' (0.0057 mg/kg bw per day) (Appendix [B](#efs25891-sec-1002){ref-type="sec"}, Table [B.5](#efs25891-tbl-0041){ref-type="table"}). This value corresponds to 191% of the ADI, but it is 95% of the ADI when considering the toxicological relevance of the residues.

#### 3.2.6.1. Conclusions on the assessment of consumer safety {#efs25891-sec-0039}

The chronic exposure to monensin residues resulting from the use of monensin sodium as a feed additive in chickens would amount to up to 10% of the ADI (toddlers). The combined chronic exposure to monensin residues resulting from use of monensin as a feed additive in chicken and as a veterinary medicine in bovine would reach up to 48% of the ADI. Acute exposure due to the consumption of poultry tissues were found below the ADI for all age classes (up to 50%). These conclusions are extrapolated to chickens reared for laying and turkeys for fattening. Based on this, the FEEDAP Panel considers that Elancoban^®^ G200 containing monensin sodium is safe for the consumer of tissues obtained from chickens for fattening or reared for laying and turkeys fed the additive under the proposed conditions of use.

The existing MRLs for poultry tissues ensure consumer safety (acute and chronic exposure; all age classes) provided that the withdrawal period of 1 day is respected.

Considering the uncertainties on the identity and characterisation of the production strain and the lack of demonstration of the absence of the production strain and its DNA on the final product, the FEEDAP Panel cannot conclude on the safety of the additive for the consumers.

### 3.2.7. Safety for the user {#efs25891-sec-0040}

#### 3.2.7.1. Effects on eyes and skin {#efs25891-sec-0041}

No new data have been submitted by the applicant.

The same studies as had been assessed in the former opinion (EFSA, [2004](#efs25891-bib-0008){ref-type="ref"}) were re‐submitted by the applicant and were re‐assessed by the FEEDAP Panel.[76](#efs25891-note-1070){ref-type="fn"}

The FEEDAP Panel concluded that both mycelial monensin and Elancoban^®^ are 'very irritant for the eye. Neither mycelial monensin nor Elancoban^®^ cause skin irritancy but systemic toxicity may occur following skin exposure. Elancoban^®^ is a weak sensitizer by skin exposure and should be regarded as a potential skin sensitizer in humans'. 'The observations of effects in exposed workers in the feed industry confirm that monensin can cause irritancy to eyes and contact dermatitis'.

#### 3.2.7.2. Effects on the respiratory system {#efs25891-sec-0042}

No new data have been submitted by the applicant.

The same studies assessed in the former opinion (EFSA, [2004](#efs25891-bib-0008){ref-type="ref"}) were re‐submitted by the applicant and re‐assessed by the FEEDAP Panel.[77](#efs25891-note-1071){ref-type="fn"} The FEEDAP Panel considered all the studies submitted and concluded that only one rat study[78](#efs25891-note-1072){ref-type="fn"} and one in dogs[79](#efs25891-note-1073){ref-type="fn"} were suitable for assessment of user safety. It was concluded that 'inhalation exposure of the dog and the rat to a high concentration of a respirable fraction of dust from Elancoban^®^ caused systemic adverse effects on the heart', Although the repeat‐concentration study in dogs (90 days with 5 days/week of 6‐h exposure/day) showed a number of limitations in design (e.g. low number of animals), the lowest no observed effect concentration (NOEC) (0.015 mg monensin/m^3^) is retained for the assessment.

Considering that Elancoban^®^ should be regarded as a potential skin sensitiser in humans, its potential for respiratory sensitisation cannot be excluded.

#### 3.2.7.3. Inhalation exposure {#efs25891-sec-0043}

The FEEDAP Panel reviewed the information on the physical properties of the additive and on the inhalation toxicity of monensin.

The potential exposure of users by handling the additive to inhaled monensin was calculated according to the Technical Guidance on User safety (EFSA FEEDAP Panel, [2012b](#efs25891-bib-0026){ref-type="ref"}) and reported in Appendix [C](#efs25891-sec-1003){ref-type="sec"}. From the dusting potential and monensin content of the dust, the monensin concentration in the inhaled air could be calculated as 36 mg/m^3^, resulting in inhalation exposure of 5 mg monensin from Elancoban^®^ G200 per person during an 8‐h working day. Exposure to monensin by the respirable fraction (\< 10 μm) of the dust only (25--31%) would be about 1.6 mg. Comparing the monensin concentration in the inhaled air of 36 mg/m^3^ and the NOEC in dogs of 0.015 mg/m^3^, the inhalation exposure of users handling Elancoban^®^ G200 is considered a risk.

#### 3.2.7.4. Conclusions on the safety for the user {#efs25891-sec-0044}

The FEEDAP Panel concludes that both mycelial monensin and Elancoban^®^ are very irritant for the eye. Neither mycelial monensin nor Elancoban^®^ cause skin irritancy but systemic toxicity may occur following skin exposure.

Elancoban^®^ should be regarded as a potential skin and respiratory sensitiser.

On the basis of the available information, inhalation exposure is considered a risk to persons handling the additive.

Considering the uncertainties on the identity and characterisation of the production strain and the lack of demonstration of the absence of the production strain and its DNA on the final product, the FEEDAP Panel cannot conclude on the safety of the additive for the users.

### 3.2.8. Safety for the environment {#efs25891-sec-0045}

The active ingredient under assessment is not a physiological/natural substance of established safety for the environment. The additive is also not intended for companion animals only. Consequently, according to Regulation (EC) No 429/2008, the Phase I assessment has to be continued to determine the predicted environmental concentration (PEC), according to the proposed conditions of use in chickens for fattening. In Phase I and Phase II, initially a total residues approach will be taken, meaning that the PECs will be calculated, based on the assumption that the additive is excreted 100% as parent compound.

The FEEDAP Panel evaluated the new studies provided in the dossier and re‐assessed the studies already considered in its previous opinions (EFSA, [2004](#efs25891-bib-0008){ref-type="ref"}). The applicant performed a literature search[80](#efs25891-note-1074){ref-type="fn"} on the environmental safety of monensin sodium.[81](#efs25891-note-1075){ref-type="fn"} The full search strategy has been provided in the dossier. The outcome of the literature review (97 literature references were identified from a total of 1248 references) is reported in Appendix [A](#efs25891-sec-1001){ref-type="sec"} and the relevant papers used for the assessment are quoted in the text below.

#### 3.2.8.1. Phase I {#efs25891-sec-0046}

**Physicochemical properties**

The physicochemical properties of monensin sodium are summarised in Table [11](#efs25891-tbl-0011){ref-type="table"}.

###### 

Physicochemical properties of monensin sodium

+---------------------------------------------------------------------------------------------+------------------------+------+
| Property                                                                                    | Value                  | Unit |
+=============================================================================================+========================+======+
| Octanol/water partition coefficient[1](#efs25891-note-0040){ref-type="fn"} (log K~ow~ 25°C) | 4.24 (pH 5)            | --   |
|                                                                                             |                        |      |
|                                                                                             | 2.75--2.87 (pH 7)      |      |
|                                                                                             |                        |      |
|                                                                                             | 3.79 (pH 9)            |      |
+---------------------------------------------------------------------------------------------+------------------------+------+
| Water solubility[2](#efs25891-note-0041){ref-type="fn"} (20°C)                              | 109.0 (Milli‐Ro water) | mg/L |
|                                                                                             |                        |      |
|                                                                                             | 4.809 (pH 7)           |      |
|                                                                                             |                        |      |
|                                                                                             | 8.912 (pH 9)           |      |
+---------------------------------------------------------------------------------------------+------------------------+------+
| Dissociation constant[3](#efs25891-note-0042){ref-type="fn"} (pKa)                          | 6.6                    | --   |
+---------------------------------------------------------------------------------------------+------------------------+------+
| Vapour pressure[4](#efs25891-note-0043){ref-type="fn"} (VP)                                 | 3 × 10^−28^            | Pa   |
+---------------------------------------------------------------------------------------------+------------------------+------+

Determined by the shake flask method, FDA environmental technical assistance section 3.02 March 1987. Technical dossier/Supplementary information May 2015/Reference 9.

Determined in accordance with OECD 105. At pH 4 monensin sodium degraded after 24 h incubation at approximately 30°C. Technical dossier/Supplementary information May 2015/Reference 7.

Merck Index, 2013. Technical dossier/Supplementary information May 2015/Reference 8.

EPI Suite, 2015.

John Wiley & Sons, Ltd

**Fate and behaviour**

*Fate in soil*

[Adsorption/desorption in soil]{.ul}

A study[82](#efs25891-note-1076){ref-type="fn"} on adsorption/desorption (K~oc~) was conducted in accordance with OECD 106 on five soils. Soil suspensions in 0.01 M CaCl~2~ were dosed with monensin and equilibrated for 2, 4, 6, 24 and 48 h. Concentration of the test substance in the aqueous phase was determined using liquid scintillation counting (LSC). Equilibrium (quasi‐equilibrium) was attained after approximately 24 h of equilibration mixing by a shaker or 0.5 h mixing by a vortexer.

For desorption data, the solid phase was re‐suspended in 0.01 M CaCl~2~, and the concentrations of monensin in both the aqueous phase and the soil solids determined at quasi‐equilibrium. The results of the adsorption of monensin sodium in different soils are presented in Table [12](#efs25891-tbl-0012){ref-type="table"}.

###### 

Adsorption of monensin sodium in different soils

  Soil                       pH    %OC   K~oc~ (mL/g)   1/n    K~om~ (mL/g)
  -------------------------- ----- ----- -------------- ------ --------------
  Clay loam (TB‐PF)          7.2   5.0   408            1.06   237
  Sandy clay loam (MSF‐PF)   6.2   1.9   555            0.97   322
  Clay loam (Du‐Loam)        5.2   4.1   396            1.07   230
  Loamy sand (Roger Myron)   5.7   1.3   439            1.04   255
  Clay (Montana Clay)        7.7   0.7   524            0.95   304
  Geometric mean                         460                   267

%OC: % of organic carbon; K~oc~: adsorption coefficient corrected for soil organic carbon content; K~om~ = K~oc~/1.724.

John Wiley & Sons, Ltd

The monensin distribution coefficients for the studied soils in the adsorption stage ranged from 3.7 to 20.4 mL/g and in the desorption stage from 5.6 to 26.8 mL/g. The organic carbon normalised distribution coefficients ranged from 396 to 555 mL/g at the adsorption stage of the test. The geometric mean value of 460 mL/g for K~oc~ will be considered the reference input data for PEC calculations.

[Degradation in soil]{.ul}

The applicant submitted the same study that was already assessed by the FEEDAP Panel in 2004 (EFSA, [2004](#efs25891-bib-0008){ref-type="ref"}). In the context of the present assessment, the same study was re‐evaluated as follow. The degradation of \[^14^C\]‐monensin under aerobic conditions was assessed in three different soils, sandy loam, silty loam and clay loam soils (pH 7.3--7.5) at an application rate of 1.5 mg a.i./kg soil at 20 ± 2 °C for up to 84 days.[83](#efs25891-note-1077){ref-type="fn"} This GLP study was conducted in accordance with the procedures outlined in SETAC document 'Procedures for assessing the Environmental Fate and Ecotoxicity of Pesticides (Lynch, [1995](#efs25891-bib-0039){ref-type="ref"}). The FEEDAP Panel noted that at the time of the initiation of the study, OECD 307 had not been adopted and the procedures followed in this study were the recognised standard at that time and are one of the procedures used for the preparation of OECD 307.

Radioactivity levels in all soil types declined over the duration of the study (84 days) which overlapped with an increase in ^14^CO~2~ evolution. At the end of the study, ^14^CO~2~ accounted for 43--81% of applied radioactivity, demonstrating significant mineralisation of monensin. Monensin degraded to a number of unidentified components, one of which increased at various intervals during incubation, up to 36% in clay loam, but declined to less than 2% at study termination. Only 1--2% of applied radioactivity was characterised as monensin at the end of the study, in all the three soils tested.

Degradation of monensin in all soils was rapid with DT~50~ values, recalculated according single first‐order (SFO) kinetics of 4, 10 and 6 days for sandy loam, silt loam and clay loam, respectively. The corresponding DT~90~ values ranges are 13, 32 and 19 days for the same soil types. This indicates that monensin would not be persistent, nor accumulate in the soil. Since just three soils are available, the worst‐case value of 10 days is considered the most appropriate for further evaluation. This value, normalised to 12°C using the Arrhenius equation,[84](#efs25891-note-1078){ref-type="fn"} corresponds to a DT~50~ of 21 days.

[Literature review]{.ul}

In addition to the above, the FEEDAP Panel reviewed the outcome of the literature review performed by the applicant regarding the sorption, degradation and environmental risk of monensin sodium.

The sorption characteristics of monensin in soil are reported in two studies (El Sayed and Prasher 2014, Sassman and Lee, [2007](#efs25891-bib-0040){ref-type="ref"}). Sassman and Lee ([2007](#efs25891-bib-0040){ref-type="ref"}) used a range of eight different soils, from United States and Korea, and reported that the sorption coefficients (log K~oc~) ranged from 2.1 to 3.8. The results derived from the OECD 106 study performed by the applicant are comprised in a shorter range, (log K~oc~ ranges from 2.6 to 2.7); however, the OECD 106 study is performed on European soils and both adsorption and desorption values were reported. The sorption value reported in the El Sayed and Prasher (2014) is related to the interaction with a non‐ionic surfactant, Brij35, added to water used to irrigate soils. While the relative data within this study provide valuable information, the single soil sorption value is considered of limited use to assess monensin used as a feed additive. The sorption of monensin was found to decrease with increasing levels of surfactant suggesting that, where water for irrigation contains surfactants, monensin could move more rapidly to greater depths in the soil and potentially into groundwater. In contrast, other studies suggest that monensin applied through the use of fertilisers is unlikely to reach groundwater due to the adsorption to particulate matter and the rapid degradation in soil. Carlson and Mabury ([2006](#efs25891-bib-0004){ref-type="ref"}) did not detect monensin below a soil depth of 25 cm despite a surface concentration up to 1,465 μg/kg.

For degradation in soil, there is 'typical range' from 2 to 13 days (El Sayed and Prasher, 2014; Carlson and Mabury, [2006](#efs25891-bib-0004){ref-type="ref"}; Sassman and Lee, [2007](#efs25891-bib-0040){ref-type="ref"}; Donoho, [1984](#efs25891-bib-0005){ref-type="ref"}; Yoshida et al., [2013](#efs25891-bib-0041){ref-type="ref"}; EFSA, [2004](#efs25891-bib-0008){ref-type="ref"}, [2005](#efs25891-bib-0009){ref-type="ref"}), but a single study falls outside of this with a range from 3 to 36 weeks. (Zizek et al., [2011](#efs25891-bib-0803){ref-type="ref"}). Explanations for the variability include differences in the organic carbon content, pH, soil type, temperature and moisture content. The majority of data reported are dissipation DT~50~ rather than degradation DT~50~.

In conclusion, data that are available from literature are generally not considered to be the most relevant data to be used in evaluating the potential concentration of monensin in environment nor its adsorption potential. The FEEDAP Panel considered more appropriate to use the values for adsorption coefficient from the study submitted by the applicant. The same approach has been taken regarding the degradation. A half‐life of 10 days in soil from the laboratory studies has been retained in the current assessment. This value is obtained from a radiolabelled degradation study using three soil types and while there is some suggestion that laboratory studies give a higher half‐life value than field plots, it is considered that the radiolabelled study provides a degradation rate rather than disappearance.

*Conclusion on fate and behaviour*

A K~oc~ of 460 L/kg and a DT~50~ of 21 days at 12°C will be used for the assessment.

**Predicted environmental concentrations (PECs)**

The calculated PEC initial values are given in Table [13](#efs25891-tbl-0013){ref-type="table"}. The highest dose recommended for chicken for fattening (125 mg monensin/kg feed) was considered, since this value provides the worst‐case exposure, which covers also chickens reared for laying and turkey.

###### 

Initial predicted environmental concentrations (PECs) of monensin sodium, in soil (μg/kg), groundwater (μg/L), surface water (μg/L) and sediment (μg/kg dry weight)

  Input                           Value
  ------------------------------- -------------
  Dose (mg monensin/kg feed)      125
  Molecular weight                692.86
  Vapour pressure (Pa)            3 × 10^−28^
  Solubility (mg/L)               4,809
  K~oc~ (L/kg)                    460
  DT~50~ in soil at 12°C (days)   21
  **Output**                      
  PEC~soil~                       649
  PEC~ground\ water~              70
  PEC~surface\ water~             23
  PEC~sediment~                   647

K~oc~: adsorption or desorption coefficient corrected for soil organic carbon content; DT~50~: disappearance time 50 (the time within which the concentration of the test substance is reduced by 50%.

John Wiley & Sons, Ltd

The Phase I PEC trigger values are exceeded; therefore a Phase II assessment is considered necessary.

#### 3.2.8.2. Phase II {#efs25891-sec-0047}

**Exposure assessment**

*PECs calculation refined in Phase II*

*PEC* ~*soil*~ *refined for metabolism and degradation in manure*

In 2004, the FEEDAP Panel considered that the ionophoric activity of monensin sodium and its metabolites in chicken excreta would not exceed in total 20% of the orally administered dose (EFSA, [2004](#efs25891-bib-0008){ref-type="ref"}). In the absence of new data, for the current assessment the FEEDAP Panel used the same approach and the dose used to calculate the PEC~soil~ refined based on metabolism was 125 × 0.2 = 25 mg/kg feed.

Further refinement of the initial PEC might be made based on the degradation in excreta. A wide variation is reported for the half‐life for both litter/manure and soil. The half‐life reported in fresh manure/litter generally falls within the ranges from 4 to 63 days, (Arikan et al., [2016](#efs25891-bib-0801){ref-type="ref"}; Dolliver et al., 2008; EFSA, [2004](#efs25891-bib-0008){ref-type="ref"}). Due the variability across Europe, a DT~50~ of 63 days may be considered appropriate to refine PEC~soil~. Refinement of the PEC is based on a storage time equal to the period of the cycle for chickens for fattening (41 days), that is to say to introduce a degradation factor in PEC calculation:$$\text{PEC}_{{soil}\,\,{refined}} = \text{PEC}_{soil} \times \exp{( - \text{kT}_{st}/2)}$$where,

k = ln2/DT~50\ manure~

T~st~ = length of time manure is stored.

The refined PEC~soil~, PEC~groundwater~, PEC~surface\ water~ and PEC~sediment~ based on metabolism and degradation in excreta are reported in Table [14](#efs25891-tbl-0014){ref-type="table"}.

###### 

Refined predicted environmental concentrations (PECs) of monensin sodium, in soil (μg/kg), groundwater (μg/L), surface water (μg/L) and sediment (μg/kg dry weight)

  Input                            Value
  -------------------------------- -------------
  Dose (mg/kg feed)                25
  Molecular weight                 692.86
  Vapour Pressure (Pa) (at 25°C)   3 × 10^−28^
  Solubility (mg/L)                4,809
  K~oc~ (L/kg)                     460
  DT~50~ in soil at 12°C (days)    21
  **Output**                       
  PEC~soil~                        104
  PEC~groundwater~                 11
  PEC~surface\ water~              3.7
  PEC~sediment~                    103

K~oc~: adsorption or desorption coefficient corrected for soil organic carbon content; DT~50~: disappearance time 50 (the time within which the concentration of the test substance.

John Wiley & Sons, Ltd

When the PEC~groundwater~ is set equal to the concentration in pore water, based on a worst‐case assumption (the total residue approach), the monensin concentration exceeds the trigger value of 0.1 μg/L identified by the EU as quality standard.[85](#efs25891-note-1079){ref-type="fn"}

*PEC* ~*groundwater*~ *refined with FOCUS*

Leaching of monensin to groundwater was simulated using the FOCUS recommended leaching model PEARL (FOCUS Version 4.4.4) (EFSA, 2008c). The calculated groundwater concentrations for the scenarios Jokioinen and Piacenza were below 0.001 μg/L. No concern for groundwater is expected from the use on monensin sodium in chickens and turkeys.

*Conclusions on PEC used for calculation*

The following values are used for the assessment: PEC~soil~ of 104 μg/kg, PEC~surface\ water~ of 3.7 μg/L and PEC~sediment~ 103 μg/kg dry weight.

**Ecotoxicity studies**

[Toxicity to soil organisms]{.ul}

*Effects on plants*

Effect of monensin sodium on the emergence and growth of seedlings of winter oat (*Avena sativa*), radish (*Raphanus sativus*) and mung bean (*Phaseolus aureu*s) was studied in accordance with OECD TG 208[86](#efs25891-note-1080){ref-type="fn"} in sandy loam soil mixed with horticultural grade sand at measured exposure concentration of 0.31, 4.35 and 35.97 mg/kg (nominal levels of 0.3, 3.0 and 30 mg/kg). The test period was 14 days after at least 50% emergence in controls. This study was already considered in EFSA opinion in 2004 (EFSA, [2004](#efs25891-bib-0008){ref-type="ref"}) and re‐evaluated in the current assessment.

A lowest NOEC of 4.35 mg/kg was determined for three species of plant, for both emergence and growth (fresh weight). However, the emergence of winter outs was not affected even at the highest tested concentration. The median lethal concentration (LC~50~) values for emergence and the median effective concentration (EC~50~) values for growth are summarised in Table [15](#efs25891-tbl-0015){ref-type="table"}. Due to the limited number of concentrations tested, the study failed to provide emergence LC~50~ value for winter outs (best estimate greater than 35.97 mg/kg) as well as the growth EC~50~ value (best estimate greater than 4.347 mg/kg) for radish.

###### 

Monensin ecotoxicological effects data for terrestrial plants (mg monensin/kg)

  Plant species   Emergence   Growth               
  --------------- ----------- ---------- --------- ------
  Winter oats     \> 35.97    \> 35.97   12.9      4.35
  Radish          9.8         4.35       \> 4.35   4.35
  Mung bean       24.1        4.35       32.9      4.35

LC~50~: median lethal concentration; NOEC: no observed effect concentration; EC~50~: median effective concentration.

John Wiley & Sons, Ltd

Radish appeared to be the most sensitive species. At the highest tested concentration (36 mg/kg), no plants emerged. The other species showed a significant reduction in growth at this concentration.

In a newly performed study,[87](#efs25891-note-1081){ref-type="fn"} the effects of monensin on emergence and growth for seven species of plants were evaluated. The species tested were Oat (*Avena sativa*), Radish (*Raphanus sativus*, the most sensitive species from the previous study), mung bean (*Phaseolus aureus*), oilseed Rape (*Brassica napus*), perennial ryegrass (*Lolium perenne*), turnip (*Brassica rapa*) and wheat (*Triticum aestivum*). Nominal concentrations tested were 0, 0.5, 1, 2, 4, 8 and 16 mg/kg for perennial ryegrass; 0, 1, 2, 4, 8, 16 and 32 mg/kg for oats and wheat; and 0, 2, 4, 8, 16 and 32 mg/kg for the other plant species. The results are summarised in Table [16](#efs25891-tbl-0016){ref-type="table"}.

###### 

Monensin ecotoxicological effects data for terrestrial plants (mg/kg)

  Plant species        Emergence   Growth          
  -------------------- ----------- -------- ------ -----
  Oats                 \> 32       ≥ 32     20.3   8.0
  Radish               26.8        8.0      11.9   8.0
  Mung Bean            12.1        4.0      18.4   8.0
  Oil seed rape        \> 32       16.0     14.6   8.0
  Perennial ryegrass   \> 16       ≥ 16     7.2    2.0
  Turnip               \> 24.1     16.0     8.4    4.0
  Wheat                \> 32       ≥ 32     16.2   4.0

LC~50~: median lethal concentration; NOEC: no observed effect concentration; EC~50~: median effective concentration.

John Wiley & Sons, Ltd

The most sensitive plant species was Perennial Ryegrass with an EC~50~ for growth of 7.2 mg/kg and a NOEC for growth of 2.0 mg/kg. However, it should be noted that either emergence LC~50~ or NOEC for this species could not be estimated, as the emergence was not significantly affected even at the highest tested concentration (16 mg/kg). For crops likely to be grown on cultivated soils receiving poultry excreta the most sensitive species was mung bean with an LC~50~ for emergence of 12.1 mg/kg and a NOEC for emergence of 4.0 mg/kg. However, it should be noted that the exposure duration in test with mung beans lasted considerably longer (28 days after 50% emergence of control plants vs. 14 days after 50% emergence in controls in tests with any other plants).

Taken together, the lowest endpoint was growth NOEC of 2.0 mg/kg for perennial ryegrass.

*Effect on earthworms*

The acute toxicity of monensin (nominal concentrations of 50, 125, 250, 500 and 1,000 mg/kg) to the earthworm *Eisenia foetida* was already assessed in the 2004 FEEDAP opinion (EFSA, [2004](#efs25891-bib-0008){ref-type="ref"}).[88](#efs25891-note-1082){ref-type="fn"} The study was conducted in accordance with OECD 207 and indicated that 7‐ and 14‐day EC~50~ was 690.3 and 264.2 mg/kg, respectively. At 14 days, the mortality values showed a nonlinear response and hence the 14‐day EC~50~ should be treated with caution.

A newly performed study, performed in accordance with OECD 222[89](#efs25891-note-1083){ref-type="fn"} was submitted to evaluate the chronic effect of monensin to the earthworm *E. foetida*. The survival and reproduction were assessed upon exposure to nominal concentrations of 13, 25, 50, 100 and 200 mg/kg monensin factor A for 28‐ and 56‐day exposure. The 28‐day LC~50~ was determined as 76 mg/kg, and the NOEC for both survival and weight change was 50 mg/kg. For reproduction the 56‐day EC~50~ was 70 mg/kg, and the 56‐day NOEC was 50 mg/kg.

Recent studies reported in the literature, on the impact of monensin on the reproductive capacity of earthworms and Isopods have shown that while Isopods are relatively unaffected by monensin in the soil or the feed (Zizek et al., [2011](#efs25891-bib-0803){ref-type="ref"}; Zidar and Zizek, [2012](#efs25891-bib-0802){ref-type="ref"}), earthworms are more sensitive. The NOEC and EC~50~ for earthworm reproduction were reported to be 3.5 and 12.7 mg/kg soil, equivalent to nominal concentrations of 5 and 16.5 mg/kg soil (Zizek et al., [2011](#efs25891-bib-0803){ref-type="ref"}). There is no apparent reason for the 10‐fold difference in the NOEC reported in the literature and those provided in the assessment provided by the applicant. Both studies are reported to be in accordance with OECD 222. It is noted that in the paper of Zizek et al. ([2011](#efs25891-bib-0803){ref-type="ref"}) a soil degradation value considerably different to other reports (25, 28, 29, 30 and 36 weeks in comparison to 2--13 days) is reported. Therefore, it is considered appropriate to retain the applicant own data for the risk evaluation.

Taken together, the lowest *E. foetida* endpoint was 28‐day survival/56‐day reproduction NOEC of 50 mg/kg.

*Effects on soil microorganisms*

The potential effects of monensin on the rate of microbial respiration and on the nitrification and nitrogen‐mineralisation capacity of soil microflora under aerobic conditions were investigated in a study conducted to OECD guidelines 216 and 217.[90](#efs25891-note-1084){ref-type="fn"} The study was already assessed in the 2014 FEEDAP opinion and it was concluded that the NOEC for effect on soil respiration and soil nitrification is established at \> 15 mg/k soil. The same conclusions are retained for the current assessment.

[Toxicity to aquatic organisms]{.ul}

*Effect on algae*

A static toxicity test (OECD 201) was conducted to evaluate the effects of monensin on the green alga *Selenastrum capricornutum*. The study was already assessed in 2004 (EFSA, [2004](#efs25891-bib-0008){ref-type="ref"}) and re‐evaluated in the context of the current opinion; the same conclusions are retained for the current assessment.[91](#efs25891-note-1085){ref-type="fn"} The 72‐h E~r~C~50~ (median effective concentration which results in 50% reduction in growth rate) values for area under the curve and average specific growth rate were 0.98 mg/L and 4.33 mg/L, respectively. The NOEC\'s were 0.055 and 0.32 mg/L for area under the curve and average specific growth rate, respectively. The E~r~C~50~ of 4.33 mg/L has been used for aquatic risk assessments.

*Effect on crustaceans*

The toxicity of monensin to *Daphnia magna* has been investigated in a 48‐h static test.[92](#efs25891-note-1086){ref-type="fn"} The results of the study were already mentioned in 2004 (EFSA, [2004](#efs25891-bib-0008){ref-type="ref"}) but the original report was not available for the evaluation. While not conducted to current OECD guidelines, it is a GLP study and the data are considered acceptable. First‐instar of *D. magna* (i.e. ≤ 24 h old) were exposed to assayed concentrations of 0.0 (control), 2.6, 4.2, 5.6, 7.1, 10.8, 14.4 and 18.1 mg/L of monensin for 48 h. The monensin sodium exposure levels remained relatively stable over the test period. Test solutions temperature averaged 20°C and had the following water quality characteristics: average dissolved oxygen 8.1 mg/L; pH averaged 8.5 and ranged from 8.2 to 8.6, total hardness 120 mg/L as CaCO~3~; total alkalinity 135 mg/L as CaCO~3~; and conductivity 250 μmhos/cm. No physical signs of toxicity were observed in *Daphnia* populations exposed to monensin concentrations ≤ 4.2 mg/L. Concentration related immobilisation frequencies of 7% to 100% occurred at monensin concentrations ≥ 5.6 mg/L. The NOEC was 4.2 mg/L and the 48‐h EC~50~ was 10.7 mg/L.

*Effect on fish*

The toxicity of monensin to fish has been investigated in a 96‐h static test.[93](#efs25891-note-1087){ref-type="fn"} The results of the study were already mentioned in 2004 (EFSA, [2004](#efs25891-bib-0008){ref-type="ref"}) but the original report was not available for the evaluation. While this study is not conducted to current OECD guidelines, it is a GLP study and the data are considered to be acceptable. Juvenile rainbow trout were exposed to test solutions with assayed monensin concentrations of 0 (control), 0.7, 1.12, 1.48, 4.3, 5.2, 6.6, 8.2, 10.6, 12.5 and 15.7 mg/L. The monensin sodium exposure levels remained relatively stable over the test period. The water quality characteristics were as follows: pH 8.0--8.4; dissolved oxygen 10.4 mg/L; temperature 25°C; total hardness 120 mg/L as CaCO~3~; total alkalinity 145 mg/L as CaCO~3~; and conductivity 240 μmhos/cm. No mortality or signs of sublethal toxicity were observed at monensin concentrations of ≤ 0.7 mg/L. Concentration related signs of toxicity ranging from hypoactivity to death occurred at monensin concentrations ≥ 1.12 mg/L. Mortality frequencies of 10% to 100% occurred at concentrations of 6.6 up to 15.7 mg/L. The acute NOEC of monensin was 0.7 mg/L and the 96‐h LC~50~ was 9 mg/L.

[Effect on sediment dwelling organisms]{.ul}

No data on sediment were submitted. A log K~oc~ or log K~ow~ ≥ 3 for an organic chemical is used as a trigger value for sediment effect assessment (ECHA, [2008](#efs25891-bib-0007){ref-type="ref"}). The predicted no effect concentration in sediment (PNEC~sed~) calculated based on equilibrium partitioning is 105.8 μg/kg for monensin sodium. Calculation was performed with a K~oc~ of 460 L/kg and a PNEC~surfacewater~ of 4.3 μg/L for monensin sodium.

[Conclusions on the ecotoxic effect of monensin sodium on soil, water and sediment]{.ul}

For the terrestrial compartment, data are available for plants, earthworms and microorganisms. The results of newly conducted study with earthworms are considered valid and reliable, so the risk characterisation is based on chronic reproduction NOEC value for earthworms of 50 mg/kg and appropriate assessment factor of 10 (EFSA, [2008c](#efs25891-bib-0017){ref-type="ref"}). The newly submitted plant study was conducted with seven plant species (including the most sensitive tested in the previous one). The results are considered valid and reliable. The NOEC of the most sensitive endpoint (2.0 mg/kg) out of seven species tested is used for risk characterisation with the appropriate assessment factor of 10 (EFSA, [2008c](#efs25891-bib-0017){ref-type="ref"}).

For the aquatic compartment, data are available for algae, aquatic invertebrates, and fish. The ErC~50~ used in the assessment is 4.3 mg/L for algae, respectively. The 48‐h EC~50~ for immobilisation of daphnids was determined to be 10.7 mg monensin sodium/L and the 96‐h LC~50~ for fish was 9.8 mg monensin sodium/L.

Ecotoxicological data for sediment‐dwelling invertebrates were not provided for the sediment compartment. The PNEC for sediment, calculated based on equilibrium partitioning, is 105.8 μg/kg for monensin sodium.

**Risk characterisation (PEC/PNEC ratio)**

The risk characterisation ratios for terrestrial and aquatic compartment are reported in Tables [17](#efs25891-tbl-0017){ref-type="table"} and [18](#efs25891-tbl-0018){ref-type="table"}. The risk characterisation for sediment is reported in Table [19](#efs25891-tbl-0019){ref-type="table"}.

###### 

Risk characterisation of monensin (PEC/PNEC ratio) for terrestrial compartment

  Taxa        PEC~soil~ (μg/kg)   NOEC (mg/kg)   AF    PNEC (μg/kg)   PEC/PNEC
  ----------- ------------------- -------------- ----- -------------- ----------
  Earthworm   104                 50             10    5,000          0.02
  Plants      2.0                 10             200   0.52           

AF: assessment factor; PEC: predicted environmental concentration; PNEC: predicted no effect concentration; NOEC: no observed effect concentration.

John Wiley & Sons, Ltd

###### 

Risk characterisation (PEC/PNEC ratio) for aquatic compartment

+-----------------------------+---------------------------------------------+---------------------------------------------+------+-------------+----------+
| Taxa                        | PEC~surfacewater~ (μg/L)                    | 72‐h E~r~C~50~/48‐EC~50~/96‐h LC~50~ (mg/L) | AF   | PNEC (μg/L) | PEC/PNEC |
+=============================+=============================================+=============================================+======+=============+==========+
| **Algae**                   | 3.7                                         | 4.3[1](#efs25891-note-0051){ref-type="fn"}  | 1000 | 4.30        | 0.86     |
|                             |                                             |                                             |      |             |          |
| *Selenastrum capricornutum* |                                             |                                             |      |             |          |
+-----------------------------+---------------------------------------------+---------------------------------------------+------+-------------+----------+
| **Aquatic invertebrates**   | 10.7[2](#efs25891-note-0052){ref-type="fn"} | 1000                                        |      |             |          |
|                             |                                             |                                             |      |             |          |
| *Daphnia magna*             |                                             |                                             |      |             |          |
+-----------------------------+---------------------------------------------+---------------------------------------------+------+-------------+----------+
| **Fish**                    | 9.0[3](#efs25891-note-0053){ref-type="fn"}  | 1000                                        |      |             |          |
|                             |                                             |                                             |      |             |          |
| *Salmo gairdneri*           |                                             |                                             |      |             |          |
+-----------------------------+---------------------------------------------+---------------------------------------------+------+-------------+----------+

AF: assessment factor (1,000 for acute studies and 100 for chronic); PEC: predicted environmental concentration; PNEC: predicted no effect concentration; E~r~C~50~: median effective concentration; EC~50~: median effective concentration; LC~50~: median lethal concentration.

72‐h E~r~C~50~.

48‐h EC~50~.

96‐h LC~50~.

John Wiley & Sons, Ltd

###### 

Risk characterisation (PEC/PNEC ratio) for sediment

  Taxa        PEC~sediment~ (μg/kg dry weight)   NOEC (mg/kg)   AF   PNEC (μg/kg)   PEC/PNEC
  ----------- ---------------------------------- -------------- ---- -------------- ----------
  ***EqP***   103                                --             --   105.8          0.97

AF: assessment factor; PEC: predicted environmental concentration; PNEC: predicted no effect concentration; NOEC: no observed effect concentration.

John Wiley & Sons, Ltd

**Bioaccumulation and risk for secondary poisoning**

No data on bioaccumulation on monensin sodium were submitted. The highest log K~OW~ of 4.24 was reported at pH 5, log K~OW~ at pH 7 was reported at range 2.75--2.87 and 3.79 at pH 9. There is evidence that monensin is degraded in the animal body (see Section [3.2.2](#efs25891-sec-0021){ref-type="sec"}), therefore, bioaccumulation and risk for secondary poisoning is unlikely.

#### 3.2.8.3. Conclusions on safety for the environment {#efs25891-sec-0048}

The use of monensin sodium from Elancoban^®^ G200 in complete feed for chickens for fattening does not pose a risk for the terrestrial compartment, aquatic compartment and sediment. The bioaccumulation potential of monensin in the environment is low. These conclusions are extended to chickens reared for laying and turkeys.

Moreover, considering the uncertainties on the identity and characterisation of the production strain and the lack of demonstration of the absence of the production strain and its DNA on the final product, the FEEDAP Panel cannot conclude on the safety of the additive for the environment.

3.3. Efficacy {#efs25891-sec-0049}
-------------

For coccidiostats under re‐evaluation, efficacy data should derive from two types of target animal experiments: (a) natural/artificial infection to simulate use conditions (e.g., floor pen studies with poultry), at least one of the locations should be in the EU, (b) actual use conditions in field trials, all should be done in the EU within the last 5 years. Anticoccidial sensitivity tests (ASTs) could replace field trials provided they follow the criteria mentioned in the relevant guidance document on coccidiostats and histomonostats (EFSA FEEDAP Panel, [2011a](#efs25891-bib-0021){ref-type="ref"}).[94](#efs25891-note-1088){ref-type="fn"}

### 3.3.1. Efficacy in chickens for fattening {#efs25891-sec-0050}

The applicant submitted three floor pens studies, three ASTs performed with recent field isolates and two ASTs performed with laboratory strains. These last two studies were not considered for the demonstration of efficacy because the laboratory strains do not represent field conditions (EFSA FEEDAP Panel, [2011a](#efs25891-bib-0021){ref-type="ref"}).

#### 3.3.1.1. Floor pen studies in chickens for fattening {#efs25891-sec-0051}

Three floor pen trials in chickens for fattening, conducted in 2011--2012, were submitted.[95](#efs25891-note-1089){ref-type="fn"} In trial 3, two parallel experiments with different inoculates were performed.[96](#efs25891-note-1090){ref-type="fn"} In each trial, 1‐day‐old chickens were penned and distributed into three treatments, an uninfected untreated control group (UUC), an infected untreated control group (IUC) and an infected treated group (IT). The IT group received feed containing 100 mg monensin sodium/kg feed, the lowest dose applied. The intended dietary monensin concentration was analytically confirmed (see Table [20](#efs25891-tbl-0020){ref-type="table"}). In the infected groups, all birds were inoculated with recent field isolates of pathogenic *Eimeria* species. Animal health and mortality were monitored daily. Feed intake and body weight of the animals were measured, feed to gain ratio was calculated. Samples of excreta were analysed for oocyst excretion. Intestinal lesions were scored on three birds per pen in trial 1, and one bird per pen in trial 2 and on four birds per pen in trial 3, following the method of Johnson and Reid ([1970](#efs25891-bib-0800){ref-type="ref"}) (0 = no lesion, 1 = very mild, 2 = mild, 3 = moderate and 4 = severe).

###### 

Experimental design of floor pen studies with chickens for fattening using Elancoban^®^ G200

+--------+---------------------------------------------------------------------------------------+--------------------------+-----------------------------------------------------------------------------------+-----------------+---------------------------+----------------+
| Trial  | Replicates per treatment (birds[1](#efs25891-note-0055){ref-type="fn"} per replicate) | Inoculum characteristics | Feed analysis monensin sodium (mg/kg feed)[2](#efs25891-note-0056){ref-type="fn"} |                 |                           |                |
+========+=======================================================================================+==========================+===================================================================================+=================+===========================+================+
| **1**  | 12 (41--42)                                                                           | 2012                     | 100,000                                                                           | *E. acervulina* | Day 14 via feed           | 98.0/96.7/95.9 |
|        |                                                                                       |                          |                                                                                   |                 |                           |                |
|        |                                                                                       | Spain                    |                                                                                   |                 |                           |                |
+--------+---------------------------------------------------------------------------------------+--------------------------+-----------------------------------------------------------------------------------+-----------------+---------------------------+----------------+
| 10,000 | *E. tenella*                                                                          |                          |                                                                                   |                 |                           |                |
+--------+---------------------------------------------------------------------------------------+--------------------------+-----------------------------------------------------------------------------------+-----------------+---------------------------+----------------+
| 50,000 | *E. maxima*                                                                           |                          |                                                                                   |                 |                           |                |
+--------+---------------------------------------------------------------------------------------+--------------------------+-----------------------------------------------------------------------------------+-----------------+---------------------------+----------------+
| **2**  | 12 (12)                                                                               | 2010                     | 33,991                                                                            | *E. acervulina* | Day 16 orally via syringe | 104.0/83.3     |
|        |                                                                                       |                          |                                                                                   |                 |                           |                |
|        |                                                                                       | UK                       |                                                                                   |                 |                           |                |
+--------+---------------------------------------------------------------------------------------+--------------------------+-----------------------------------------------------------------------------------+-----------------+---------------------------+----------------+
| 25,349 | *E. tenella/necatrix*                                                                 |                          |                                                                                   |                 |                           |                |
+--------+---------------------------------------------------------------------------------------+--------------------------+-----------------------------------------------------------------------------------+-----------------+---------------------------+----------------+
| 2,916  | *E. maxima*                                                                           |                          |                                                                                   |                 |                           |                |
+--------+---------------------------------------------------------------------------------------+--------------------------+-----------------------------------------------------------------------------------+-----------------+---------------------------+----------------+
| 15,432 | *E. mitis*                                                                            |                          |                                                                                   |                 |                           |                |
+--------+---------------------------------------------------------------------------------------+--------------------------+-----------------------------------------------------------------------------------+-----------------+---------------------------+----------------+
| 714    | *E. praecox/brunetti*                                                                 |                          |                                                                                   |                 |                           |                |
+--------+---------------------------------------------------------------------------------------+--------------------------+-----------------------------------------------------------------------------------+-----------------+---------------------------+----------------+
| **3a** | 8                                                                                     | 2011                     | 104,000                                                                           | *E. acervulina* | Day 14 orally via syringe | 82.7/101.0     |
|        |                                                                                       |                          |                                                                                   |                 |                           |                |
|        | \(20\)                                                                                | The Netherlands          |                                                                                   |                 |                           |                |
+--------+---------------------------------------------------------------------------------------+--------------------------+-----------------------------------------------------------------------------------+-----------------+---------------------------+----------------+
| 30,000 | *E. tenella*                                                                          |                          |                                                                                   |                 |                           |                |
+--------+---------------------------------------------------------------------------------------+--------------------------+-----------------------------------------------------------------------------------+-----------------+---------------------------+----------------+
| 86,000 | *E. maxima*                                                                           |                          |                                                                                   |                 |                           |                |
+--------+---------------------------------------------------------------------------------------+--------------------------+-----------------------------------------------------------------------------------+-----------------+---------------------------+----------------+
| 12,000 | *E. praecox/necatrix*                                                                 |                          |                                                                                   |                 |                           |                |
+--------+---------------------------------------------------------------------------------------+--------------------------+-----------------------------------------------------------------------------------+-----------------+---------------------------+----------------+
| 4,000  | *E. mitis*                                                                            |                          |                                                                                   |                 |                           |                |
+--------+---------------------------------------------------------------------------------------+--------------------------+-----------------------------------------------------------------------------------+-----------------+---------------------------+----------------+
| **3b** | 8                                                                                     | 2011                     | 77,000                                                                            | *E. acervulina* |                           |                |
|        |                                                                                       |                          |                                                                                   |                 |                           |                |
|        | \(20\)                                                                                | Belgium                  |                                                                                   |                 |                           |                |
+--------+---------------------------------------------------------------------------------------+--------------------------+-----------------------------------------------------------------------------------+-----------------+---------------------------+----------------+
| 12,000 | *E. tenella*                                                                          |                          |                                                                                   |                 |                           |                |
+--------+---------------------------------------------------------------------------------------+--------------------------+-----------------------------------------------------------------------------------+-----------------+---------------------------+----------------+
| 20,000 | *E. maxima*                                                                           |                          |                                                                                   |                 |                           |                |
+--------+---------------------------------------------------------------------------------------+--------------------------+-----------------------------------------------------------------------------------+-----------------+---------------------------+----------------+
| 3,000  | *E. praecox/necatrix*                                                                 |                          |                                                                                   |                 |                           |                |
+--------+---------------------------------------------------------------------------------------+--------------------------+-----------------------------------------------------------------------------------+-----------------+---------------------------+----------------+
| 2,000  | *E. mitis*                                                                            |                          |                                                                                   |                 |                           |                |
+--------+---------------------------------------------------------------------------------------+--------------------------+-----------------------------------------------------------------------------------+-----------------+---------------------------+----------------+

Male Ross 308 in trial 1, female Ross cobs in trial 2, breed and gender not reported for trial 3.

The experimental diets were fed for 41 days in trial 1 and for 42 days in trials 2 and 3. In trial 1, birds received starter diet from day 0 to 14, grower diet from day 14 to 29 and finisher diet from day 29 to 41. In trial 2, birds received starter diet from day 0 to 10, grower diet from day 10 until study completion. In trial 3, birds received starter diet from day 0 to 14 and grower diet from day 14 to 42.

John Wiley & Sons, Ltd

In trial 1, oocyst counts and lesions scores were analysed by non‐parametric Kruskal‐Wallis test. Performance parameters were analysed by a randomised block design using the pen as experimental unit. Differences between the IUC and the IT groups were compared with post hoc tests (least significant difference (LSD) test. In trial 2, Wilcoxon--Mann--Whitney test was used to analyse oocyst count and lesions scores. Performance parameters were analysed by a t‐test (IT vs IUC). In trial 3, an ANOVA was performed with the data and IUC and IT were compared with post hoc tests (not reported). Level of significance was set at a p value ≤ 0.05.

Mortality (Table [21](#efs25891-tbl-0021){ref-type="table"}) in the IT groups of all trials was lower than in the IUC groups; however, the difference reached significance only in trial 3a. In trial 3a, nine birds were culled and eight birds were found dead. The dead birds were subjected to post‐mortem examination; four of them, all belonging to IUC, showed signs of coccidiosis. In trial 3b, 10 birds were culled and four birds were found dead and taken for post‐mortem examination; two of them, all belonging to IUC, showed signs of coccidiosis.

###### 

Mortality (number of dead animals) registered in the floor pen trials[1](#efs25891-note-0058){ref-type="fn"}

        Trial 1   Trial 2   Trial 3a   Trial 3b
  ----- --------- --------- ---------- ----------
  UUC   16 (2)    18 (0)    5          5
  IUC   10 (5)    20 (6)    11         6
  IT    7 (0)     7 (5)     1\*        3

Mean values with \* are significantly different from IUC (p ≤ 0.05).

Results of trials 1 and 2 refer to total mortality in the post‐inoculation period; results of trials 3a and 3b refer to the whole study duration. In brackets coccidiosis‐related mortalities are indicated.

John Wiley & Sons, Ltd

Table [22](#efs25891-tbl-0022){ref-type="table"} shows the results of intestinal lesion scoring. A significant reduction of the lesion scores was observed in the IT group compared to IUC in trial 1 (upper and middle intestine) and in trial 2 (upper intestine). Lesion scores in trial 3 were comparable in the IT and IUC groups.

###### 

*Eimeria* infection related intestinal lesion scores in different intestinal sections 6 days post‐inoculation^(1)^

                 Upper                                         Middle                                        Lower   Caecal   Total
  -------------- --------------------------------------------- --------------------------------------------- ------- -------- -------
  **Trial 1**                                                                                                                 
  UUC            0                                             0                                             −       0        −
  IUC            1.9                                           1.4                                           −       2.1      −
  IT             1.3[\*](#efs25891-note-0060){ref-type="fn"}   0.6[\*](#efs25891-note-0060){ref-type="fn"}   −       1.8      −
  **Trial 2**                                                                                                                 
  UUC            0                                             0                                             −       0        1
  IUC            2.3                                           2.4                                           −       1.3      2.4
  IT             1.3[\*](#efs25891-note-0060){ref-type="fn"}   2.5                                           −       1.1      2.1
  **Trial 3a**                                                                                                                
  UUC            0.7                                           0.4                                           0.1     0.1      −
  IUC            1.2                                           0.4                                           0.1     1.0      −
  IT             1.0                                           0.6                                           0.2     0.7      −
  **Trial 3b**                                                                                                                
  UUC            0.7                                           0.4                                           0.1     0.1      −
  IUC            1.0                                           0.4                                           0.2     1.6      −
  IT             1.0                                           0.7                                           0.1     1.1      −

− : not reported or not measured.

IT mean significantly different from IUC mean (p ≤ 0.05).

Lesions in the upper intestine were probably due to *E. acervulina*, in the middle intestine to *E. maxima* and in the caecal intestine to *E. tenella*.

John Wiley & Sons, Ltd

Oocyst excretion on day 23 (9 days post‐inoculation) was significantly reduced in the IT group compared to the IUC group for all three different *Eimeria* species in trial 1 (See Appendix [D](#efs25891-sec-1004){ref-type="sec"}). In trial 2, species‐specific results were not reported. Total oocyst counts measured on days 22, 24, 27, 29 and 31 showed numerically lower counts in the IT group compared to the IUC group. Significant differences were seen only on the last day of the trial (IT 592 vs. IUC 39,841). In trial 3a, oocyst excretion for *E. maxima* was significantly lower in IT compared to IUC at all time points (days 20, 22 and 28). In trial 3b, oocyst excretion per gram faeces (OPG) was significantly reduced by the treatment on day 22 for *E. mitis*, however, it is noted that the excretion of the same *Eimeria* species on day 20 was significantly higher in the IT group compared to the IUC group.

Table [23](#efs25891-tbl-0023){ref-type="table"} summarises the results concerning the zootechnical endpoints. In all four experiments, weight gain of the IT birds was significantly higher compared to the IUC birds and reached the level of the UUC groups in trials 1 and 2. In trial 3, increased feed intake of the IT groups resulted in higher body weight gain than in the UUC groups with significant improvement of the feed to gain ratio.

###### 

Performance parameters of chickens for fattening in floor pen trials

                 Feed intake[1](#efs25891-note-0064){ref-type="fn"} (g)   Final body weight (g)                           Weight gain[2](#efs25891-note-0065){ref-type="fn"} (g)   Feed to gain ratio[3](#efs25891-note-0066){ref-type="fn"}
  -------------- -------------------------------------------------------- ----------------------------------------------- -------------------------------------------------------- -----------------------------------------------------------
  **Trial 1**                                                                                                                                                                      
  UUC            126                                                      3,057                                           73                                                       1.72
  IUC            126                                                      2,924                                           70                                                       1.79
  IT             125                                                      3,064[\*](#efs25891-note-0063){ref-type="fn"}   73[\*](#efs25891-note-0063){ref-type="fn"}               1.70[\*](#efs25891-note-0063){ref-type="fn"}
  **Trial 2**                                                                                                                                                                      
  UUC            3,262                                                    2,557                                           2,046                                                    1.59
  IUC            3,132                                                    2,427                                           1,886                                                    1.66
  IT             3,448[\*](#efs25891-note-0063){ref-type="fn"}            2,593[\*](#efs25891-note-0063){ref-type="fn"}   2,064[\*](#efs25891-note-0063){ref-type="fn"}            1.67
  **Trial 3a**                                                                                                                                                                     
  UUC            3,348                                                    −                                               1,538                                                    2.18
  IUC            3,690                                                    −                                               1,684                                                    2.19
  IT             3,783                                                    −                                               1,836[\*](#efs25891-note-0063){ref-type="fn"}            2.06[\*](#efs25891-note-0063){ref-type="fn"}
  **Trial 3b**                                                                                                                                                                     
  UUC            3,348                                                    −                                               1,538                                                    2.18
  IUC            3,365                                                    −                                               1,551                                                    2.18
  IT             3,535                                                    −                                               1,719[\*](#efs25891-note-0063){ref-type="fn"}            2.06[\*](#efs25891-note-0063){ref-type="fn"}

− : not reported.

IT mean significantly different from IUC mean (p ≤ 0.05).

Mean results of trial 1 refer to daily feed intake per bird during the whole study duration; those of trial 2 refer to total feed intake per bird in the period after inoculation (days 16--42); those of trial 3 refer to total feed intake per bird during the whole study duration.

Mean results of trial 1 refer to daily weight gain per bird considering the whole study duration; those of trial 2 refer to the total weight gain per bird in the period after inoculation (days 16--42); those of trials 3a and 3b refer to total weight gain per bird during the whole study duration.

Results of trials 1 and 3 refer to the feed to gain ratio calculated for the whole study duration; results of trial 2 refer to the ratios calculated for the period 16--42 days.

John Wiley & Sons, Ltd

#### 3.3.1.2. Anticoccidial sensitivity tests in chickens for fattening {#efs25891-sec-0052}

Three ASTs performed in 2012 were submitted.[97](#efs25891-note-1091){ref-type="fn"} Recent field isolates of *Eimeria* species were used for inoculation. The birds were randomly allocated to the groups (UUC, IUC, IT). The IT group received feed containing 100 mg monensin sodium/kg feed, the lowest dose applied. Three other anticoccidial additives were also tested in all studies. The experimental design is described in Table [24](#efs25891-tbl-0024){ref-type="table"}. The intended dietary monensin concentration was analytically confirmed (Table [24](#efs25891-tbl-0024){ref-type="table"}). Animal health and mortality were monitored. Feed intake and body weight of the animals were measured, feed to gain ratio was calculated. Samples of excreta were analysed for oocyst excretion. Intestinal lesions were scored following the method of Johnson and Reid ([1970](#efs25891-bib-0800){ref-type="ref"}) (0 = no lesion, 1 = very mild, 2 = mild, 3 = moderate and 4 = severe).

The statistical tests were two‐sided; the level of significance was set at a p value ≤ 0.05. In AST‐1 and AST‐2, performance parameters and oocyst counts (log~10~ transformed) were compared by t‐test (IT vs IUC). Intestinal lesions scores were analysed by Fisher\'s Exact test. In AST‐3, intestinal lesion scores and mortality were analysed by Kruskal--Wallis test. Performance parameters and oocyst counts (log~10~ transformed) were analysed by ANOVA. Least squares means were compared by LSD test.

###### 

Experimental design of ASTs with chickens for fattening using Elancoban^®^ G200

+--------+---------------------------------------------------------------------------------------+--------------------------+-------------------------------------------------------------------------------+--------------------------------------------+----+----------------------------------------------+------+
| Trial  | Replicates per treatment (birds[1](#efs25891-note-0067){ref-type="fn"} per replicate) | Inoculum characteristics | Anticoccidial treatment[2](#efs25891-note-0068){ref-type="fn"} (days of life) | Feed analysis monensin sodium (mg/kg feed) |    |                                              |      |
+========+=======================================================================================+==========================+===============================================================================+============================================+====+==============================================+======+
| **1**  | 4                                                                                     | 03/2012                  | 296,375                                                                       | *E. acervulina*                            | 14 | 7--21                                        | 97.7 |
|        |                                                                                       |                          |                                                                               |                                            |    |                                              |      |
|        | \(5\)                                                                                 | UK                       |                                                                               |                                            |    |                                              |      |
+--------+---------------------------------------------------------------------------------------+--------------------------+-------------------------------------------------------------------------------+--------------------------------------------+----+----------------------------------------------+------+
| 23,399 | *E. maxima*                                                                           |                          |                                                                               |                                            |    |                                              |      |
+--------+---------------------------------------------------------------------------------------+--------------------------+-------------------------------------------------------------------------------+--------------------------------------------+----+----------------------------------------------+------+
| 31,198 | *E. tenella*                                                                          |                          |                                                                               |                                            |    |                                              |      |
+--------+---------------------------------------------------------------------------------------+--------------------------+-------------------------------------------------------------------------------+--------------------------------------------+----+----------------------------------------------+------+
| 31,198 | *E. praecox*                                                                          |                          |                                                                               |                                            |    |                                              |      |
+--------+---------------------------------------------------------------------------------------+--------------------------+-------------------------------------------------------------------------------+--------------------------------------------+----+----------------------------------------------+------+
| 7,799  | *E. mitis*                                                                            |                          |                                                                               |                                            |    |                                              |      |
+--------+---------------------------------------------------------------------------------------+--------------------------+-------------------------------------------------------------------------------+--------------------------------------------+----+----------------------------------------------+------+
| **2**  | 4                                                                                     | 12/2011                  | 218,548                                                                       | *E. acervulina*                            | 14 | 7--21                                        | 95.0 |
|        |                                                                                       |                          |                                                                               |                                            |    |                                              |      |
|        | \(5\)                                                                                 | France                   |                                                                               |                                            |    |                                              |      |
+--------+---------------------------------------------------------------------------------------+--------------------------+-------------------------------------------------------------------------------+--------------------------------------------+----+----------------------------------------------+------+
| 29,802 | *E. maxima*                                                                           |                          |                                                                               |                                            |    |                                              |      |
+--------+---------------------------------------------------------------------------------------+--------------------------+-------------------------------------------------------------------------------+--------------------------------------------+----+----------------------------------------------+------+
| 21,855 | *E. tenella*                                                                          |                          |                                                                               |                                            |    |                                              |      |
+--------+---------------------------------------------------------------------------------------+--------------------------+-------------------------------------------------------------------------------+--------------------------------------------+----+----------------------------------------------+------+
| 11,722 | *E. praecox*                                                                          |                          |                                                                               |                                            |    |                                              |      |
+--------+---------------------------------------------------------------------------------------+--------------------------+-------------------------------------------------------------------------------+--------------------------------------------+----+----------------------------------------------+------+
| 3,974  | *E. mitis*                                                                            |                          |                                                                               |                                            |    |                                              |      |
+--------+---------------------------------------------------------------------------------------+--------------------------+-------------------------------------------------------------------------------+--------------------------------------------+----+----------------------------------------------+------+
| **3**  | 4                                                                                     | 03/2012 Spain            | 100,000                                                                       | *E. acervulina*                            | 15 | 8--21[3](#efs25891-note-0069){ref-type="fn"} | 90.1 |
|        |                                                                                       |                          |                                                                               |                                            |    |                                              |      |
|        | \(8\)                                                                                 |                          |                                                                               |                                            |    |                                              |      |
+--------+---------------------------------------------------------------------------------------+--------------------------+-------------------------------------------------------------------------------+--------------------------------------------+----+----------------------------------------------+------+
| 25,000 | *E. maxima*                                                                           |                          |                                                                               |                                            |    |                                              |      |
+--------+---------------------------------------------------------------------------------------+--------------------------+-------------------------------------------------------------------------------+--------------------------------------------+----+----------------------------------------------+------+
| 25,000 | *E. brunetti*                                                                         |                          |                                                                               |                                            |    |                                              |      |
+--------+---------------------------------------------------------------------------------------+--------------------------+-------------------------------------------------------------------------------+--------------------------------------------+----+----------------------------------------------+------+
| 10,000 | *E. tenella*                                                                          |                          |                                                                               |                                            |    |                                              |      |
+--------+---------------------------------------------------------------------------------------+--------------------------+-------------------------------------------------------------------------------+--------------------------------------------+----+----------------------------------------------+------+
| 10,000 | *E. necatrix*                                                                         |                          |                                                                               |                                            |    |                                              |      |
+--------+---------------------------------------------------------------------------------------+--------------------------+-------------------------------------------------------------------------------+--------------------------------------------+----+----------------------------------------------+------+

Female Ross 308 in AST‐1 and AST‐2; Cobb 500 in AST‐3, sex not indicated.

Birds in the IT group were fed a basal diet supplemented with Elancoban^®^ G200. Animals in the control groups UUC and IUC received the same basal diet without inclusion of the coccidiostat.

Performance and intestinal lesions were assessed on day 21, oocyst excretion was measured on day 24.

John Wiley & Sons, Ltd

There were no mortalities in AST‐1, and one IUC bird died in AST‐2. Increased mortality due to coccidiosis was seen only in IUC of AST‐3; 12 birds died which is significantly different to the IT group in which no mortality occurred.

Table [25](#efs25891-tbl-0025){ref-type="table"} summarises the results of the ASTs. Significantly lower OPG value in the IT group, showing the effect of the coccidiostatic treatment, was seen only in AST‐3. A reduction of lesion scores by treatment (IT) was observed in all tests; however, significance was reached only in AST‐1 (upper intestine) and AST‐3 (mid and lower intestine).

In AST‐2, bodyweight gain and feed intake were significantly better in the IT than in the IUC group over the 7 days post‐inoculation (feed to gain ratio not reported for this period). In the same period, in AST‐3, results of weight gain and feed to gain ratio were significantly better in IT than in the IUC group.

###### 

Results of anticoccidial sensitivity tests with chickens for fattening

  Group                                        Final body weight (g)   Feed intake (g)                                 Average body weight gain (g)                  Feed to gain ratio                             Total log~10~OPG                               Intestinal lesion scores                                                                                                           
  -------------------------------------------- ----------------------- ----------------------------------------------- --------------------------------------------- ---------------------------------------------- ---------------------------------------------- -------------------------- --------------------------------------------- --------------------------------------------- ----- ----- -----
  **AST‐1**                                                                                                                                                                                                                                                                                                                                                                                           
  UUC[1](#efs25891-note-0072){ref-type="fn"}   700                     2,518                                           355                                           --                                             0                                              0                          0                                             0                                             0     0     0
  IUC                                          530                     2,073                                           194                                           --                                             6.52                                           6.51                       5.64                                          2.6                                           1.1   0     0.7
  IT                                           544                     2,070                                           213                                           --                                             6.60                                           6.42                       5.72                                          1.4[\*](#efs25891-note-0071){ref-type="fn"}   0.9   0     0.1
  **AST‐2**                                                                                                                                                                                                                                                                                                                                                                                           
  UUC[1](#efs25891-note-0072){ref-type="fn"}   473                     2,433                                           214                                           --                                             0                                              0                          0                                             0                                             0     0     --
  IUC                                          491                     2,015                                           187                                           --                                             6.12                                           6.65                       6.49                                          2.2                                           0.9   2.7   --
  IT                                           628                     2,480[\*](#efs25891-note-0071){ref-type="fn"}   276[\*](#efs25891-note-0071){ref-type="fn"}   --                                             6.13                                           6.49                       6.31                                          2.3                                           0.8   2.0   --
                                               **D21**                 **D15**--**21**                                 **D15**--**21**                               **D15**--**21**                                **D21**--**24**                                **D21**                                                                                                                            
  **AST‐3**                                                                                                                                                                                                                                                                                                                                                                                           
  UUC                                          538                     --                                              253[\*](#efs25891-note-0071){ref-type="fn"}   1.29[\*](#efs25891-note-0071){ref-type="fn"}   0                                              0                          0                                             0                                             0           
  IUC                                          370                     --                                              86                                            2.46                                           5.07                                           2.6                        1.9                                           2.1                                           2.8         
  IT                                           409                     --                                              125[\*](#efs25891-note-0071){ref-type="fn"}   1.56[\*](#efs25891-note-0071){ref-type="fn"}   4.71[\*](#efs25891-note-0071){ref-type="fn"}   2.3                        1.3[\*](#efs25891-note-0071){ref-type="fn"}   0.5[\*](#efs25891-note-0071){ref-type="fn"}   2.6         

--: Not reported.

IT mean/UUC mean significantly different from IUC mean (p ≤ 0.05).

The cages of the UUC group were kept in another building than those of IUC and IT groups. The zootechnical data of UUC group are therefore not directly comparable to IUC and IT.

John Wiley & Sons, Ltd

#### 3.3.1.3. Synopsis of efficacy studies in chickens for fattening {#efs25891-sec-0053}

The synopsis is based on three floor pen studies and three ASTs made with the lowest recommended dietary concentration of the coccidiostat Elancoban^®^ G200 (100 mg monensin sodium/kg feed).

Mortality in the floor pen studies did not indicate a coccidiostatic effect since mortality rates were not significantly different and appeared even not to be influenced by *Eimeria* inoculation (mean UUC 6.3%, mean IUC 7.1%). In the ASTs, mortality was very low in two trials; however, it was affected by oocyst inoculation in a third trial (AST‐3) and significantly reduced by monensin treatment.

Lesion scores in the upper, middle and lower intestine of *Eimeria* inoculated birds were numerically reduced by monensin sodium in all three floor pen studies and ASTs. However, this reduction reached significance only in two floor pen studies (in trial 1 for the upper and middle intestine and in trial 2 in the upper intestine) and in two ASTs (in AST‐1 for the upper intestine and in AST‐3 also for the middle and low intestine).

Oocyst excretion of all tested four *Eimeria* species was significantly reduced by Elancoban^®^ G200 in one floor pen study (trial 1) and for *Eimeria maxima* in another study (trial 3a). A third study (trial 2) showed only numerical reductions of oocyst excretion (except on the last day of the trial where significance was reached). In AST‐1 and AST‐2, *Eimeria* oocyst excretion on days 3 to 7 post‐inoculation was not affected by the Elancoban^®^ treatment, whereas it was significantly reduced in AST‐3.

Body weight gain of birds in the floor pen studies was significantly higher for the Elancoban^®^ G200‐treated groups compared to the infected non treated birds. These results are considered as further evidence of the coccidiostatic efficacy supported by the results of the specific endpoints.

In summary, the anticoccidial efficacy of 100 mg monensin sodium/kg feed from Elancoban^®^ G200 is demonstrated in three floor pen studies (in floor pen study 1 by the endpoints lesion scores and oocyst excretion, in floor pen study 2 by reduced oocyst excretion and improved body weight, in floor pen study 3 by reduced oocyst excretion) and in two ASTs (in AST‐1 by lesion scores and in AST‐3 by reduced mortality, lesion scores and oocyst excretion). A third AST (AST‐2) failed to demonstrate any significant improvement of the coccidiosis related endpoints.

### 3.3.2. Efficacy in chickens reared for laying {#efs25891-sec-0054}

The applicant submitted four floor pens studies with the duration of 112 days and three floor pen studies with the duration of 23, 28 and 28 days. The FEEDAP Panel did not consider these last three studies as they did not meet the requirement for the minimum duration of efficacy studies in chickens reared for laying (EFSA FEEDAP Panel, [2011b](#efs25891-bib-0022){ref-type="ref"}). The applicant submitted four ASTs performed with recent field isolates and one AST performed with laboratory strains. This last study was not considered for the demonstration of efficacy because the laboratory strains do not represent field conditions (EFSA FEEDAP Panel, [2011a](#efs25891-bib-0021){ref-type="ref"}).

#### 3.3.2.1. Floor pen studies in chickens reared for laying {#efs25891-sec-0055}

Four floor pen studies in chickens reared for laying, conducted in 2012, were submitted.[98](#efs25891-note-1092){ref-type="fn"} Two of the trials were conducted in the same institute and using the same feed but with different inocula and control group (UUC); therefore, they will be reported here as trials 3a and 3b.[96](#efs25891-note-1090){ref-type="fn"} In each trial, replacement pullets (Hyline brown) were penned and distributed into the treatments (in trial 1, IUC and IT groups; in trials 2 and 3, UUC, IUC and IT groups). The IT group received feed containing 100 mg monensin sodium/kg feed, the lowest dose applied. The experimental design is summarised in Table [26](#efs25891-tbl-0026){ref-type="table"}. The intended dietary monensin concentrations were analytically confirmed (see Table [26](#efs25891-tbl-0026){ref-type="table"}). The experimental diets were fed for 112 days. In the infected groups, all birds were inoculated with recent field isolates of pathogenic *Eimeria* species. Animal health and mortality were monitored daily. Feed intake and body weight of the animals were measured, feed to gain ratio was calculated. Samples of excreta were analysed for oocyst excretion. Intestinal lesions were scored on three birds per pen in trial 1, on two birds per pen in trials 3a and 3b and on one bird per pen in trial 2, following the method of Johnson and Reid ([1970](#efs25891-bib-0800){ref-type="ref"}) (0 = no lesion, 1 = very mild, 2 = mild, 3 = moderate and 4 = severe).

In trial 1, an ANOVA was performed with the performance data and oocyst counts (after log~10~ transformation). Lesions scores were analysed by Kruskal‐Wallis test and mortality was analysed by Chi squared test. In all tests IUC was compared with IT. In trial 2, Wilcoxon--Mann--Whitney test was used to analyse oocyst count and lesions scores. Performance parameters were analysed by a t‐test (IUC vs IT). In trials 3a and 3b, an ANOVA was performed with the data and IUC and IT were compared with post hoc tests (not reported). Level of significance was set at a p value ≤ 0.05.

###### 

Experimental design of floor pen studies with chickens reared for laying using Elancoban^®^ G200

+--------+------------------------------------------------+--------------------------+-----------------------------------------------------------------------------------+-----------------+----------------------------+-------------+
| Trial  | Replicates per treatment (birds per replicate) | Inoculum characteristics | Feed analysis monensin sodium (mg/kg feed)[1](#efs25891-note-0073){ref-type="fn"} |                 |                            |             |
+========+================================================+==========================+===================================================================================+=================+============================+=============+
| **1**  | 10                                             | 2012                     | 100,000                                                                           | *E. acervulina* | Day 14, via feed           | 84.4--95.1  |
|        |                                                |                          |                                                                                   |                 |                            |             |
|        | \(30\)                                         | Spain                    |                                                                                   |                 |                            |             |
+--------+------------------------------------------------+--------------------------+-----------------------------------------------------------------------------------+-----------------+----------------------------+-------------+
| 10,000 | *E. tenella*                                   |                          |                                                                                   |                 |                            |             |
+--------+------------------------------------------------+--------------------------+-----------------------------------------------------------------------------------+-----------------+----------------------------+-------------+
| 55,000 | *E. maxima*                                    |                          |                                                                                   |                 |                            |             |
+--------+------------------------------------------------+--------------------------+-----------------------------------------------------------------------------------+-----------------+----------------------------+-------------+
| 50,000 | *E. brunetti*                                  |                          |                                                                                   |                 |                            |             |
+--------+------------------------------------------------+--------------------------+-----------------------------------------------------------------------------------+-----------------+----------------------------+-------------+
| 10,000 | *E. necatrix*                                  |                          |                                                                                   |                 |                            |             |
+--------+------------------------------------------------+--------------------------+-----------------------------------------------------------------------------------+-----------------+----------------------------+-------------+
| **2**  | 12                                             | 2012                     | 341                                                                               | *E. acervulina* | Day 15, by oral gavage     | 73.9--114.0 |
|        |                                                |                          |                                                                                   |                 |                            |             |
|        | \(12\)                                         | UK                       |                                                                                   |                 |                            |             |
+--------+------------------------------------------------+--------------------------+-----------------------------------------------------------------------------------+-----------------+----------------------------+-------------+
| 5,000  | *E. tenella/necatrix*                          |                          |                                                                                   |                 |                            |             |
+--------+------------------------------------------------+--------------------------+-----------------------------------------------------------------------------------+-----------------+----------------------------+-------------+
| 114    | *E. praecox/brunetti*                          |                          |                                                                                   |                 |                            |             |
+--------+------------------------------------------------+--------------------------+-----------------------------------------------------------------------------------+-----------------+----------------------------+-------------+
| 170    | *E. mitis*                                     |                          |                                                                                   |                 |                            |             |
+--------+------------------------------------------------+--------------------------+-----------------------------------------------------------------------------------+-----------------+----------------------------+-------------+
| **3a** | 10                                             | 2012                     | 70,800                                                                            | *E. acervulina* | Day 14, orally via syringe | 96.3--98.3  |
|        |                                                |                          |                                                                                   |                 |                            |             |
|        | \(15\)                                         | The Netherlands          |                                                                                   |                 |                            |             |
+--------+------------------------------------------------+--------------------------+-----------------------------------------------------------------------------------+-----------------+----------------------------+-------------+
| 14,000 | *E. tenella*                                   |                          |                                                                                   |                 |                            |             |
+--------+------------------------------------------------+--------------------------+-----------------------------------------------------------------------------------+-----------------+----------------------------+-------------+
| 8,800  | *E. maxima*                                    |                          |                                                                                   |                 |                            |             |
+--------+------------------------------------------------+--------------------------+-----------------------------------------------------------------------------------+-----------------+----------------------------+-------------+
| 10,400 | *E. brunetti*                                  |                          |                                                                                   |                 |                            |             |
+--------+------------------------------------------------+--------------------------+-----------------------------------------------------------------------------------+-----------------+----------------------------+-------------+
| 4,800  | *E. praecox/necatrix*                          |                          |                                                                                   |                 |                            |             |
+--------+------------------------------------------------+--------------------------+-----------------------------------------------------------------------------------+-----------------+----------------------------+-------------+
| 12,000 | *E. mitis*                                     |                          |                                                                                   |                 |                            |             |
+--------+------------------------------------------------+--------------------------+-----------------------------------------------------------------------------------+-----------------+----------------------------+-------------+
| **3b** | 10                                             | 2012                     | 62.400                                                                            | *E. acervulina* | Day 14, orally via syringe | 96.3--98.3  |
|        |                                                |                          |                                                                                   |                 |                            |             |
|        | \(15\)                                         | Belgium                  |                                                                                   |                 |                            |             |
+--------+------------------------------------------------+--------------------------+-----------------------------------------------------------------------------------+-----------------+----------------------------+-------------+
| 25.600 | *E. tenella*                                   |                          |                                                                                   |                 |                            |             |
+--------+------------------------------------------------+--------------------------+-----------------------------------------------------------------------------------+-----------------+----------------------------+-------------+
| 25.600 | *E. maxima*                                    |                          |                                                                                   |                 |                            |             |
+--------+------------------------------------------------+--------------------------+-----------------------------------------------------------------------------------+-----------------+----------------------------+-------------+
| 8.800  | *E. brunetti*                                  |                          |                                                                                   |                 |                            |             |
+--------+------------------------------------------------+--------------------------+-----------------------------------------------------------------------------------+-----------------+----------------------------+-------------+
| 1,600  | *E. praecox/necatrix*                          |                          |                                                                                   |                 |                            |             |
+--------+------------------------------------------------+--------------------------+-----------------------------------------------------------------------------------+-----------------+----------------------------+-------------+
| 8,000  | *E. mitis*                                     |                          |                                                                                   |                 |                            |             |
+--------+------------------------------------------------+--------------------------+-----------------------------------------------------------------------------------+-----------------+----------------------------+-------------+

In trial 1, birds received starter diet from day 0 to 42, grower diet from day 42 to 84 and developer diet from day 84 to 112. In trial 2, birds received starter diet from day 0 to 36 followed by grower diet until study completion. In trials 3 and 4, birds received starter diet from day 0 to 56 followed by grower diet until study completion.

John Wiley & Sons, Ltd

Mortality is reported in Table [27](#efs25891-tbl-0027){ref-type="table"}. In trial 1, inoculation with *Eimeria* oocyst resulted in 38% losses. This mortality rate was reduced by the treatment to 9% which is considered as a clear evidence of the coccidiostatic efficacy of monensin sodium. Mortality of trials 2, 3a and 3b was very low also in the IUC group and could therefore not contribute in supporting monensin efficacy.

###### 

Mortality (number of dead animals) post‐inoculation in floor pen trials^(1)^

        Trial 1       Trial 2                                    Trial 3a   Trial 3b
  ----- ------------- ------------------------------------------ ---------- ----------
  UUC   --            1                                          1          0
  IUC   115 (114)     0                                          3          0
  IT    29\* (28\*)   1[1](#efs25891-note-0075){ref-type="fn"}   0          0

Mean values with \* are significantly different from IUC (p ≤ 0.05).

In brackets coccidiosis‐related mortalities are indicated.

John Wiley & Sons, Ltd

Table [28](#efs25891-tbl-0028){ref-type="table"} provides information on the lesion scores in different intestinal sections. Lesion scores were significantly reduced by the treatment in trial 1 in the lower intestine and in trial 3a in the caecum (Table [28](#efs25891-tbl-0028){ref-type="table"}). No other consistent changes were observed.

###### 

*Eimeria* infection related intestinal lesion scores in different intestinal sections 7 days post‐infection (5 days post‐infection trial 2)

                 Upper   Middle   Low                                           Caecal
  -------------- ------- -------- --------------------------------------------- ---------------------------------------------
  **Trial 1**                                                                   
  IUC            1.4     1.3      1.4                                           2.4
  IT             1.5     1.1      0.9[\*](#efs25891-note-0077){ref-type="fn"}   2.1
  **Trial 2**                                                                   
  UUC            0       0        --                                            0
  IUC            0.9     0.3      --                                            1.4
  IT             0.8     0.3      --                                            2.1
  **Trial 3a**                                                                  
  UUC            0.1     0.7      0.4                                           0.2
  IUC            0.5     0.7      0.3                                           0.6
  IT             0.4     0.9      0.4                                           0.1[\*](#efs25891-note-0077){ref-type="fn"}
  **Trial 3b**                                                                  
  UUC            0.2     0.6      0.4                                           0.2
  IUC            0.2     0.7      0.4                                           1.1
  IT             0.3     0.7      0.4                                           1.0

--: not reported.

IT mean significantly different from IUC mean (p ≤ 0.05).

John Wiley & Sons, Ltd

In trial 1, mean OPG was significantly reduced by the treatment at days 8 (log~10~OPG 4.67 vs. 5.08) and 11 (log~10~OPG 3.74 vs. 4.65) after inoculation. In trial 2, OPG was measured on days 19, 21, 23, 26, 28, 30, 33, 35 and in biweekly intervals until day 77. Among these 11 control points, only at days 28 and 30, 13 and 15 days after inoculation, a significant reduction by the treatment could be seen (log~10~OPG 5.17 vs. 5.60 and 5.38 vs. 5.57, respectively). Although 62 days after inoculation the difference in OPGs was significant, total OPG of IT (log~10~OPG 1.98) and IUC (log~10~OPG 2.80) was low, particularly when compared to the UUC group (log~10~OPG 4.48). In trials 3a and 3b, OPG was measured on days 21, 28 and 70 (7, 14 and 56 days post‐inoculation). *Eimeria* oocysts were counted for *E. acervulina*,*tenella*,*maxima*,*brunetti*,*nectarix/praecox* and *mitis*. The sum was also considered. Although for all *Eimeria* species at all three timepoints of trial 3a a numerical reduction of oocyst excretion by the treatment became evident (with the exception of days 28 and 70 for *E. necatrix/praecox*) none of these differences (including the sum of all *Eimeria* species) reached significance. In trial 3b, total OPG 7 days after inoculation (log~10~OPG IUC 5.69, IT 5.47) was higher compared to study 3a (log~10~OPG IUC 5.37, IT 5.04). The only significant differences in OPG observed in trial 3b were found 7 days after inoculation for *E. tenella* (log~10~OPG IT 3.79 vs IUC 4.74) and *E. necatrix/praecox* (log~10~OPG IT 2.08 vs IUC 3.52).

Table [29](#efs25891-tbl-0029){ref-type="table"} summarises the results concerning zootechnical endpoints. No statistically significant differences were seen in any of the parameters in the four experiments except for the feed to gain ratio in trial 3b showing improvement in the IT birds compared to IUC birds.

###### 

Performance parameters of chickens reared for laying in floor pen trials

                 Feed intake[1](#efs25891-note-0080){ref-type="fn"} (g)   Final body weight (g)   Weight gain[2](#efs25891-note-0081){ref-type="fn"} (g)   Feed to gain ratio[3](#efs25891-note-0082){ref-type="fn"}
  -------------- -------------------------------------------------------- ----------------------- -------------------------------------------------------- -----------------------------------------------------------
  **Trial 1**                                                                                                                                              
  IUC            45                                                       1,316                   11                                                       3.95
  IT             44                                                       1,309                   11                                                       3.90
  **Trial 2**                                                                                                                                              
  UUC            7,573                                                    1,645                   1,605                                                    --
  IUC            7,481                                                    1,570                   1,529                                                    --
  IT             7,514                                                    1,558                   1,517                                                    --
  **Trial 3a**                                                                                                                                             
  UUC            5,017                                                    --                      1,477                                                    3.40
  IUC            5,092                                                    --                      1,501                                                    3.39
  IT             5,057                                                    --                      1,498                                                    3.38
  **Trial 3b**                                                                                                                                             
  UUC            5,295                                                    --                      1,520                                                    3.48
  IUC            5,352                                                    --                      1,531                                                    3.50
  IT             5,192                                                    --                      1,546                                                    3.36[\*](#efs25891-note-0079){ref-type="fn"}

− : not reported.

IT mean significantly different from IUC mean (p ≤ 0.05).

Mean results of trial 1 refer to daily feed intake per bird; those of trials 2, 3a and 3b to total feed intake per bird during the whole study duration.

Mean results of trial 1, refer to daily weight gain per bird considering the whole study duration; those of trials 2, 3a and 3b refer to the total weight gain per bird during the whole study duration.

Results refer to the feed to gain ratio calculated for the whole study duration.

John Wiley & Sons, Ltd

#### 3.3.2.2. Anticoccidial sensitivity tests in chickens reared for laying {#efs25891-sec-0056}

Four ASTs performed in 2012--2013 were submitted.[99](#efs25891-note-1093){ref-type="fn"} Recent field isolates of *Eimeria* species were used for inoculation. The birds were randomly allocated to the groups UUC, IUC and IT, the latter receiving feed supplemented with Elancoban^®^ at an intended concentration of 100 mg monensin sodium/kg feed, the lowest dose applied. One other anticoccidial additive was also tested in all studies. The experimental design is described in Table [30](#efs25891-tbl-0030){ref-type="table"}. The intended dietary monensin concentration was analytically confirmed (Table [30](#efs25891-tbl-0030){ref-type="table"}). Animal health and mortality were monitored. Feed intake and body weight of the animals were measured, feed to gain ratio was calculated. Samples of excreta were analysed for oocyst excretion. Intestinal lesions were scored following the method of Johnson and Reid ([1970](#efs25891-bib-0800){ref-type="ref"}) (0 = no lesion, 1 = very mild, 2 = mild, 3 = moderate and 4 = severe).

The statistical tests were two‐sided; the level of significance was set at a p value ≤ 0.05. For pair‐wise comparisons, the reference group was the IUC. Performance parameters and oocyst counts (natural log) were analysed by ANOVA and pair‐wise comparisons were done by LSD test. Intestinal lesions were analysed by a non‐parametric trend test (Jonckheere‐Terpstra). In AST‐2, intestinal lesion scores and mortality were analysed by Kruskal--Wallis test. Performance parameters and oocyst counts (ln or log~10~ transformed) were analysed by ANOVA. Least squares means were compared by LSD test. In AST‐3 and AST‐4, performance parameters and oocyst counts (log~10~ transformed) were compared by t‐test (IT vs IUC). Intestinal lesions scores were analysed by Fisher\'s Exact test.

###### 

Experimental design of ASTs with chickens reared for laying using Elancoban^®^ G200

+-----------+---------------------------------------------------------------------------------------+--------------------------+---------------------------------------------------------------------+--------------------------------------------+----+----------------------------------------------+------+
| AST       | Replicates per treatment (birds[1](#efs25891-note-0083){ref-type="fn"} per replicate) | Inoculum characteristics | Anticoccidial treatment[2](#efs25891-note-0084){ref-type="fn"} days | Feed analysis monensin sodium (mg/kg feed) |    |                                              |      |
+===========+=======================================================================================+==========================+=====================================================================+============================================+====+==============================================+======+
| **1**     | 6                                                                                     | 2012                     | 16,400                                                              | *E. acervulina*                            | 31 | 25--37                                       | 90   |
|           |                                                                                       |                          |                                                                     |                                            |    |                                              |      |
|           | \(5\)                                                                                 | Belgium                  |                                                                     |                                            |    |                                              |      |
+-----------+---------------------------------------------------------------------------------------+--------------------------+---------------------------------------------------------------------+--------------------------------------------+----+----------------------------------------------+------+
| 8,600     | *E. tenella*                                                                          |                          |                                                                     |                                            |    |                                              |      |
+-----------+---------------------------------------------------------------------------------------+--------------------------+---------------------------------------------------------------------+--------------------------------------------+----+----------------------------------------------+------+
| 11,800    | *E. maxima*                                                                           |                          |                                                                     |                                            |    |                                              |      |
+-----------+---------------------------------------------------------------------------------------+--------------------------+---------------------------------------------------------------------+--------------------------------------------+----+----------------------------------------------+------+
| 1,600     | *E. brunetti*                                                                         |                          |                                                                     |                                            |    |                                              |      |
+-----------+---------------------------------------------------------------------------------------+--------------------------+---------------------------------------------------------------------+--------------------------------------------+----+----------------------------------------------+------+
| 200       | *E. mitis*                                                                            |                          |                                                                     |                                            |    |                                              |      |
+-----------+---------------------------------------------------------------------------------------+--------------------------+---------------------------------------------------------------------+--------------------------------------------+----+----------------------------------------------+------+
| 1,400     | *E. necatrix*                                                                         |                          |                                                                     |                                            |    |                                              |      |
+-----------+---------------------------------------------------------------------------------------+--------------------------+---------------------------------------------------------------------+--------------------------------------------+----+----------------------------------------------+------+
| **2**     | 6                                                                                     | 2012                     | 100,000                                                             | *E. acervulina*                            | 15 | 8--21[3](#efs25891-note-0085){ref-type="fn"} | 94.7 |
|           |                                                                                       |                          |                                                                     |                                            |    |                                              |      |
|           | \(8\)                                                                                 | Spain                    |                                                                     |                                            |    |                                              |      |
+-----------+---------------------------------------------------------------------------------------+--------------------------+---------------------------------------------------------------------+--------------------------------------------+----+----------------------------------------------+------+
| 25,000    | *E. maxima*                                                                           |                          |                                                                     |                                            |    |                                              |      |
+-----------+---------------------------------------------------------------------------------------+--------------------------+---------------------------------------------------------------------+--------------------------------------------+----+----------------------------------------------+------+
| 25,000    | *E. brunetti*                                                                         |                          |                                                                     |                                            |    |                                              |      |
+-----------+---------------------------------------------------------------------------------------+--------------------------+---------------------------------------------------------------------+--------------------------------------------+----+----------------------------------------------+------+
| 10,000    | *E. tenella*                                                                          |                          |                                                                     |                                            |    |                                              |      |
+-----------+---------------------------------------------------------------------------------------+--------------------------+---------------------------------------------------------------------+--------------------------------------------+----+----------------------------------------------+------+
| 10,000    | *E. necatrix*                                                                         |                          |                                                                     |                                            |    |                                              |      |
+-----------+---------------------------------------------------------------------------------------+--------------------------+---------------------------------------------------------------------+--------------------------------------------+----+----------------------------------------------+------+
| **3**     | 4                                                                                     | 2012                     | 201,457                                                             | *E. acervulina*                            | 14 | 7--21                                        | 96.8 |
|           |                                                                                       |                          |                                                                     |                                            |    |                                              |      |
|           | \(5\)                                                                                 | UK                       |                                                                     |                                            |    |                                              |      |
+-----------+---------------------------------------------------------------------------------------+--------------------------+---------------------------------------------------------------------+--------------------------------------------+----+----------------------------------------------+------+
| 21,207    | *E. maxima*                                                                           |                          |                                                                     |                                            |    |                                              |      |
+-----------+---------------------------------------------------------------------------------------+--------------------------+---------------------------------------------------------------------+--------------------------------------------+----+----------------------------------------------+------+
| 21,207    | *E. tenella*                                                                          |                          |                                                                     |                                            |    |                                              |      |
+-----------+---------------------------------------------------------------------------------------+--------------------------+---------------------------------------------------------------------+--------------------------------------------+----+----------------------------------------------+------+
| 15,905    | *E. mitis*                                                                            |                          |                                                                     |                                            |    |                                              |      |
+-----------+---------------------------------------------------------------------------------------+--------------------------+---------------------------------------------------------------------+--------------------------------------------+----+----------------------------------------------+------+
| 5,302     | *E. praecox*                                                                          |                          |                                                                     |                                            |    |                                              |      |
+-----------+---------------------------------------------------------------------------------------+--------------------------+---------------------------------------------------------------------+--------------------------------------------+----+----------------------------------------------+------+
| **4**     | 4                                                                                     | 2012                     | 211,200                                                             | *E. acervulina*                            | 14 | 7--21                                        | 98.3 |
|           |                                                                                       |                          |                                                                     |                                            |    |                                              |      |
|           | \(5\)                                                                                 | France                   |                                                                     |                                            |    |                                              |      |
+-----------+---------------------------------------------------------------------------------------+--------------------------+---------------------------------------------------------------------+--------------------------------------------+----+----------------------------------------------+------+
| 24,000    | *E. maxima*                                                                           |                          |                                                                     |                                            |    |                                              |      |
+-----------+---------------------------------------------------------------------------------------+--------------------------+---------------------------------------------------------------------+--------------------------------------------+----+----------------------------------------------+------+
| 19,968    | *E. tenella*                                                                          |                          |                                                                     |                                            |    |                                              |      |
+-----------+---------------------------------------------------------------------------------------+--------------------------+---------------------------------------------------------------------+--------------------------------------------+----+----------------------------------------------+------+
| 18,048    | *E. brunetti*                                                                         |                          |                                                                     |                                            |    |                                              |      |
+-----------+---------------------------------------------------------------------------------------+--------------------------+---------------------------------------------------------------------+--------------------------------------------+----+----------------------------------------------+------+
| 6,144     | *E. necatrix*                                                                         |                          |                                                                     |                                            |    |                                              |      |
+-----------+---------------------------------------------------------------------------------------+--------------------------+---------------------------------------------------------------------+--------------------------------------------+----+----------------------------------------------+------+
| \< 10,000 | *E. praecox*                                                                          |                          |                                                                     |                                            |    |                                              |      |
+-----------+---------------------------------------------------------------------------------------+--------------------------+---------------------------------------------------------------------+--------------------------------------------+----+----------------------------------------------+------+
| \< 10,000 | *E. mitis*                                                                            |                          |                                                                     |                                            |    |                                              |      |
+-----------+---------------------------------------------------------------------------------------+--------------------------+---------------------------------------------------------------------+--------------------------------------------+----+----------------------------------------------+------+

ISA brown layer in AST‐1, AST‐3 and AST‐4. Hyline brown in AST‐2.

Birds in the IT group were fed a basal diet supplemented with Elancoban^®^ G200. Animals in the control groups UUC and IUC received the same basal diet without inclusion of the coccidiostat.

Performance and intestinal lesions were assessed on day 21, oocyst excretion was measured on day 24.

John Wiley & Sons, Ltd

There were no mortalities in AST‐1, AST‐3 and AST‐4. In AST‐2, three IUC birds died due to coccidiosis and none in the IT group. Tables [31](#efs25891-tbl-0031){ref-type="table"} and [32](#efs25891-tbl-0032){ref-type="table"} summarise the results of the ASTs.

Significantly lower OPG value in the IT group, showing the effect of the coccidiostatic treatment, was seen in AST‐1 and AST‐2. A reduction of lesion scores by treatment (IT) was observed in all tests.

In AST‐1, bodyweight gain was significantly better in the IT than in the IUC group over the seven days post‐inoculation. In the same period, in AST‐2, results of weight gain and feed to gain ratio were significantly better in IT than in the IUC group.

###### 

Results of anticoccidial sensitivity tests with chickens for fattening: AST‐1

  Group       Body weight (g)   Feed intake (g/day)   Weight gain (g/day)   Feed to gain ratio   Total lnOPG   Intestinal lesion scores[1](#efs25891-note-0086){ref-type="fn"}               
  ----------- ----------------- --------------------- --------------------- -------------------- ------------- ----------------------------------------------------------------- ----- ----- -----
  **AST‐1**                                                                                                                                                                                  
  UUC         349\*             41.4                  12.0\*                3.47\*               0\*           0.2                                                               0.3   0     0.4
  IUC         330               44.1                  9.1                   4.95                 14.0          1.5                                                               1.8   1.3   4.7
  IT          340               49.2                  11.3\*                4.35                 13.2\*        0.6\*                                                             1.8   1.6   3.9

*Eimeria* species are *Acervulina* (*acer*), *Tenella* (*ten*), *Maxima* (*max*).

IT mean/UUC mean significantly different from IUC mean (p ≤ 0.05).

John Wiley & Sons, Ltd

###### 

Results of anticoccidial sensitivity tests with chickens for fattening:; AST‐2, AST‐3 and AST‐4

  Group                                        Final body weight (g)   Feed intake (g)   Weight gain (g)                                Feed to gain ratio                             Total log~10~OPG                               Intestinal lesion scores                                                                                                                                
  -------------------------------------------- ----------------------- ----------------- ---------------------------------------------- ---------------------------------------------- ---------------------------------------------- --------------------------------------------- --------------------------------------------- --------------------------------------------- ------- ----- ------
  **AST‐2**                                                                                                                                                                                                                                                                                                                                                                                   
  UUC                                          170                     --                61.6[\*](#efs25891-note-0089){ref-type="fn"}   2.29[\*](#efs25891-note-0089){ref-type="fn"}   0                                              0                                             0                                             0                                             0             
  IUC                                          124                     --                16.0                                           3.65                                           5.34                                           2.6                                           1.8                                           2.0                                           2.7           
  IT                                           154                     --                45.3[\*](#efs25891-note-0089){ref-type="fn"}   2.67[\*](#efs25891-note-0089){ref-type="fn"}   4.77[\*](#efs25891-note-0089){ref-type="fn"}   2.3[\*](#efs25891-note-0089){ref-type="fn"}   1.2[\*](#efs25891-note-0089){ref-type="fn"}   0.6[\*](#efs25891-note-0089){ref-type="fn"}   2.4\*         
                                               **D21**                 **D14--21**       **D14--21**                                    **D14--21**                                    **D19**                                        **D20**                                       **D21**                                       **D21**                                                     
  **AST‐3**                                                                                                                                                                                                                                                                                                                                                                                   
  UUC[1](#efs25891-note-0090){ref-type="fn"}   220                     1,410             85.6                                           --                                             0                                              0                                             0                                             0                                             0       --    0
  IUC                                          189                     808               59.0                                           --                                             6.72                                           5.70                                          6.37                                          1.8                                           1.4     --    0.25
  IT                                           178                     793               53.4                                           --                                             6.40                                           6.35                                          6.23                                          1.3                                           0.6\*   --    0.6
  **AST‐4**                                                                                                                                                                                                                                                                                                                                                                                   
  UUC[1](#efs25891-note-0090){ref-type="fn"}   219                     1,810             87.8                                           --                                             0                                              0                                             0                                             0                                             0       0     0
  IUC                                          199                     975               75.3                                           --                                             6.03                                           7.05                                          6.22                                          2.5                                           0.8     0.8   2.1
  IT                                           203                     905               75.1                                           --                                             5.93                                           6.99                                          6.48                                          1.4\*                                         1.1     0.9   2.3

--: not reported.

IT mean/UUC mean significantly different from IUC mean (p ≤ 0.05).

The cages of the UUC group were kept in another building than those of IUC and IT groups. The zootechnical data of UUC group are therefore not directly comparable to IUC and IT.

John Wiley & Sons, Ltd

#### 3.3.2.3. Synopsis of efficacy studies in chickens reared for laying {#efs25891-sec-0057}

Monensin sodium significantly reduced coccidiosis related mortality in floor pen study 1. Intestinal lesion scores were significantly reduced by the treatment in the lower intestine of trial 1 and in the caecum in trial 3a. The treatment significantly reduced oocyst excretion measured as total oocyst in the period up to approximately 2 weeks after inoculation in trials 1 and 2; in trial 3b, where total oocyst excretion was not significantly affected by the treatment, a significant reduction was found for two *Eimeria* species (*E. tenella*,*E. necatrix/praecox*) due to the monensin treatment.

In two of four ASTs, oocyst excretion was significantly reduced in the monensin‐treated groups. In all four ASTs, the intestinal lesion scores were lower in the IT roups compared to the IUC groups. In AST‐1, the total intestinal lesions scores were significantly reduced; in AST‐2, significantly lower lesion scores were observed in all intestinal segments assessed. In AST‐3 and AST‐4, significant reduction of the intestinal lesions was seen in the middle and upper intestine, respectively.

In summary, the results of all submitted studies (four floor pen studies and four ASTs) are considered indicative for the coccidiostatic potential of 100 mg monensin sodium from Elancoban^®^ G200/kg complete feed for chickens reared for laying.

### 3.3.3. Efficacy in turkeys for fattening {#efs25891-sec-0058}

The applicant submitted four floor pens studies, three ASTs performed with recent field isolates and one AST performed with laboratory strains. This last study was not considered for the demonstration of efficacy because the laboratory strains do not represent field conditions (EFSA FEEDAP Panel, [2011a](#efs25891-bib-0021){ref-type="ref"}). A field study was also submitted.

#### 3.3.3.1. Floor pen studies in turkeys for fattening {#efs25891-sec-0059}

Four floor pen studies in turkeys for fattening, conducted in 2012--2013, were submitted.[100](#efs25891-note-1094){ref-type="fn"} Two trials were conducted in the same institute and using the same feed but different inocula and control group (UUC); therefore, they will be reported here as trials 2a and 2b.[101](#efs25891-note-1095){ref-type="fn"} In each study, turkeys were penned and distributed into the treatment groups (UUC, IUC, IT). The IT group received feed containing 60 mg monensin sodium/kg feed, the lowest dose applied. The experimental design is summarised in Table [33](#efs25891-tbl-0033){ref-type="table"}. The intended dietary monensin concentration was analytically confirmed (see Table [33](#efs25891-tbl-0033){ref-type="table"}). In the infected groups, all birds were inoculated with recent field isolates of pathogenic *Eimeria* species. Animal health and ortality were monitored daily. Feed intake and body weight of the animals were measured, feed to gain ratio was calculated. Samples of excreta were analysed for oocyst excretion. Faecal consistency was examined in trial 3.

###### 

Experimental design of floor pen studies with turkeys using Elancoban^®^ G200

+---------+---------------------------------------------------------------------------------------+--------------------------+-----------------------------------------------------------------------------------+--------------------+---------------------------+------------------------+
| Trial   | Replicates per treatment (Birds[1](#efs25891-note-0091){ref-type="fn"} per replicate) | Inoculum characteristics | Feed analysis monensin sodium (mg/kg feed)[2](#efs25891-note-0092){ref-type="fn"} |                    |                           |                        |
+=========+=======================================================================================+==========================+===================================================================================+====================+===========================+========================+
| **1**   | 8                                                                                     | 2012                     | 60,000                                                                            | *E. meleagrimitis* | Day 14 via feed           | 58.2/61.4/58.0         |
|         |                                                                                       |                          |                                                                                   |                    |                           |                        |
|         | \(29\)                                                                                | France                   |                                                                                   |                    |                           |                        |
+---------+---------------------------------------------------------------------------------------+--------------------------+-----------------------------------------------------------------------------------+--------------------+---------------------------+------------------------+
| 111,600 | *E. gallopavonis + E. adenoeides*                                                     |                          |                                                                                   |                    |                           |                        |
+---------+---------------------------------------------------------------------------------------+--------------------------+-----------------------------------------------------------------------------------+--------------------+---------------------------+------------------------+
| 70,000  | *E. meleagridis*                                                                      |                          |                                                                                   |                    |                           |                        |
+---------+---------------------------------------------------------------------------------------+--------------------------+-----------------------------------------------------------------------------------+--------------------+---------------------------+------------------------+
| **2a**  | 10                                                                                    | 2011                     | 104,000                                                                           | *E. meleagrimitis* | Day 14 orally via syringe | 58.2/55.9/55.6/58.9    |
|         |                                                                                       |                          |                                                                                   |                    |                           |                        |
|         | \(15\)                                                                                | Germany                  |                                                                                   |                    |                           |                        |
+---------+---------------------------------------------------------------------------------------+--------------------------+-----------------------------------------------------------------------------------+--------------------+---------------------------+------------------------+
| 30,000  | *E. dispersa*                                                                         |                          |                                                                                   |                    |                           |                        |
+---------+---------------------------------------------------------------------------------------+--------------------------+-----------------------------------------------------------------------------------+--------------------+---------------------------+------------------------+
| 86,000  | *E. adenoeides*                                                                       |                          |                                                                                   |                    |                           |                        |
+---------+---------------------------------------------------------------------------------------+--------------------------+-----------------------------------------------------------------------------------+--------------------+---------------------------+------------------------+
| **2b**  | 10                                                                                    | 2011                     | 77,000                                                                            | *E. meleagrimitis* |                           |                        |
|         |                                                                                       |                          |                                                                                   |                    |                           |                        |
|         | \(15\)                                                                                | Belgium                  |                                                                                   |                    |                           |                        |
+---------+---------------------------------------------------------------------------------------+--------------------------+-----------------------------------------------------------------------------------+--------------------+---------------------------+------------------------+
| 12,000  | *E. dispersa*                                                                         |                          |                                                                                   |                    |                           |                        |
+---------+---------------------------------------------------------------------------------------+--------------------------+-----------------------------------------------------------------------------------+--------------------+---------------------------+------------------------+
| 20,000  | *E. adenoeides*                                                                       |                          |                                                                                   |                    |                           |                        |
+---------+---------------------------------------------------------------------------------------+--------------------------+-----------------------------------------------------------------------------------+--------------------+---------------------------+------------------------+
| **3**   | 12                                                                                    | 2011                     | 80,274                                                                            | *E. meleagrimitis* | Day 15 orally via syringe | 52/29.1‐49.2/44.8‐55.0 |
|         |                                                                                       |                          |                                                                                   |                    |                           |                        |
|         | \(12\)                                                                                | France                   |                                                                                   |                    |                           |                        |
+---------+---------------------------------------------------------------------------------------+--------------------------+-----------------------------------------------------------------------------------+--------------------+---------------------------+------------------------+
| 8,386   | *E. dispersa*                                                                         |                          |                                                                                   |                    |                           |                        |
+---------+---------------------------------------------------------------------------------------+--------------------------+-----------------------------------------------------------------------------------+--------------------+---------------------------+------------------------+
| 31,151  | *E. adenoeides*                                                                       |                          |                                                                                   |                    |                           |                        |
+---------+---------------------------------------------------------------------------------------+--------------------------+-----------------------------------------------------------------------------------+--------------------+---------------------------+------------------------+

Female BUT9 in trial 1, male and female Wirral White in trial 3, breed and gender not reported for trial 2.

The experimental diets were fed for 84, in trial 1 and for 112 days in trials 2 and 3. In trial 1, birds received starter diet from week 0 to 4, grower diet from week 4 to 8 and finisher diet until study completion. In trial 2, birds received starter diet from day 0 to 28, rearer diet from day 28 to 56, grower diet from day 56 to 84 and finisher diet from day 84 until 112. In trial 3, birds received starter, grower 1 and grower 2 diets.

John Wiley & Sons, Ltd

In trial 1, an ANOVA was performed with the performance data. Oocyst counts were analysed by Kruskal‐Wallis test and mortality was analysed by chi‐squared test. In all tests, IUC was compared with IT using LSD test. In trials 2a and 2b, an ANOVA was performed with the data and IUC and IT were compared with post hoc tests (not reported). In trial 3, Wilcoxon--Mann--Whitney test was used to analyse oocyst counts. Performance parameters were analysed by a t‐test (IUC vs IT). Level of significance was set at a p value ≤ 0.05 for two‐sided tests.

In trial 1, 64 birds died during the 2 weeks following inoculation (days 14--26), all belonging to IUC and confirmed by post‐mortem examination to be coccidiosis‐related (about 27% loss). Statistical analysis confirmed this difference as significant. Five more birds died in the following grower period (days 26--56), one from UUC and 4 from IUC, all confirmed coccidiosis related. Mortality in trials 2a and 2b was low (18 out of 450 in 2a and 16 out of 450 in 2b). No significant differences were seen between the groups. Dead birds were not necropsied/examined for coccidiosis. In trial 3, losses in the critical period two weeks after inoculation were low (between 1 and 2 per group). Not all birds, which died or were euthanised after inoculation, were sent for post‐mortem analysis or were necropsied. Mortality rate could not be used as an endpoint for the assessment of the monensin efficacy in trial 3.

In trial 1, oocyst excretion was counted on days 25, 56 and 84 (11, 42 and 70 days post‐inoculation). Distinction was made between big oocysts (*E. gallopavonis, E. meleagridis, E. adenoides*) and small oocysts (*E. meleagrimitis*). No statistically significant difference in OPGs was found between IT and IUC at any days examined. In trials 2a and 2b, total oocyst excretion values on days 21, 28 and 70 (7, 14 and 56 days post‐inoculation) did not show significant differences between the IUC and IT groups. Concerning individual OPG counts, OPGs of *E. dispersa* in trial 2a and of *E. adenoides* in trial 2b were significantly higher on day 21 in IUC birds compared to IT birds (log~10~OPG 4.68 vs 3.30 and 2.73 vs below detection limit, respectively). No other significant differences were observed in any other individual OPG counts. In trial 3, OPG was measured on days 19, 21, 23, 26, 28, 30, 33, 35 and in biweekly intervals until day 77. The data showed an inconsistent pattern concerning the difference between IUC and IT. Only OPG on day 18 post‐inoculation (day 33) was significantly lower in the IT group (log~10~OPG 2.49) than in the IUC group (log~10~OPG 3.30). However, the low number of excreted oocyst indicates a low infection level.

In contrast to chicken, the intestinal lesion score is not considered a sensitive indicator for the efficacy of a coccidiostat in turkeys. The faecal score should be used instead (Guidance on the assessment of the efficacy of feed additives; FEEDAP Panel, 2018). Faecal score was measured in trial 3 on days 15, 19, 20, 21, 22 with scores ranging from 1 (normal) to 4 (runny mucous‐like consistency).[102](#efs25891-note-1096){ref-type="fn"} Four days after inoculation, a mean faecal score of 1.0 was observed for all experimental groups. On days 5, 6 and 7 post‐inoculation, faecal scores for the UUC groups were between 1.17 and 1.33; in the IT group between 1.0 and 1.6; the IUC groups showing constantly higher scores of 1.75. The difference between IUC and IT (1.75 vs 1.0) reached near significance (p = 0.056) on day 7 post‐infection.

Table [34](#efs25891-tbl-0034){ref-type="table"} summarises the results concerning zootechnical endpoints.

After completion of the 84‐day experimental period of trial 1, average daily feed intake and daily weight gain were significantly higher in the IT group compared to the IUC group. This is probably a result of the significant increase in feed intake and average daily gain during 6 weeks after inoculation, the more sensitive period of the study. Feed to gain ratio was significantly improved by the treatment only in the two weeks immediately after inoculation. Cumulative feed intake and weight gain of the 112‐day experimental period of studies 2a and 2b were not significantly different, however, there was a transient significant positive effect compared to IUC on weight gain and feed to gain ratio in the first two weeks after inoculation of trial 2a and on weight gain and feed intake in trial 2b in the same time period.

No significant differences in total body weight gain were seen in trial 3, cumulative data on feed intake were not statistically assessed. For earlier experimental periods (7--43 days) significant differences between IUC and IT became apparent for males and females, demonstrating a partial compensation of the growth depression caused by the *Eimeria* infection. A comparable effect on feed to gain ratio was only seen in the first week after inoculation. No consistent differences in the feed to gain ratio between IT and IUC were observed in the following periods.

###### 

Performance data of turkeys in floor pen trials

                                                        Feed intake[1](#efs25891-note-0095){ref-type="fn"} (g)   Final body weight (g)                           Weight gain[2](#efs25891-note-0096){ref-type="fn"}   Feed to gain ratio
  ----------------------------------------------------- -------------------------------------------------------- ----------------------------------------------- ---------------------------------------------------- --------------------
  **Trial 1**                                                                                                                                                                                                         
  UUC                                                   175.3                                                    6,831                                           80.7                                                 2.17
  IUC                                                   157.3                                                    6,537                                           77.2                                                 2.04
  IT                                                    166.7[\*](#efs25891-note-0094){ref-type="fn"}            6,747[\*](#efs25891-note-0094){ref-type="fn"}   79.7[\*](#efs25891-note-0094){ref-type="fn"}         2.09
  **Trial 2a**                                                                                                                                                                                                        
  UUC                                                   34,981                                                   --                                              15,567                                               2.25
  IUC                                                   35,074                                                   --                                              15,431                                               2.27
  IT                                                    35,181                                                   --                                              15,591                                               2.26
  **Trial 2b**                                                                                                                                                                                                        
  UUC                                                   34,981                                                   --                                              15,567                                               2.25
  IUC                                                   35,110                                                   --                                              15,382                                               2.28
  IT                                                    34,932                                                   --                                              15,608                                               2.24
  **Trial 3** [3](#efs25891-note-0097){ref-type="fn"}                                                                                                                                                                 
  UUC                                                   19,732/25,565                                            7,204/10,248                                    7,143/10,190                                         --
  IUC                                                   19,460/24,323                                            7,030/9,855                                     6,971/9,795                                          --
  IT                                                    20,066/24,454                                            7,269/10,060                                    7,209/10,000                                         --

--: not reported.

IT is significantly different from IUC (p ≤ 0.05).

Mean results in trial 1 refer to daily feed intake per bird; those of trial 2 and 3 refer to total feed intake per bird during the whole study duration.

Mean results in trial 1 refer to daily gain per bird, results of trial 2a and 2b are given as total gain per bird.

Female/male.

John Wiley & Sons, Ltd

#### 3.3.3.2. Anticoccidial sensitivity tests in turkeys for fattening {#efs25891-sec-0060}

Three ASTs performed in 2012--2013 were submitted.[103](#efs25891-note-1097){ref-type="fn"} Recent field isolates of Eimeria species were used for inoculation. BIG‐6 turkeys were randomly allocated to the groups UUC, IUC and IT, the latter receiving feed supplemented with Elancoban^®^ G200 at an intended concentration of 60 mg monensin sodium/kg feed, the lowest dose applied. One other anticoccidial additive was also tested in all studies. The experimental design is described in Table [35](#efs25891-tbl-0035){ref-type="table"}. The intended dietary monensin concentration was analytically confirmed (Table [35](#efs25891-tbl-0035){ref-type="table"}). Animal health and mortality were monitored. Feed intake and body weight of the animals were measured, feed to gain ratio was calculated. Samples of excreta were analysed for oocyst excretion. ntestinal lesions were examined in AST‐2 and AST‐3, but only a descriptive summary was provided (not individual scores).

The statistical tests were two‐sided; the level of significance was set at a p value ≤ 0.05. For pair‐wise comparisons, the reference group was the IUC. In AST‐1, mortality was analysed by Kruskal--Wallis test. Performance parameters and oocyst counts (log~10~ transformed) were analysed by ANOVA. Least squares means were compared by LSD test. In AST‐2 and AST‐3, performance parameters and oocyst counts (log~10~ transformed) were compared by t‐test (IT vs IUC).

###### 

Experimental design of ASTs with turkeys for fattening using Elancoban^®^ G200

+---------+------------------------------------------------+--------------------------+----------------------------------------------------------------+--------------------------------------------+----+------------+------+
| AST     | Replicates per treatment (birds per replicate) | Inoculum characteristics | Anticoccidial treatment[1](#efs25891-note-0100){ref-type="fn"} | Feed analysis monensin sodium (mg/kg feed) |    |            |      |
+=========+================================================+==========================+================================================================+============================================+====+============+======+
| **1**   | 6                                              | --                       | 45,000                                                         | *E. meleagrimitis*                         | 15 | 8--21^(2)^ | 59.3 |
|         |                                                |                          |                                                                |                                            |    |            |      |
|         | \(8\)                                          | France                   |                                                                |                                            |    |            |      |
+---------+------------------------------------------------+--------------------------+----------------------------------------------------------------+--------------------------------------------+----+------------+------+
| 52,200  | *E. gallopavonis*                              |                          |                                                                |                                            |    |            |      |
+---------+------------------------------------------------+--------------------------+----------------------------------------------------------------+--------------------------------------------+----+------------+------+
| 27,200  | *E. adenoeides*                                |                          |                                                                |                                            |    |            |      |
+---------+------------------------------------------------+--------------------------+----------------------------------------------------------------+--------------------------------------------+----+------------+------+
| 122,200 | *E. meleagridis*                               |                          |                                                                |                                            |    |            |      |
+---------+------------------------------------------------+--------------------------+----------------------------------------------------------------+--------------------------------------------+----+------------+------+
| **2**   | 4                                              | 2012                     | 21,100                                                         | *E. meleagrimitis*                         | 14 | 7--21      | 59.0 |
|         |                                                |                          |                                                                |                                            |    |            |      |
|         | \(5\)                                          | UK                       |                                                                |                                            |    |            |      |
+---------+------------------------------------------------+--------------------------+----------------------------------------------------------------+--------------------------------------------+----+------------+------+
| 9,591   | *E. dispersa*                                  |                          |                                                                |                                            |    |            |      |
+---------+------------------------------------------------+--------------------------+----------------------------------------------------------------+--------------------------------------------+----+------------+------+
| 7,673   | *E. adenoeides*                                |                          |                                                                |                                            |    |            |      |
+---------+------------------------------------------------+--------------------------+----------------------------------------------------------------+--------------------------------------------+----+------------+------+
| **3**   | 4                                              | 2012                     | 80,720                                                         | *E. meleagrimitis*                         | 14 | 7--21      | 54.2 |
|         |                                                |                          |                                                                |                                            |    |            |      |
|         | \(5\)                                          | France                   |                                                                |                                            |    |            |      |
+---------+------------------------------------------------+--------------------------+----------------------------------------------------------------+--------------------------------------------+----+------------+------+
| 46,898  | *E. meleagridis*                               |                          |                                                                |                                            |    |            |      |
+---------+------------------------------------------------+--------------------------+----------------------------------------------------------------+--------------------------------------------+----+------------+------+
| 104,432 | *E. adenoeides*                                |                          |                                                                |                                            |    |            |      |
+---------+------------------------------------------------+--------------------------+----------------------------------------------------------------+--------------------------------------------+----+------------+------+

--: not reported.

Birds in the IT group were fed a basal diet supplemented with Elancoban^®^ G200. Animals in the control groups UUC and IUC received the same basal diet without inclusion of the coccidiostat.

Performance and intestinal lesions were assessed on day 21, oocyst excretion was measured on day 24.

John Wiley & Sons, Ltd

In AST‐1, a total of 18 birds died between 5 and 8 days post‐infection, all in the IUC group (mortality rate 37.5%) Clinical coccidiosis was confirmed in all these 18 birds. In AST‐3, a total of 13 birds died, all in the IUC group (mortality rate 65%). Post‐mortem analysis was foreseen but not reported. No coccidiosis‐related mortality was reported in AST‐2.

In ASTs 2 and 3, the intestinal content was assessed particularly considering its consistency and presence of parasites in smears. In AST‐2, no *Eimeria* were seen in the intestinal content of the UUC group. In contrast, few *E. meleagrimitis, E. dispersa* and *E*. *adenoeides* were seen in the intestinal content of the IUC group and only a few *Eimeria dispersa* were found in the mid‐intestine of the IT group. Consistency of intestine content was normal in UUC, in contrast it was mucoid and watery in IUC and IT. Some mild diarrhoea was reported in three of four replicates of the IUC group on day 4 post‐inoculation. In AST‐3, the consistency of the intestinal content of the UUC group was reported as normal whereas in the IUC group the consistency was described as mucoid and 'cheesy cores' in caeca were reported. The content of duodenum and caeca in the IT group appeared to be watery. No parasites were detected in the smears of the UUC and the IT group whereas for the IUC group numerous *Eimeria meleagrimitis, meleagridis and adenoeides* oocysts were found.

Table [36](#efs25891-tbl-0036){ref-type="table"} summarises the performance parameters and OPGs. In AST‐1, the samples used for OPG determination were collected on day 24, however, they contained droppings from day 21 until day 24. A significantly smaller OPG value was found in the IT group compared to the IUC group. In AST‐2, in days 19, 20 and 21 oocysts were found in the droppings of both the IUC and IT groups. The differences between the groups were not significant at any time point (and did not show a consistent trend). In AST‐3, oocyst excretion could first be observed on day 19 in the IUC group but not in the IT group. On day 20 OPGs were highest but very similar in both groups. No significant differences between IUC and IT were detected on days 20 and 21.

In all three ASTs, bodyweight gain in the sensitive period (of 7 days) after inoculation was significantly better in the IT group than in the IUC group as also feed to gain ratio in AST‐1 (which was not reported for AST‐2 and 3 for the sensitive period).

###### 

Results of anticoccidial sensitivity tests in turkeys for fattening

  Group                                        Body weight (g)   Feed intake (g)                                 Weight gain (g)                               Feed to gain ratio                             Total log~10~OPG                                         
  -------------------------------------------- ----------------- ----------------------------------------------- --------------------------------------------- ---------------------------------------------- ---------------------------------------------- --------- ---------
  **AST 1**                                                                                                                                                                                                                                                            
  UUC                                          489               --                                              231[\*](#efs25891-note-0103){ref-type="fn"}   1.62[\*](#efs25891-note-0103){ref-type="fn"}   0                                                        
  IUC                                          322               --                                              64                                            3.12                                           5.29                                                     
  IT                                           393               --                                              135[\*](#efs25891-note-0103){ref-type="fn"}   1.93[\*](#efs25891-note-0103){ref-type="fn"}   4.91[\*](#efs25891-note-0103){ref-type="fn"}             
  **AST 2**                                                                                                                                                                                                   **D19**                                        **D20**   **D21**
  UUC[1](#efs25891-note-0104){ref-type="fn"}   537               2,031                                           259                                           --                                             0                                              0         0
  IUC                                          359               1,376                                           76                                            --                                             4.47                                           6.24      5.78
  IT                                           378               1,429                                           101[\*](#efs25891-note-0103){ref-type="fn"}   --                                             4.64                                           6.35      5.77
  **AST 3**                                                                                                                                                                                                   **D19**                                        **D20**   **D21**
  UUC[1](#efs25891-note-0104){ref-type="fn"}   577               2,013                                           273                                           --                                             0                                              0         0
  IUC                                          340               1,050                                           49                                            --                                             4.99                                           6.15      5.82
  IT                                           423               1,465[\*](#efs25891-note-0103){ref-type="fn"}   123[\*](#efs25891-note-0103){ref-type="fn"}   --                                             0[\*](#efs25891-note-0103){ref-type="fn"}      5.94      5.69

--: not reported.

IT mean significantly different from IUC mean (p ≤ 0.05).

The cages of the UUC group were kept in another building than those of the IUC and IT groups. The zootechnical data of the UUC group are therefore not directly comparable to IUC and IT.

John Wiley & Sons, Ltd

#### 3.3.3.3. Field trial {#efs25891-sec-0061}

The applicant provided a field trial from 2012 carried out under controlled field conditions.[104](#efs25891-note-1098){ref-type="fn"} Two treatments were considered, complete feed either supplemented with 60 mg monensin sodium from Elancoban^®^ G200 or with another chemically synthesised coccidiostat. The trial was carried out in two different poultry houses, each containing one of the two experimental treatments. Both groups were treated with antibiotics on day 33 for 4 days and on day 60 for 5 days. For these reasons, the trial could not be considered further.

**Synopsis of efficacy studies in turkeys for fattening**

In floor pen study 1, the absence of coccidiosis‐related mortality was observed in the IT group during the first six weeks after artificial infection which per se introduced a high mortality. In studies 2a and 2b, the only coccidiosis related direct positive effect of the monensin treatment was a reduction of excretion of one *Eimeria* species (of a total of three) in each study part 7 days after inoculation. With respect to these findings, the significant compensation of growth depression in the IUC group by the treatment in the first two weeks after inoculation is considered a coccidiosis related effect. A turkey‐specific endpoint for coccidiosis control is faecal consistency. In trial 3, faecal score was significantly improved (higher faecal consistency) by monensin sodium 7 days post‐inoculation.

The absence of coccidiosis‐related mortality in the presence of high‐mortality rates of the IUC groups in two ASTs (AST‐1 and AST‐3) indicates the severe challenge by the inoculation and the effectiveness of the treatment in reducing mortality. In AST‐1, also oocyst excretion was significantly reduced by the treatment. No parasites could be found in the intestinal content of duodenum and caeca in the IT group of AST‐3 whereas in the UUC group numerous *Eimeria* oocysts were found. None of the coccidiostatic endpoints in AST‐2 supported the evidence of efficacy of monensin sodium.

### 3.3.4. Conclusions on efficacy for the target species {#efs25891-sec-0062}

In chickens for fattening, the efficacy of 100 mg monensin sodium/kg complete feed from Elancoban^®^ G200 was demonstrated in three floor pen studies and in two ASTs, a third AST failing to show anticoccidial efficacy. In chickens reared for laying, the efficacy of 100 mg monensin sodium/kg complete feed from Elancoban^®^ G200 was demonstrated in four floor pen studies and in four ASTs.

Considering the total number of studies showing efficacy in chickens for fattening and in chickens reared for laying and that the same *Eimeria* species are prevalent in these two species, the FEEDAP Panel concludes that monensin sodium from Elancoban^®^ G200 has the potential to effectively control coccidiosis at the minimum applied dose of 100 mg/kg complete feed in chickens for fattening and chickens reared for laying.

In turkeys for fattening, the efficacy of 60 mg monensin sodium/kg complete feed from Elancoban^®^ G200 was demonstrated in three floor pen studies and in two ASTs, a third AST failing to show anticoccidial efficacy. The FEEDAP Panel is therefore not in the position to conclude on the efficacy of monensin sodium from Elancoban^®^ G200 as a coccidiostat for turkeys for fattening.

3.4. Post‐market monitoring {#efs25891-sec-0063}
---------------------------

Field monitoring of *Eimeria* spp. resistance in chickens for fattening, chickens reared for laying and turkeys to monensin sodium should be undertaken, preferably during the latter part of the period of authorisation.

4. Conclusions {#efs25891-sec-0064}
==============

Elancoban^®^ G200 contains the active substance monensin sodium which is produced by fermentation. Limited data on the taxonomic identification of the production strain does not allow the proper identification of the strain as *S. cinnamonensis*. The FEEDAP Panel cannot conclude on the absence of genetic determinants for antimicrobial resistance in the production strain, on the presence of viable cells/spores of the production strain/DNA in the final product. Therefore, the FEEDAP Panel cannot conclude on the safety of the additive for the target species, consumer, user and environment with regard to the safety of the production strain.

The following conclusions apply to monensin sodium included in the additive.

Based on the available data set, the FEEDAP Panel cannot conclude on the safety of the highest applied dietary concentration of monensin (125 mg/kg) for chickens for fattening and to derive a margin of safety. Monensin sodium is safe for turkeys for fattening at inclusion level of 100 mg/kg complete feed, with a margin of safety of 1.5. Gram‐positive bacteria are susceptible to monensin. Monensin sodium is not considered to be involved in cross‐resistance to other antibiotics. The use of monensin as a coccidiostat in chickens did not affect the colonisation or shedding of *Salmonella* in the gastrointestinal tract. The simultaneous use of Elancoban^®^ G200 and certain antibiotic drugs (e.g. tiamulin) is contraindicated.

Monensin sodium is not genotoxic and, based on the results of chronic carcinogenicity studies performed in rats and mice, is not carcinogenic. The lowest NOAEL identified from all the toxicological studies was 1.1 mg/kg bw per day based on a 2‐year chronic toxicity/carcinogenicity assay in rat. The pharmacological NOAEL of 0.345 mg monensin sodium/kg bw per day identified in dog for acute pharmacological effects on the cardiovascular system has been considered as an appropriate basis for the acute health‐based guidance value of 0.003 mg monensin sodium/kg bw per day already established by the FEEDAP Panel in its former opinion applying an uncertainty factor of 100.

The chronic exposure to monensin residues resulting from the use of monensin sodium as a feed additive in chickens would amount to up to 10% of the ADI (toddlers). The combined chronic exposure to monensin residues resulting from use of monensin as a feed additive in chicken and as a veterinary medicine in bovine would reach up to 48% of the ADI. Acute exposures due to the consumption of poultry tissues were found below the ADI for all age classes. These conclusions are extrapolated to chickens reared for laying and turkeys for fattening. Based on this, the FEEDAP Panel considers that Elancoban^®^ G200 containing monensin sodium is safe for the consumer.

The existing MRLs for poultry tissues ensure consumer safety (acute and chronic exposure; all age classes) provided that the withdrawal period of 1 day is respected.

Elancoban^®^ G200 is very irritant for the eye, but it is not a skin irritant. However, systemic toxicity may occur following skin exposure. Elancoban^®^ G200 should be regarded as a potential skin and respiratory sensitiser. Inhalation exposure is considered a risk to persons handling the additive.

The use of monensin sodium from Elancoban^®^ G200 in complete feed for chickens for fattening does not pose a risk for the terrestrial compartment, aquatic compartment and for sediment. The bioaccumulation potential of monensin in the environment is low. These conclusions are extended to chickens reared for laying and turkeys.

Monensin sodium from Elancoban^®^ G200 has the potential to effectively control coccidiosis at the minimum applied dose of 100 mg/kg complete feed in chickens for fattening and chickens reared for laying. In turkeys for fattening, the efficacy of 60 mg monensin sodium/kg complete feed from Elancoban^®^ G200 was demonstrated in three floor pen studies and in two ASTs, a third AST failing to show anticoccidial efficacy. The FEEDAP Panel is therefore not in the position to conclude on the efficacy of monensin sodium from Elancoban^®^ G200 as a coccidiostat for turkeys for fattening.

5. Remark {#efs25891-sec-0065}
=========

Monensin sodium is toxic to horses at doses proposed for feed supplementation in poultry.
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ADIacceptable daily intakeAFassessment factorANOVAanalysis of varianceAPalkaline phosphataseASTaspartate aminotransferase/anticoccidial sensitivity testsbwbody weightCASChemical Abstracts ServiceCFUcolony forming unitCKcreatine kinaseCVcoefficient of variationCVMPCommittee for Medicinal Products for Veterinary UseDMdry matterDT~50~disappearance time 50 (the time within which the concentration of the test substance is reduced by 50%)DT~90~disappearance time 90 (the time within which the concentration of the test substance is reduced by 90%)EC~50~median effective concentrationErC~50~median effective concentration which results in 50% reduction in growth rateEMAEuropean Medicines AgencyEURLEuropean Union Reference LaboratoryFACEFeed Additives Consumer ExposureFOCUSFOrum for Co‐ordination of pesticide fate models and their USeGLDHglutamate dehydrogenaseGLPGood Laboratory PracticeHPLChigh‐performance liquid chromatographyHRPhighest reliable percentileJECFAThe Joint FAO/WHO Expert Committee on Food AdditivesKdsoil adsorption coefficientKocadsorption or desorption coefficient corrected for soil organic carbon contentLC~50~median lethal concentrationLC--MS/MSliquid chromatography with tandem mass spectrometryLOAELlowest observed adverse effect levelLOELlowest observed effect levelLODlimit of detectionLOQlimit of quantificationlog K~ow~logarithm of octanol‐water partition coefficientLSCliquid scintillation countingLSDleast significant differenceMEmetabolisable energyMICminimum inhibitory concentrationMRLmaximum residue limitNOAELno observed adverse effect levelNOECno observed effect concentrationOCorganic carbonOECDOrganisation for Economic Co‐operation and DevelopmentOPGoocysts per gram of excretapKadissociation constantPECpredicted environmental concentrationPNECpredicted no effect concentrationRACraw agricultural commoditiesRHrelative humidityRMTRratio marker to total residueSFOsingle first‐orderTPtotal proteinTRCtotal residue concentrationVPvapour pressure
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Appendix B -- Calculation of consumer exposure with <https://www.efsa.europa.eu/en/press/news/190219> {#efs25891-sec-1002}
=====================================================================================================

 {#efs25891-sec-0069}

**Methodology**

As described in the Guidance on the safety of feed additives for consumers (EFSA FEEDAP Panel, [2017b](#efs25891-bib-0029){ref-type="ref"}), consumption data of edible tissues and products as derived from the EFSA Comprehensive European Food Consumption Database (Comprehensive Database) will be used to assess exposure to residues from the use of feed additives in different EU countries, age classes[105](#efs25891-note-1099){ref-type="fn"} and special population groups. For each EU country and age class, only the latest survey available in the Comprehensive Database will be used.

While the residue data reported for feed additives refer to organs and tissues (raw agricultural commodities. RAC), the Comprehensive Database includes consumption data for foods as consumed. In order to match those consumption data with the available residue data for feed additives, the consumption data reported in the Comprehensive Database have been converted into RAC equivalents. For assessing the exposure to coccidiostats from their use in (non‐reproductive) poultry, the following list of commodities is considered: meat, fat, liver, other offals (including kidney).

Depending on the nature of the health‐based guidance derived, either a chronic or acute exposure assessment may be required.

For chronic exposure assessments, the total relevant residues will be combined for each individual with the average daily consumptions of the corresponding food commodities, and the resulting exposures per food will be summed in order to obtain total chronic exposure at individual level (standardised by using the individual body weight). The mean and the higher percentile (usually the 95th percentile) of the individual exposures will be subsequently calculated for each dietary survey (country) and each age class separately.

As opposed to the chronic exposure assessments, acute exposure calculation will be carried out for each RAC value separately. The higher percentile (usually the 95th percentile) exposures based on the consuming days only will be calculated for each food commodity, dietary survey and age class separately.

**Detailed results on chronic exposure calculation**

###### 

Chronic dietary exposure per population class, country and survey of consumers (mg/kg bw per day) to monensin total residues based on residue data in chicken tissues

  Population class   Survey\'s country   Number of subjects   HRP[1](#efs25891-note-0106){ref-type="fn"}   HRP description
  ------------------ ------------------- -------------------- -------------------------------------------- -----------------
  Infants            Bulgaria            523                  0.0006023004                                 95th
  Infants            Germany             142                  0.0001132686                                 95th
  Infants            Denmark             799                  0.0001313668                                 95th
  Infants            Finland             427                  0.0001964025                                 95th
  Infants            United Kingdom      1,251                0.0002695864                                 95th
  Infants            Italy               9                    0.0000000000                                 50th
  Toddlers           Belgium             36                   0.0002896951                                 90th
  Toddlers           Bulgaria            428                  0.0007189578                                 95th
  Toddlers           Germany             348                  0.0001884209                                 95th
  Toddlers           Denmark             917                  0.0001457581                                 95th
  Toddlers           Spain               17                   0.0002839744                                 75th
  Toddlers           Finland             500                  0.0003137353                                 95th
  Toddlers           United Kingdom      1,314                0.0003008401                                 95th
  Toddlers           United Kingdom      185                  0.0003054779                                 95th
  Toddlers           Italy               36                   0.0002587523                                 90th
  Toddlers           Netherlands         322                  0.0003178539                                 95th
  Other children     Austria             128                  0.0002509460                                 95th
  Other children     Belgium             625                  0.0003465484                                 95th
  Other children     Bulgaria            433                  0.0006309453                                 95th
  Other children     Czech Republic      389                  0.0005365447                                 95th
  Other children     Germany             293                  0.0002035676                                 95th
  Other children     Germany             835                  0.0001974921                                 95th
  Other children     Denmark             298                  0.0001629345                                 95th
  Other children     Spain               399                  0.0003689514                                 95th
  Other children     Spain               156                  0.0005163667                                 95th
  Other children     Finland             750                  0.0002756368                                 95th
  Other children     France              482                  0.0002542903                                 95th
  Other children     United Kingdom      651                  0.0002696993                                 95th
  Other children     Greece              838                  0.0002639457                                 95th
  Other children     Italy               193                  0.0002781187                                 95th
  Other children     Latvia              187                  0.0002996973                                 95th
  Other children     Netherlands         957                  0.0002318732                                 95th
  Other children     Netherlands         447                  0.0002919776                                 95th
  Other children     Sweden              1,473                0.0002187615                                 95th
  Adolescents        Austria             237                  0.0001733979                                 95th
  Adolescents        Belgium             576                  0.0001586059                                 95th
  Adolescents        Cyprus              303                  0.0001676798                                 95th
  Adolescents        Czech Republic      298                  0.0004063538                                 95th
  Adolescents        Germany             393                  0.0001516495                                 95th
  Adolescents        Germany             1,011                0.0001244170                                 95th
  Adolescents        Denmark             377                  0.0001274236                                 95th
  Adolescents        Spain               651                  0.0002142808                                 95th
  Adolescents        Spain               209                  0.0002875639                                 95th
  Adolescents        Spain               86                   0.0002348923                                 95th
  Adolescents        Finland             306                  0.0001607405                                 95th
  Adolescents        France              973                  0.0001679927                                 95th
  Adolescents        United Kingdom      666                  0.0001976671                                 95th
  Adolescents        Italy               247                  0.0001235962                                 95th
  Adolescents        Latvia              453                  0.0001826405                                 95th
  Adolescents        Netherlands         1,142                0.0002188828                                 95th
  Adolescents        Sweden              1,018                0.0001647145                                 95th
  Adults             Austria             308                  0.0001985704                                 95th
  Adults             Belgium             1,292                0.0001596687                                 95th
  Adults             Czech Republic      1,666                0.0001984561                                 95th
  Adults             Germany             10,419               0.0001233192                                 95th
  Adults             Denmark             1,739                0.0000830659                                 95th
  Adults             Spain               981                  0.0001999179                                 95th
  Adults             Spain               410                  0.0001996245                                 95th
  Adults             Finland             1,295                0.0001584927                                 95th
  Adults             France              2,276                0.0001466797                                 95th
  Adults             United Kingdom      1,265                0.0001458976                                 95th
  Adults             Hungary             1,074                0.0002468397                                 95th
  Adults             Ireland             1,274                0.0001969244                                 95th
  Adults             Italy               2,313                0.0001083925                                 95th
  Adults             Latvia              1,271                0.0001643512                                 95th
  Adults             Netherlands         2,055                0.0001846426                                 95th
  Adults             Romania             1,254                0.0003039818                                 95th
  Adults             Sweden              1,430                0.0001681158                                 95th
  Elderly            Austria             67                   0.0001749422                                 95th
  Elderly            Belgium             511                  0.0001351120                                 95th
  Elderly            Germany             2,006                0.0000962208                                 95th
  Elderly            Denmark             274                  0.0000671801                                 95th
  Elderly            Finland             413                  0.0001271367                                 95th
  Elderly            France              264                  0.0001142862                                 95th
  Elderly            United Kingdom      166                  0.0001249615                                 95th
  Elderly            Hungary             206                  0.0002054980                                 95th
  Elderly            Ireland             149                  0.0001631647                                 95th
  Elderly            Italy               289                  0.0001253259                                 95th
  Elderly            Netherlands         173                  0.0001368953                                 95th
  Elderly            Netherlands         289                  0.0001163296                                 95th
  Elderly            Romania             83                   0.0002125537                                 95th
  Elderly            Sweden              295                  0.0001565474                                 95th
  Very elderly       Austria             25                   0.0000417360                                 75th
  Very elderly       Belgium             704                  0.0001434023                                 95th
  Very elderly       Germany             490                  0.0001051597                                 95th
  Very elderly       Denmark             12                   0.0000350785                                 75th
  Very elderly       France              84                   0.0001164876                                 95th
  Very elderly       United Kingdom      139                  0.0000901233                                 95th
  Very elderly       Hungary             80                   0.0001577334                                 95th
  Very elderly       Ireland             77                   0.0001629198                                 95th
  Very elderly       Italy               228                  0.0001079636                                 95th
  Very elderly       Netherlands         450                  0.0001152571                                 95th
  Very elderly       Romania             45                   0.0001994053                                 90th
  Very elderly       Sweden              72                   0.0001195411                                 95th

HRP: highest reliable percentile, i.e. the highest percentile that is considered statistically robust for combinations of dietary survey, age class and possibly raw primary commodity, considering that a minimum of 5, 12, 30 and 61 observations are respectively required to derive 50th, 75th and 90th and 95th percentile estimates. Estimates with less than 5 observations were not included in this table.
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###### 

Acute dietary exposure of consumers (mg/kg bw per day) to monensin total residues based on residue data in chicken -- Summary statistics across European dietary surveys

  Raw primary commodity                                       Population class   Number of surveys   Maximum HRP[1](#efs25891-note-0108){ref-type="fn"}
  ----------------------------------------------------------- ------------------ ------------------- ----------------------------------------------------
  Birds liver                                                 Other children     7                   0.0033990000
  Birds liver                                                 Adults             12                  0.0029957288
  Birds liver                                                 Adolescents        4                   0.0016854545
  Birds meat                                                  Other children     20                  0.0012669800
  Birds meat                                                  Infants            5                   0.0010565963
  Birds meat                                                  Toddlers           11                  0.0009887022
  Birds liver                                                 Infants            2                   0.0009270000
  Birds meat                                                  Adolescents        20                  0.0007771852
  Birds liver                                                 Elderly            6                   0.0007357143
  Birds meat                                                  Adults             23                  0.0005679430
  Birds meat                                                  Elderly            16                  0.0004825660
  Birds meat                                                  Very elderly       14                  0.0004692519
  Birds liver                                                 Toddlers           1                   0.0004635000
  Birds offals and slaughtering products (other than liver)   Adults             3                   0.0004453125
  Birds liver                                                 Very elderly       4                   0.0002990323
  Birds fat tissue                                            Adolescents        2                   0.0002748261
  Birds fat tissue                                            Other children     4                   0.0002661474
  Birds fat tissue                                            Toddlers           1                   0.0002247467
  Birds fat tissue                                            Adults             8                   0.0001980147
  Birds fat tissue                                            Very elderly       3                   0.0001023400
  Birds fat tissue                                            Elderly            4                   0.0000752500

Maximum of the highest reliable percentile values across European dietary surveys.

John Wiley & Sons, Ltd

###### 

Chronic combined exposure of consumers per population class, country and survey of consumers (mg/kg bw per day) to monensin total residues based on residue data in chicken and bovine tissues and milk

  Population class   Survey\'s country   Number of subjects   HRP[1](#efs25891-note-0110){ref-type="fn"}   HRP description
  ------------------ ------------------- -------------------- -------------------------------------------- -----------------
  Infants            Bulgaria            523                  0.0025795276                                 95th
  Infants            Germany             142                  0.0014547696                                 95th
  Infants            Denmark             799                  0.0020668941                                 95th
  Infants            Finland             427                  0.0015294067                                 95th
  Infants            United Kingdom      1,251                0.0012772728                                 95th
  Infants            Italy               9                    0.0006203849                                 50th
  Toddlers           Belgium             36                   0.0019626350                                 90th
  Toddlers           Bulgaria            428                  0.0023722484                                 95th
  Toddlers           Germany             348                  0.0020802463                                 95th
  Toddlers           Denmark             917                  0.0022701722                                 95th
  Toddlers           Spain               17                   0.0016183958                                 75th
  Toddlers           Finland             500                  0.0024682670                                 95th
  Toddlers           United Kingdom      1,314                0.0020698643                                 95th
  Toddlers           United Kingdom      185                  0.0019356257                                 95th
  Toddlers           Italy               36                   0.0016299638                                 90th
  Toddlers           Netherlands         322                  0.0019377226                                 95th
  Other children     Austria             128                  0.0029663681                                 95th
  Other children     Belgium             625                  0.0019696607                                 95th
  Other children     Bulgaria            433                  0.0020019580                                 95th
  Other children     Czech Republic      389                  0.0020093355                                 95th
  Other children     Germany             293                  0.0016126611                                 95th
  Other children     Germany             835                  0.0012521815                                 95th
  Other children     Denmark             298                  0.0017740835                                 95th
  Other children     Spain               399                  0.0014008329                                 95th
  Other children     Spain               156                  0.0016667807                                 95th
  Other children     Finland             750                  0.0018880110                                 95th
  Other children     France              482                  0.0017635718                                 95th
  Other children     United Kingdom      651                  0.0013924741                                 95th
  Other children     Greece              838                  0.0016647713                                 95th
  Other children     Italy               193                  0.0014725156                                 95th
  Other children     Latvia              187                  0.0014360723                                 95th
  Other children     Netherlands         957                  0.0015537739                                 95th
  Other children     Netherlands         447                  0.0013142318                                 95th
  Other children     Sweden              1,473                0.0015842171                                 95th
  Adolescents        Austria             237                  0.0008900732                                 95th
  Adolescents        Belgium             576                  0.0006819726                                 95th
  Adolescents        Cyprus              303                  0.0006060521                                 95th
  Adolescents        Czech Republic      298                  0.0013220976                                 95th
  Adolescents        Germany             393                  0.0009387438                                 95th
  Adolescents        Germany             1,011                0.0006868897                                 95th
  Adolescents        Denmark             377                  0.0008316968                                 95th
  Adolescents        Spain               651                  0.0008075476                                 95th
  Adolescents        Spain               209                  0.0009650033                                 95th
  Adolescents        Spain               86                   0.0007418586                                 95th
  Adolescents        Finland             306                  0.0009103862                                 95th
  Adolescents        France              973                  0.0009490053                                 95th
  Adolescents        United Kingdom      666                  0.0006904988                                 95th
  Adolescents        Italy               247                  0.0008230436                                 95th
  Adolescents        Latvia              453                  0.0009474830                                 95th
  Adolescents        Netherlands         1,142                0.0008921214                                 95th
  Adolescents        Sweden              1,018                0.0009512468                                 95th
  Adults             Austria             308                  0.0007121166                                 95th
  Adults             Belgium             1,292                0.0006386811                                 95th
  Adults             Czech Republic      1,666                0.0007309850                                 95th
  Adults             Germany             10,419               0.0006345642                                 95th
  Adults             Denmark             1,739                0.0005774042                                 95th
  Adults             Spain               981                  0.0006644088                                 95th
  Adults             Spain               410                  0.0006479132                                 95th
  Adults             Finland             1,295                0.0007399569                                 95th
  Adults             France              2,276                0.0006614246                                 95th
  Adults             United Kingdom      1,265                0.0004972914                                 95th
  Adults             Hungary             1,074                0.0007046084                                 95th
  Adults             Ireland             1,274                0.0005702101                                 95th
  Adults             Italy               2,313                0.0005247628                                 95th
  Adults             Latvia              1,271                0.0006511800                                 95th
  Adults             Netherlands         2,055                0.0006546694                                 95th
  Adults             Romania             1,254                0.0006732205                                 95th
  Adults             Sweden              1,430                0.0005954770                                 95th
  Elderly            Austria             67                   0.0006494093                                 95th
  Elderly            Belgium             511                  0.0006419146                                 95th
  Elderly            Germany             2,006                0.0005983576                                 95th
  Elderly            Denmark             274                  0.0005629677                                 95th
  Elderly            Finland             413                  0.0006286208                                 95th
  Elderly            France              264                  0.0005978217                                 95th
  Elderly            United Kingdom      166                  0.0005293803                                 95th
  Elderly            Hungary             206                  0.0005981138                                 95th
  Elderly            Ireland             149                  0.0006029148                                 95th
  Elderly            Italy               289                  0.0004540141                                 95th
  Elderly            Netherlands         173                  0.0005613266                                 95th
  Elderly            Netherlands         289                  0.0005486190                                 95th
  Elderly            Romania             83                   0.0005302204                                 95th
  Elderly            Sweden              295                  0.0006285113                                 95th
  Very elderly       Austria             25                   0.0004458340                                 75th
  Very elderly       Belgium             704                  0.0007087520                                 95th
  Very elderly       Germany             490                  0.0006093196                                 95th
  Very elderly       Denmark             12                   0.0003850268                                 75th
  Very elderly       France              84                   0.0005832936                                 95th
  Very elderly       United Kingdom      139                  0.0005898587                                 95th
  Very elderly       Hungary             80                   0.0006274331                                 95th
  Very elderly       Ireland             77                   0.0005430224                                 95th
  Very elderly       Italy               228                  0.0004586513                                 95th
  Very elderly       Netherlands         450                  0.0005456926                                 95th
  Very elderly       Romania             45                   0.0005814443                                 90th
  Very elderly       Sweden              72                   0.0006775374                                 95th

HRP: highest reliable percentile, i.e. the highest percentile that is considered statistically robust for combinations of dietary survey, age class and possibly raw primary commodity, considering that a minimum of 5, 12, 30 and 61 observations are respectively required to derive 50th, 75th and 90th and 95th percentile estimates. Estimates with less than 5 observations were not included in this table.
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###### 

Chronic dietary exposure per population class, country and survey (mg/kg bw per day) of consumers exposure of consumers to monensin total residues derived from poultry MRLs

  Population class   Survey\'s country   Number of subjects   HRP[1](#efs25891-note-0112){ref-type="fn"}   HRP description
  ------------------ ------------------- -------------------- -------------------------------------------- -----------------
  Infants            Bulgaria            523                  0.0026412521                                 95th
  Infants            Germany             142                  0.0004815856                                 95th
  Infants            Denmark             799                  0.0005930780                                 95th
  Infants            Finland             427                  0.0008866932                                 95th
  Infants            United Kingdom      1,251                0.0011695825                                 95th
  Infants            Italy               9                    0.0000000000                                 50th
  Toddlers           Belgium             36                   0.0013078788                                 90th
  Toddlers           Bulgaria            428                  0.0030840855                                 95th
  Toddlers           Germany             348                  0.0008506587                                 95th
  Toddlers           Denmark             917                  0.0006580501                                 95th
  Toddlers           Spain               17                   0.0012820513                                 75th
  Toddlers           Finland             500                  0.0014164124                                 95th
  Toddlers           United Kingdom      1,314                0.0013486905                                 95th
  Toddlers           United Kingdom      185                  0.0013791325                                 95th
  Toddlers           Italy               36                   0.0011681818                                 90th
  Toddlers           Netherlands         322                  0.0014350065                                 95th
  Other children     Austria             128                  0.0011329392                                 95th
  Other children     Belgium             625                  0.0015122316                                 95th
  Other children     Bulgaria            433                  0.0025659761                                 95th
  Other children     Czech Republic      389                  0.0024154589                                 95th
  Other children     Germany             293                  0.0008832389                                 95th
  Other children     Germany             835                  0.0008916123                                 95th
  Other children     Denmark             298                  0.0007355960                                 95th
  Other children     Spain               399                  0.0016656946                                 95th
  Other children     Spain               156                  0.0023312266                                 95th
  Other children     Finland             750                  0.0011949041                                 95th
  Other children     France              482                  0.0010114065                                 95th
  Other children     United Kingdom      651                  0.0011924485                                 95th
  Other children     Greece              838                  0.0011916283                                 95th
  Other children     Italy               193                  0.0012556148                                 95th
  Other children     Latvia              187                  0.0013530353                                 95th
  Other children     Netherlands         957                  0.0010468318                                 95th
  Other children     Netherlands         447                  0.0013181835                                 95th
  Other children     Sweden              1,473                0.0009876366                                 95th
  Adolescents        Austria             237                  0.0007828349                                 95th
  Adolescents        Belgium             576                  0.0007146809                                 95th
  Adolescents        Cyprus              303                  0.0007570196                                 95th
  Adolescents        Czech Republic      298                  0.0017332514                                 95th
  Adolescents        Germany             393                  0.0006846480                                 95th
  Adolescents        Germany             1,011                0.0005606271                                 95th
  Adolescents        Denmark             377                  0.0005752760                                 95th
  Adolescents        Spain               651                  0.0009674077                                 95th
  Adolescents        Spain               209                  0.0012982568                                 95th
  Adolescents        Spain               86                   0.0010604620                                 95th
  Adolescents        Finland             306                  0.0007256906                                 95th
  Adolescents        France              973                  0.0006501045                                 95th
  Adolescents        United Kingdom      666                  0.0008924024                                 95th
  Adolescents        Italy               247                  0.0005579962                                 95th
  Adolescents        Latvia              453                  0.0008245619                                 95th
  Adolescents        Netherlands         1,142                0.0009881844                                 95th
  Adolescents        Sweden              1,018                0.0007436319                                 95th
  Adults             Austria             308                  0.0008964804                                 95th
  Adults             Belgium             1,292                0.0006750652                                 95th
  Adults             Czech Republic      1,666                0.0008783021                                 95th
  Adults             Germany             10,419               0.0005502277                                 95th
  Adults             Denmark             1,739                0.0003750154                                 95th
  Adults             Spain               981                  0.0009014085                                 95th
  Adults             Spain               410                  0.0009012392                                 95th
  Adults             Finland             1,295                0.0007101270                                 95th
  Adults             France              2,276                0.0005436905                                 95th
  Adults             United Kingdom      1,265                0.0006586801                                 95th
  Adults             Hungary             1,074                0.0008071707                                 95th
  Adults             Ireland             1,274                0.0008829231                                 95th
  Adults             Italy               2,313                0.0004731626                                 95th
  Adults             Latvia              1,271                0.0007368243                                 95th
  Adults             Netherlands         2,055                0.0008100476                                 95th
  Adults             Romania             1,254                0.0009388828                                 95th
  Adults             Sweden              1,430                0.0007589879                                 95th
  Elderly            Austria             67                   0.0007126895                                 95th
  Elderly            Belgium             511                  0.0005483946                                 95th
  Elderly            Germany             2,006                0.0004233469                                 95th
  Elderly            Denmark             274                  0.0003032962                                 95th
  Elderly            Finland             413                  0.0005739806                                 95th
  Elderly            France              264                  0.0004450013                                 95th
  Elderly            United Kingdom      166                  0.0005254240                                 95th
  Elderly            Hungary             206                  0.0006154615                                 95th
  Elderly            Ireland             149                  0.0007217702                                 95th
  Elderly            Italy               289                  0.0004585927                                 95th
  Elderly            Netherlands         173                  0.0006180373                                 95th
  Elderly            Netherlands         289                  0.0005251902                                 95th
  Elderly            Romania             83                   0.0008284211                                 95th
  Elderly            Sweden              295                  0.0007067604                                 95th
  Very elderly       Austria             25                   0.0001884245                                 75th
  Very elderly       Belgium             704                  0.0006294046                                 95th
  Very elderly       Germany             490                  0.0004577186                                 95th
  Very elderly       Denmark             12                   0.0001583679                                 75th
  Very elderly       France              84                   0.0005259034                                 95th
  Very elderly       United Kingdom      139                  0.0004068770                                 95th
  Very elderly       Hungary             80                   0.0005908067                                 95th
  Very elderly       Ireland             77                   0.0007355296                                 95th
  Very elderly       Italy               228                  0.0004749960                                 95th
  Very elderly       Netherlands         450                  0.0005047293                                 95th
  Very elderly       Romania             45                   0.0008302886                                 90th
  Very elderly       Sweden              72                   0.0005396889                                 95th

HRP: highest reliable percentile, i.e. the highest percentile that is considered statistically robust for combinations of dietary survey, age class and possibly raw primary commodity, considering that a minimum of 5, 12, 30 and 61 observations are respectively required to derive 50th, 75th and 90th and 95th percentile estimates. Estimates with less than 5 observations were not included in this table.

John Wiley & Sons, Ltd

###### 

Acute dietary exposure of consumers (mg/kg bw per day) to monensin total residues derived from poultry MRLs -- Summary statistics across European dietary surveys

  Raw primary commodity                                       Population class   Number of surveys   Maximum HRP[1](#efs25891-note-0114){ref-type="fn"}
  ----------------------------------------------------------- ------------------ ------------------- ----------------------------------------------------
  Birds meat                                                  Other children     20                  0.0057200000
  Birds meat                                                  Infants            5                   0.0047701863
  Birds meat                                                  Toddlers           11                  0.0044636667
  Birds meat                                                  Adolescents        20                  0.0035087368
  Birds meat                                                  Adults             22                  0.0025640769
  Birds liver                                                 Other children     7                   0.0022000000
  Birds meat                                                  Elderly            16                  0.0021786275
  Birds meat                                                  Very elderly       14                  0.0021185185
  Birds liver                                                 Adults             12                  0.0019389831
  Birds liver                                                 Adolescents        4                   0.0011804878
  Birds offals and slaughtering products (other than liver)   Adults             3                   0.0009375000
  Birds liver                                                 Infants            2                   0.0006000000
  Birds liver                                                 Elderly            6                   0.0004761905
  Birds liver                                                 Toddlers           1                   0.0003000000
  Birds liver                                                 Very elderly       4                   0.0001935484
  Birds fat tissue                                            Adolescents        2                   0.0001333043
  Birds fat tissue                                            Other children     4                   0.0001290947
  Birds fat tissue                                            Toddlers           1                   0.0001090133
  Birds fat tissue                                            Adults             8                   0.0000960470
  Birds fat tissue                                            Very elderly       3                   0.0000496400
  Birds fat tissue                                            Elderly            4                   0.0000365000

Maximum of the highest reliable percentile values across European dietary surveys.

John Wiley & Sons, Ltd

Appendix C -- Estimation of user exposure to monensin sodium from the additive Elancoban^®^ G200, including consideration of using a filter mask FF P2 or FF P3 as a preventative measure {#efs25891-sec-1003}
=========================================================================================================================================================================================

 {#efs25891-sec-0070}

CalculationIdentifierDescriptionAmountSource*a*Monensin in the dust (mg/g)■■■■■Technical dossier*b*Dusting potential (g/m^3^)■■■■■Technical dossiera × b*c*monensin in the air (mg/m^3^)36.1*d*No of premixture batches prepared/working day10EFSA Guidance on user safety (EFSA FEEDAP Panel, [2012b](#efs25891-bib-0026){ref-type="ref"})*e*Time of exposure per production of one batch (s)20EFSA Guidance on user safety (EFSA FEEDAP Panel, [2012b](#efs25891-bib-0026){ref-type="ref"})d × e*f*Total duration of daily exposure/worker (s)200*g*Uncertainty factor2EFSA Guidance on user safety (EFSA FEEDAP Panel, [2012b](#efs25891-bib-0026){ref-type="ref"})f × g*h*Refined total duration of daily exposure/worker (s)400*h*/3 600*i*Refined total duration of daily exposure (h)0.11*j*Inhaled air per hour (m^3^)1.25EFSA Guidance on user safety (EFSA FEEDAP Panel, [2012b](#efs25891-bib-0026){ref-type="ref"})j × i*k*Inhaled air during exposure (m^3^)0.14c × k*l*Monensin inhaled during exposure per eight‐hour working day (mg)5.0*m*Particles below 10 μm in the dust (%) generated during the Stauber‐Heubach measurement31Technical dossier*l* × *m*/100*n*Monensin inhaled per eight‐hour working day (mg) reduced by respirable fraction1.6*n*/10*o*Monensin inhaled per eight‐hour working day (mg) reduced by filter mask FF P2 (reduction factor 10)0.16*n*/20*p*Monensin inhaled per eight‐hour working day (mg) reduced by filter mask FF P3 (reduction factor 20)0.08

Appendix D -- Total number of *Eimeria* oocysts per gram of faeces (OPG) in floor pen trials with chickens for fattening[1](#efs25891-note-1100){ref-type="fn"} {#efs25891-sec-1004}
===============================================================================================================================================================

 {#efs25891-sec-0071}

Day 23 log~10~opg*E. acervulinaE. maximaE. tenellaTotal***Trial 1**UUCndndndndIUC4.384.074.294.75IT3.74\*3.52\*3.72\*4.16\*Geometric mean of faecal oocyst counts at different days22242729313642**Trial 2**UUC00100212IUC16,682,94712,338,4503,377,339740,500100,09110,98739,841IT8,553,8535,187,342322,431557,880131,75543,038592\*OPG × 10^3^*E. acer* [2](#efs25891-note-1101){ref-type="fn"}*E. tenE. maxE. bruE. nec/praeE. mit*Total**Trial 3aDay 20**UUC3028.1000.33.2313IUC42012.051.606.927.1517IT3846.53.0\*027.2\*48.8469**Day 22**UUC7900.3006.686IUC13614.518.7028.625.9223IT746.51.0\*08.311.7101**Day 28**UUC1117.90023.822.1165IUC262.671.4705.25.841IT640.530.15\*06.95.678OPG × 10^3^*E. acerE. tenE. maxE. bruE. nec/praeE. mit*Total**Trial 3bDay 20**UUC3028.1000.33.2313IUC6778.2006.019.5710IT1,2683.20039.8\*93.0\*1404**Day 22**UUC7900.3006.686IUC57618819.205641341481IT4755021.8020540\*792**Day 28**UUC1117.90023.822.1165IUC341.310.304.33.453IT111\*1.4712.20.2510.39.5145\*[^1][^2]

Annex A -- Executive Summary of the Evaluation Report of the European Union Reference Laboratory for Feed Additives on the Method(s) of Analysis for Elancoban {#efs25891-sec-1005}
==============================================================================================================================================================

 {#efs25891-sec-0072}

Elancoban^®^G200 is a feed additive currently authorized for turkeys, chickens for fattening and reared for laying by Commission Regulation (EC) No 1356/2004 belonging to the "Coccidiostats and other medicinal substances" group listed in Directive 70/524/EEC. The authorisation was further amended by Commission Regulation (EC) No 1096/2008. In the current application an authorisation according to article 10 (2) of Regulation (EC) No 1831/2003 is requested. Elancoban^®^G200 consists of granular monensin (active substance) containing 20% (w/w) monensin, anti‐dusting oil, and rice hulls or limestone granular as base material. It is intended to be preferably incorporated into feedingstuffs through premixtures. The Applicant proposed a concentration of monensin in feedingstuffs ranging from 60 to 125 mg/kg, depending on the target species.

Furthermore the Applicant suggested the following Maximum Residue Limits (MRLs) in tissues of turkeys and chickens for fattening and reared for laying: 8 μg/kg in liver, muscle and kidney and 25 μg/kg in skin/fat tissues, as already established by Commission Regulation (EC) No 1096/2008.

For the quantification of monensin in the feed additive, premixes and feedingstuffs the Applicant submitted the AOAC ring‐trial validated methods (AOAC 997.04) based on High Performance Liquid Chromatography with post‐column derivatisation coupled to spectrophotometric detection (HPLC‐PCD‐UV‐Vis.). In addition, the EURL identified another multi‐analyte ring‐trial validated method (EN ISO 14183) using a similar experimental protocol. Based on the performance characteristics available the EURL recommends for official control both methods for the quantification of monensin in the feed additive, premixtures and/or feedingstuffs.

For the quantification of monensin in chicken and turkey tissues the Applicant submitted the ring trial validated method (AOAC 2011.24) based on Reversed Phase High Performance Liquid Chromatography coupled to a triple quadrupole mass spectrometer (RP‐HPLC‐MS/MS) in electrospray ionisation mode using matrix matched standards. Based on the performance characteristics available the EURL recommends for official control this AOAC ring‐trial validated method or any equivalent methods complying with the requirements set by Commission Decision 2002/657/EC, to enforce the monensin MRLs in the relevant tissues.

Further testing or validation of the methods to be performed through the consortium of National Reference Laboratories as specified by Article 1.

Regulation (EC) No 1831/2003 of the European Parliament and of the Council of 22 September 2003 on additives for use in animal nutrition. OJ L 268, 18.10.2003, p. 29.

On 15/6/2018, EFSA was informed by the applicant that the applicant company changed to Elanco GmbH (Heinz‐Lohmann‐Str. 4, 27472 Cuxhaven Germany).

Commission Regulation (EC) No 1356/2004 of 26 July 2004 concerning the authorisation for 10 years of the additive 'Elancoban' in feedingstuffs, belonging to the group of coccidiostats and other medicinal substances. OJ L 251, 27.7.2004, p. 6.

Commission Regulation (EC) No 180/2007 of 5 February 2007 amending Regulation (EC) No 1356/2004 as regards the conditions for authorisation of the feed additive Elancoban, belonging to the group of coccidiostats and other medicinal substances. OJ L 31, 6.2.2007, p. 4.

Commission Regulation (EC) No 1096/2008 of 6 November 2008 amending Regulation (EC) No 1356/2004 as regards the conditions for authorisation of the feed additive Elancoban, belonging to the group of coccidiostats and other medicinal substances. OJ L 298, 7.11.2008, p. 5.

Commission Implementing Regulation (EU) No 495/2011 of 20 May 2011 amending Regulation (EC) No 109/2007 as regards the composition of the feed additive monensin sodium. OJ L 134, 21.5.2011, p. 6.

Commission Implementing Regulation (EU) No 140/2012 of 17 February 2012 concerning the authorisation of monensin sodium as a feed additive for chickens reared for laying. OJ L 47, 18.2.2012, p. 18.

FEED dossier reference: FAD‐2013‐0037.

The full report is available on the EURL website: <https://ec.europa.eu/jrc/sites/default/files/finrep-fad-2013-0037-elancoban.pdf>

Commission Regulation (EC) No 429/2008 of 25 April 2008 on detailed rules for the implementation of Regulation (EC) No 1831/2003 of the European Parliament and of the Council as regards the preparation and the presentation of applications and the assessment and the authorisation of feed additives. OJ L 133, 22.5.2008, p. 1.

Technical dossier/Section II/Annex II.8 and II.9.

■■■■■

Chemical formula and the molecular structure for variant D was not reported by the applicant.

■■■■■

Technical dossier/Supplementary information January 2018/Annex 36.

■■■■■

Databases searched: Agriculture Online Access/STN, Biosis Previews/STN, CAB Abstracts/STN, Chemical Abstracts Plus/STN, Derwent Biotechnology Resource/STN, Derwent Drug Backfile/STN, Derwent Drug File/STN, Embase/STN, Embase Alert/STN, Food Science and Technology Abstracts/STN, Foodline Science/STN, International Pharmaceutical Abstracts/STN, Medline/STN, Pascal/STN, ProQuest Science & Technology/STN, Science Citation Index/STN; Period: 2005--2015.

Technical dossier/Supplementary information January 2018/Annex 37.

■■■■■

■■■■■

■■■■■

■■■■■

■■■■■

■■■■■

■■■■■

■■■■■

■■■■■

Technical dossier/Section II and Supplementary information July 2014.

Technical dossier/Section II/Annex II.15 and II.16.

Technical dossier/Section II/Annex II.17.

Technical dossier/Section II/Annex II.18.

Technical dossier/Section II/Annex II.15.

Technical dossier/Supplementary information January 2018/Annex 47.

Study 1: Technical dossier/Section III/Annex III.18. Study 2: Annex III.19. Study 3: Annex III.16 and Study 4: Annex III.17.

Technical dossier/Section III/Annex III.155.

Technical dossier/Section III/Annex III.156.

Technical dossier/Section III/Annex III.163.

Technical dossier/Section III/Annex III.162.

Technical dossier/Section III/Annex III.18.

Technical dossier/Section III/Annex III.19.

Technical dossier/Section III/Annex III.16.

Technical dossier/Section III/Annex III.17.

Technical dossier/Supplementary information January 2018/Annex 46.

Haematology: haematocrit, haemoglobin, heterophils, basophils, eosinophils, lymphocytes, monocytes, white blood cells. Serum biochemistry: sodium, potassium, chloride, calcium, phosphate, magnesium, total protein, albumin, globulin, glucose, uric acid, cholesterol, triglycerides, bilirubin, amylase, aspartate aminotransferase (AST), glutamate dehydrogenase (GLDH), alkaline phosphatase (AP) and creatine kinase (CK).

Databases searched: ScienceDirect, PubMed: British National Library of Medicine, Google Scholar. Period: 2000--2014.

Technical dossier/Supplementary information May 2015.

Technical dossier/Supplementary information May 2015/MICROBIOLOGICAL EXPERT REPORT_FINAL.

A PubMed search was conducted on Monday 18th August 2014 using the terms 'Monensin' 'Elancoban' 'ionophores' 'resistant' 'cross‐resistance' 'tolerance' 'adaptation' and 'resistance'.

Technical dossier/Section IV/Annex IV.4

Technical dossier/Section IV/Annex IV.13. and IV.14.

Technical dossier/Section III/Annex 60.

Technical dossier/Section III/Annex 61 and 62.

Technical dossier/Section III/References 93, 94, 95.

Technical dossier/Section III/References 96 and 97.

Technical dossier/Section III/Reference 104.

Technical dossier/Section III/References 105 and 106.

Technical dossier/Section III/Reference 98.

Technical dossier/Section III/Reference 100.

Technical dossier/Section III/Reference 101.

Technical dossier/Section III/Reference 102.

Technical dossier/Section III/Reference 103.

Technical dossier/Section III/Reference 99.

Technical dossier/Section III/Reference 109.

Technical dossier/Section III/Reference 110.

Technical dossier/Section III/Reference 111.

Technical dossier/Section III/Reference 107.

Technical dossier/Section III/Reference 112.

Technical dossier/Section III/Reference 113.

Technical dossier/Section III/Reference 114.

Technical dossier/Section III/Reference 115.

Technical dossier/Section III/Reference 116.

Technical dossier/Section III/Reference 117.

Technical dossier/Section III/References 124, 125, 127, 127.

COMMISSION REGULATION (EU) No 37/2010 of 22 December 2009 on pharmacologically active substances and their classification regarding maximum residue limits in foodstuffs of animal origin OJ L 15, 20.1.2010, p. 1. amended by Commission Implementing Regulation (EU) No 59/2013, OJ L 21, 24.1.2013, p. 21.

Reg. (EC) No 180/2007.

Technical dossier/Section III/Annexes 88, 89, 143, 144, 147, 149.

Technical dossier/Section III/Annexes 88, 134, 135, 136, 137, 138, 139, 140, 141.

Technical dossier/Section III/Annexes 88.

Technical dossier/Section III/Annexes 139.

Technical dossier/Supplementary information January 2018/Reference 48.

Agricola, BIOSIS Previews, CAB Abstracts, Chemical Abstracts Plus, Elsevier Biobase, Embase, Food Science and Technology Abstracts, IPA, Medline, ProQuest Science & Technology, Registry, SciSearch, Toxcenter; Period: 2000--2016.

Technical dossier/Supplementary information May 2015/Reference 6.

Technical dossier/Supplementary information May 2015/Reference 10.

The temperature correction was performed according to the scientific opinion of the Panel on Plant Protection Products and their Residues on a request from EFSA related to the default Q10 value used to describe the temperature effect on transformation rates of pesticides in soil (EFSA, [2007b](#efs25891-bib-0014){ref-type="ref"}).

Directive 2006/118/EC of the European Parliament and of the Council of 12 December 2006 on the protection of groundwater against pollution and deterioration. OJ L 372, 27.12.2006, p. 19.

Technical dossier/Supplementary information May 2015/Reference 11.

Technical dossier/Supplementary information May 2015/Reference 12.

Technical dossier/Supplementary information May 2015/Reference 13.

Technical dossier/Supplementary information May 2015/Reference 14.

Technical dossier/Supplementary information May 2015/Reference 15.

Technical dossier/Supplementary information May 2015/Reference 18.

Technical dossier/Supplementary information May 2015/Reference 16.

Technical dossier/Supplementary information May 2015/Reference 17.

The FEEDAP Panel stated in its guidance for the preparation of dossiers for coccidiostats and histomonostats (EFSA FEEDAP Panel, [2011a](#efs25891-bib-0021){ref-type="ref"}) that studies with artificial infection would be preferred over field trials due to their inherent weaknesses. These short term studies should use field strains of *Eimeria*, recently confirmed as pathogenic/resistant by a sensitivity test or recognised problems in the poultry operation (confirmed by veterinary certificate). The *Eimeria* field strains should ideally undergo one, but in any case not more than two passage(s) before use in such trials.

Trial 1: Technical dossier/Section IV/Annex IV.2. Trial 2: Technical dossier/Section IV/Annex IV.3. and Trial 3: Technical dossier/Section IV/Annex IV.4.

Trials 3a and 3b were conducted in the same research institute, at the same time, with the same feed, and used the same UUC group. Taking into account that the inoculum with sporulated oocysts is the most critical factor in this type of studies and that the UUC group (common control) is used only to verify the growth of the animals under farming conditions, 3a and 3b can be considered as separate studies in the assessment of the coccidiostatic efficacy of the additive against *Eimeria* infection.

AST‐1: Technical dossier/Section IV/Annex IV.21. AST‐2: Technical dossier/Section IV/Annex IV.22. AST‐3: Technical dossier/Section IV/Annex IV.20.

Trial 1: Technical dossier/Section IV/Annex IV.5. Trial 2: Technical dossier/Section IV/Annex IV.7. Trial 3: Technical dossier/Section IV/Annex IV.9. and Trial 4: Technical dossier/Section IV/Annex IV.11.

AST‐1: Technical dossier/Section IV/Annex IV.23. AST‐2: Technical dossier/Section IV/Annex IV.24. AST‐3: Technical dossier/Section IV/Annex IV.25. and AST‐4: Technical dossier/Section IV/Annex IV.26.

Trial 1: Technical dossier/Section IV/Annex IV.12. Trial 2a: Technical dossier/Section IV/Annex IV.13. Trial 2b: Technical dossier/Section IV/Annex IV.14. Trial 3: Technical dossier/Section IV/Annex IV.15.

Trials 2a and 2b were conducted in the same research institute, at the same time, with the same feed, and used the same UUC group. Taking into account that the inoculum with sporulated oocysts is the most critical factor in this type of studies and that the UUC group (common control) is used only to verify the growth of the animals under farming conditions, 3a and 3b can be considered as separate studies in the assessment of the coccidiostatic efficacy of the additive against *Eimeria* infection.

Score 1= Normal, Score 2‐ Any In pen showing mucous‐like consistency, faeces still well formed Score 3 Some showing mucous‐like consistency, some well formed, some runny. Score 4 -- all showing runny mucous‐like consistency.

AST‐1: Technical dossier/Section IV/Annex IV.28. AST‐2: Technical dossier/Section IV/Annex IV.29. AST‐3: Technical dossier/Section IV/Annex IV.30.

Technical dossier/Section IV/Annex IV.27.

Infants: \< 12 months old, toddlers: ≥ 12 months to \< 36 months old, other children: ≥ 36 months to \< 10 years old, adolescents: ≥ 10 years to \< 18 years old, adults: ≥ 18 years to \< 65 years old, elderly: ≥ 65 years to \< 75 years old, and very elderly: ≥ 75 years old.

[^1]: IT with \* is significantly different from control (IUC).

[^2]: *Eimeria* species are *Acervulina* (*acer*), *Tenella* (*ten*), *Maxima* (*max*), *Brunetti* (*bru*), *Necatrix*/*Praecox* (*nec*/*prae*), *Mitis* (*mit*).
